CURRICULUM VITAE

Univ.-Prof. Dr. med. Christian Weber

Institut für Prophylaxe & Epidemiologie der Kreislaufkrankheiten (IPEK)
Lehrstuhl für Präventive Vaskuläre Medizin, August-Lenz-Stiftung
Poliklinik, Klinikum der Universität München (KUM)
Ludwig-Maximilians-Universität (LMU) München
Pettenkoferstrasse 9, D-80336 München

Geboren am 15.10.1967 in München
Verheiratet, 2 Söhne

1986	Abitur am Mathematisch-Naturwissenschaftlichen Gymnasium Olching mit der Note 1,0, Stipendium des Bayerischen Kultusministeriums
1986 - 1993	Studium Humanmedizin, Ludwig-Maximilians-Universität München, University Hospital Galway, Irland, Queensland University, Brisbane, Australien
1989 - 1993	Doktorand am Institut für Prophylaxe der Kreislaufkrankheiten an der LMU (Direktor: Prof. Dr. P.C. Weber), Stipendium der August-Lenz-Stiftung
1993, April	Ärztliche Prüfung mit der Gesamtnote *gut*, *Foreign Medical Graduate Examination in the Medical Sciences* der USA (ECFMG)
1993 - 1994	Arzt im Praktikum und am Institut für Prophylaxe und Epidemiologie der Kreislaufkrankheiten der LMU, München, BWL Studium, Fernuniversität Hagen
1994, März	**Promotion** zum Dr. med., LMU München, Thema: *Differenzierung und funktionelle Parameter in humanen, monozytoiden Zellen* mit *summa cum laude*
1995	**Ärztliche Approbation**
1995 - 1996	DFG Postdoktorand und Research Fellow am Center for Blood Research and Dept. of Pathology (Prof. T. Springer), Harvard Medical School, Boston, USA
1997	Wissenschaftlicher Assistent am Institut für Prophylaxe der Kreislaufkrankheiten der LMU, München
1998 - 2001	Leiter einer DFG Nachwuchsgruppe in den Biowissenschaften am Institut für Prophylaxe der Kreislaufkrankheiten
1998 - 2001	Wissenschaftlicher Assistent an der Med. Poliklinik (Direktor: Prof. Dr. D. Schlöndorff) und am Gefäßzentrum der LMU (Leiter: Prof. Dr. U. Hoffmann)
1999	Fakultätskolloquium *Koordination der Integrinaktivität durch Chemokine bei der Leukozytenmigration in entzündlichen und kardiovaskulären Erkrankungen*
1999, Dezember 2000, Januar	**Habilitation** und Facultas docendi für Experimentelle Innere Medizin **Venia legendi** und Lehrbefugnis an der LMU München
2001, Juni	**Ernennung zum Universitätsprofessor (C3)** für Kardiovaskuläre Molekularbiologie, Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen
2001 - 2005	Klinische Weiterbildung in Innerer Medizin mit Schwerpunkt Kardiologie in der Med. Klinik I (Direktor: Prof. Dr. P. Hanrath), Universitätsklinikum Aachen
2003, Juli	**Erwerb der Gebietsbezeichnung Innere Medizin**
2003	Organisator des *Euregio-Symposium on Atherosclerosis*
2004	Ernennung zum Fellow der *European Society of Cardiology* (FESC)
2004, September	**Erwerb der Schwerpunktbezeichnung Kardiologie**
2004	Ruf auf einen Chair in Cardiology, Cardiovascular Division Chief und Director Heart & Vascular Center, University of Virginia

2005	Ruf auf einen Chair in Cardiology, King's College, University of London
2005, Dezember	**Ernennung zum Universitätsprofessor (W3)** und Direktor des Instituts für Kardiovaskuläre Molekularbiologie, RWTH Aachen
2006 -	**Ernennung zum Professor** am Cardiovascular Research Institute Maastricht (CARIM) der Universität Maastricht, Van der Laar Professor of Atherosclerosis
2007 - 2014	Einrichtung der DFG Forschergruppe 809 *Chemokine und Adhäsionsmoleküle in der kardiovaskulären Pathogenese* (**Sprecher**: Prof. Dr. C. Weber)
2007	Ruf auf die W3 Professur für Molekulare Kardiologie und Leitung des Instituts für Herz-Kreislauf-Physiologie, Heinrich-Heine-Universität Düsseldorf
2007	Umbenennung in Institut für Molekulare Herz-Kreislaufforschung, Institute for Molecular Cardiovascular Research (IMCAR), RWTH Aachen
2008 - 2010	Sprecher des Internationalen Graduiertenkollegs GRK1508 mit der Universität Maastricht (*European Cardiovascular Research School EuCAR*)
2008	Organisator und Präsident, Jahrestagung der Gesellschaft für Mikrozirkulation und Vaskuläre Biologie (GfMVB 2008) und *2nd Euregio-Symposium*
2009	ERC Advanced Investigator Grant *Atheroprotect*
2010 -	**Editor-in-Chief**, *Thrombosis & Haemostasis*
2010 -	**Ernennung zum Universitätsprofessor (W3)** für Vaskuläre Medizin, Direktor des Instituts für Prophylaxe & Epidemiologie der Kreislaufkrankheiten (IPEK), Klinikum der Universität München und LMU, Vorstand August-Lenz-Stiftung
2011 - 2020	Stellvertret. Standortsprecher, Munich Heart Alliance im Dt. Zentrum für Herz-Kreislaufforschung (DZHK), Mitglied Centre for Advanced Studies (CAS), LMU
2011 - 2016	Europäischer Koordinator des *Transatlantic Networks of Excellence (TNE) CVGene(Fx)* der Fondation Leducq
2012	Co-Organisator/Präsident, *International Vascular Biology Meeting* IVBM 2012
2012 -	**Senior Associate Editor**, *Arteriosclerosis, Thrombosis & Vascular Biology*
2014 -	Einrichtung des **SFB1123** *Atherosklerose – Molekulare Mechanismen & Netzwerke neuer therapeutischer Zielstrukturen* (**Sprecher**: Prof. Dr. C.Weber)
2016	ERC Advanced Investigator Grant *PROVASC*
2016 - 2021	Weltweit Platz 1 im Experten-Ranking für Atherosklerose (ExpertScape)
2018, 2020 - 2023	Nennung als ***Highly Cited Researcher*** (*cross-field*) durch Clarivate Analytics
2019 -	Mitglied und Principal Investigator, DFG Excellence Cluster SyNergy
2019	Wahl zum Mitglied der Nationalen Akademie der Wissenschaften Leopoldina
2021 -	Standortsprecher der **Munich Heart Alliance** im DZHK
2025	ERC Advanced Investigator Grant *MONOFUN-CV*

Listenplätze/Rufe

2001	C3 Molekulare Medizin, Universität Erlangen (*secundo loco*)
2004	Chair in Cardiology, University of Virginia (*primo loco*, Ruf)
2005	Berufungssymposium MPI für Molekulare Biomedizin & Herz-Lungenforschung
2005	Chair in Cardiology, King's College London (*primo loco*, Ruf)
2007	W3 Mol. Kardiologie, Heinrich-Heine-Universität Düsseldorf (*secundo loco*, Ruf)
2010	W3 Direktor, Leibniz-Institut Arterioskleroseforschung, Münster (*primo loco* Ruf)

Auszeichnungen

2000	Young Master Award 2000 der Deutschen Gesellschaft für Innere Medizin
2002	Förderpreis der Gesellschaft für Mikrozirkulation & Vaskuläre Biologie
2003	Wissenschaftspreis für Med. Grundlagenforschung, GlaxoSmithKline Stiftung
2004	Arthur-Weber-Preis, Dt. Ges. f. Kardiologie - Herz- und Kreislaufforschung (DGK)
2004	Preis der Hans & Gertie Fischer-Stiftung, Rhein.-Westf. Ges. f. Innere Medizin
2005	Forßmann-Preis, Stiftung Kardiologie der Ruhr-Universität Bochum
2005	Hermann-Rein-Förderpreis, Ges. für Mikrozirkulation & Vaskuläre Biologie
2005	Preis im Hochschulwettbewerb Patente Erfinder, Nordrhein-Westfalen
2008	W.H. Hauss-Preis, Deutsche Gesellschaft für Atheroskleroseforschung (DGAF)
2008	Paul-Martini-Preis, Paul-Martini-Stiftung
2008	Outstanding Achievement Award, European Society of Cardiology (ESC)
2009	Galenus-von-Pergamon-Preis, Internationaler Stifterverband Prix Galien
2009	ATVB Special Recognition Award, American Heart Association (AHA)
2010	VICI Preis, NWO (Nederlandse Organisatie voor Wetenschappelijk Onderzoek)
2015	Alexander-Schmidt-Preis, Ges. f. Thrombose & Hämostaseforschung (GTH)
2016 - 2020	Weltweit Platz 1 im Experten-Ranking für Atherosklerose (ExpertScape)
2018 - 2023	Benennung als *Highly Cited Researcher* (Cross-Field) durch Clarivate Analytics
2022 - 2025	research.com Ranking für Biochemie/Medizin: weltweit #126/853, **national #7/24**
2022	William Harvey Lecture in Basic Science Award der ESC
2023	European Atherosclerosis Society (EAS) Keynote Lecture

Mitgliedschaften & Funktionen

2001 -	Mitglied, Dt. Ges. für Innere Medizin (DGIM) und Dt. Ges. für Kardiologie (DGK)
2002 - 2010	Kardiovaskulärer Koordinator und Vorstandsmitglied IZKF Biomat, RWTH Aachen
2002 -	Mitglied der Gesellschaft für Mikrozirkulation und Vaskuläre Biologie (GfMVB)
2004 -	Mitglied & Fellow of the European Society of Cardiology (ESC)
2004 -	Mitglied der Dt. Gesellschaft für Atheroskleroseforschung (DGAF)
2004 -	Mitglied, American Heart Association (AHA), Basic Science Council
2006 -	Gründungsmitglied der European Vascular Biology Organisation (EVBO)
2007 - 2008	Präsident und Tagungspräsident der GfMVB
2008	Mitglied, European Atherosclerosis Society (EAS), Scientific Council Member
2010 -	Mitglied, Gesellschaft für Thrombose und Hämostaseforschung (GTH)
2011 -	Mitglied, International Society of Thrombosis and Haemostasis (ISTH)
2011 -	Mitglied & Principal Investigator, Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), Koordinator des Standorts Munich Heart Alliance (MHA) an der LMU
2012	Ko-Organisator und Präsident, International Vascular Biology Meeting (IVBM)
2012 - 2014	Vorsitzender, ESC Working Group on Atherosclerosis & Vascular Biology
2014 -	Mitglied, ESC Council of Basic Cardiovascular Science (Treasurer 2016-2018)
2018 - 2020	Vize-Vorsizender (Chair elect), ESC Council of Basic Cardiovascular Science
2019	Wahl zum Mitglied der Nationalen Akademie der Wissenschaften Leopoldina
2020	Gutachter, Nobel-Komitee, Karolinska Institutet, Stockholm, Schwerden
2020 - 2022	Vorsizender (Chair), ESC Council of Basic Cardiovascular Science

Sonstige Aktivitäten

Herausgeberschaften / Wissenschaftliche Redaktion

2010 - Editor-in-Chief, *Thrombosis & Haemostasis*

2012 - 2022 Senior Associate Editor, *Arteriosclerosis, Thrombosis & Vascular Biology*

2013 - Regional Editor Europe, *Molecular Metabolism*

2014 - 2017 Consulting Editor, *Circulation Research*

2018 - Guest Editor, *Circulation*

2022 - 2023 Consulting Editor, *Cacrdiovascular Research*

2023 - Associate Editor, *Circulation*

Editorial Boards

- *Basic Research in Cardiology*
- *Cardiovascular Research*
- *Circulation Research*
- *EMBO Molecular Medicine*
- *European Heart Journal*

Gutachter (Auswahl) *Blood, Cell Metabolism, Circulation, EMBO Journal, Immunity, Journal of Clinical Investigation, Journal of Experimental Medicine, Journal of the American College of Cardiology, Lancet, Nature, Nature Medicine, PNAS, Science (Signaling, Transl Med)*

Gutachter (Organisation)

- Deutsche Forschungsgemeinschaft, Schweizerischer Nationalfonds
- European Research Council (ERC), Consolidator Grant Panelist
- MPG Minerva Foundation, Israel Science Foundation
- The Wellcome Trust, British Heart Foundation

Wissenschaftl. Beiräte

- Helmoltz Gesellschaft, Health
- Paris Cardiovascular Research Center (PARCC)
- Dept. Cardiologie, Universität Zürich (Mitglied Evaluationscommittee)
- *Carolus Therapeutics Inc.* (Vorsitz SAB 2008-2016)
- *ProterixBio Inc.* (2014-2016)

Patente/Anmeldungen

- DE 10014516.1 (RANTES antagonists for treatment of restenosis)
- US 10411397 (JAM-1 small molecule antagonists and antibodies)
- DE 10328277.7 (customized parallel wall flow chamber)
- US8110552 B2 & US8501680 B2 (peptide antagonist CKEY2)
- US65701601 & WO2009117710A2/A3 (MIF antagonists)
- WO 2009/015884 A1 (GAG-antagonising MCP-1 mutants)
- WO 2009/073921 (microRNA and tissue repair)
- WO 2011/064354 A2 (MicroRNAs in atherosclerosis)
- EP 10001208.7-2406 (CCL17 inhibitors in T_{helper} cell-driven disease)
- EP2888228B1 (Inhibitors of CD40-TRAF6 interaction)
- US9750717B2 (Inhibitors of CD40-TRAF6 interaction)
- WO2017077062A1 (peptide derived from human neutrophil peptide 1)
- EP3889262A1 (Inhibition of caspase-3 by microRNA-126-5p)

Gründer

- *Carolus Therapeutics Inc.*
- *Cartesio Therapeutics Inc.*

Drittmitteleinwerbungen

Deutsche Forschungsgemeinschaft

1995-1996	DFG Ausbildungsstipendium Integrin activation by chemokines	WE 1913/1-1	ca. 50 T€
1997-1999	Nachwuchsgruppe in den Biowissenschaften Integrins and chemokine receptors: regulatory mechanisms and pathophysiological role	WE 1913/2-1	ca. 400 T€
2000-2001	Fortsetzungsbewilligung Integrin and chemokine signalling in inflammatory leukocyte recruitment	WE 1913/2-2	ca. 200 T€
1999-2001	Graduiertenkolleg Endothelial chemokine receptors & apoptosis	GRK438	ca. 150 T€
2002-2004	Sachmittelbeihilfe Integrins & chemokines in atherogenic recruitment	WE 1913/2-3	ca. 250 T€
2003-2006	Sachmittelbeihilfe Functional role of platelet chemokines	WE 1913/5-1+2	ca. 250 T€
2004-2007	Sachmittelbeihilfe (mit J. Bernhagen) MIF in inflammatory processes & atherogenesis	BE 1977/2-1	ca. 110 T€
2004-2007	Sachmittelbeihilfe (mit A. Schober) SDF-1α and vascular progenitor cells	WE 1913/7-1+2	ca. 190 T€
2005-2008	**SFB542** Teilprojekt (mit P. Mertens) YB-1 and functional RANTES expression	C12	ca. 240 T€
2006-2008	Sachmittelbeilhilfe JAM-A in inflammation and atherosclerosis	WE 1913/9-1+2	ca. 400 T€
2006	Zellanalyse-Sortiersystem (federführend)	HBFG 148/711-1	ca. 400 T€
2007	2-Photonen-Mikroskop (federführend)	HBFG 222/778-1	ca. 500 T€
2007-2010	**DFG Forschergruppe 809** (Sprecher: C. Weber) *Chemokines & adhesion molecules in cardio-vascular pathogenesis*: Role of MIF (TP1) platelet chemokines (TP2), dendritic cells (TP3), progenitors (TP4) & junctional molecules (TP6) inkl. WE 1913/10-1 & 12-1	TP1 TP2 TP3 TP4 TP6	ca. 2.500 T€
2008-2011	**SFB542**		
	MIF receptor complexes (mit J. Bernhagen)	A07	ca. 360 T€
	Shedding by ADAMs (inkl. WE1913/13-1)	A12	ca. 250 T€
	YB-1 and RANTES expression (mit P. Mertens)	C12	ca. 360 T€
2009-2011	**SFB TR57**		
	MIF and CXCR2 in liver fibrosis (mit H. Wasmuth)	P07	ca. 100 T€
2009-2013	**GRK1508** *Euregio Cardiovascular Research School*		ca. 2.600 T€
2010-2013	**GRK1035** *Biointerface* (mit A. Zernecke/ D. Klee)		ca. 100 T€
2008-2011	*Excellence Growth Area Molecular Science & Engineering*	MSE6	ca. 860 T€
2011	Zellanalyse-Sortiersystem (federführend)	INST 408/97-1	ca. 400 T€
2011	2-Photonen-Mikroskop (federführend)	INST 408/98-1	ca. 700 T€

2011-2014	**DFG Forschergruppe 809** (Sprecher: C. Weber) *Chemokines and adhesion molecules in cardiovascular pathogenesis*: Role of MIF (TP1) platelet chemokines (TP2), dendritic cells (TP3), progenitors (TP4), junctional molecules (TP6), molecular imaging (TP12), WE 1913/10-2 & 12-2	TP1 TP2 TP3 TP4 TP6 TP12	ca. 3.500 T€
2012-2015	**SFB914** (mit O. Söhnlein) Differential recruitment of monocyte subsets	B08	ca. 400 T€
2013-2016	**SFB1054** Chemokine control of DC and T-cell plasticity	B04	ca. 450 T€
2014	STED-Mikroskop (federführend)	INST 409/150-1	ca. 970 T€
2014-2018	**SFB1123** *Atherosclerosis* (Sprecher: C. Weber) A1, B4, Z3 Chemokines and miRs in atherosclerosis		ca. 2.200 T€
2018-2022	**SFB1123** *Atherosclerosis* (Sprecher: C. Weber) A1, A10, Z3 Chemokine receptors in atherosclerosis		ca. 2.700 T€
2019-2025	Principal Investigator, DFG Excellence Cluster **SyNergy**		ca. 700 T€
2019-2027	**TRR267** *Non-coding RNA in cardiovascular system* (mit M. Sattler) **A02** Differential trafficking and function of miR-126 strands		ca. 700 T€
2022-2026	**SFB1123** *Atherosclerosis* (Sprecher: C. Weber) A1, A10, Z3 Chemokine receptors in atherosclerosis		ca. 3.000 T€
2022-2026	**Reinhart-Koselleck-Projeck**		ca. 1.500 T€

Bundesministerium für Bildung und Forschung (BMBF)

2011-2030	**Munich Heart Alliance (Ko-Koordinator) im DZHK** (davon C. Weber, MHA VD1.2)	ca. 3.650 T€
2011-2014	IntenC Grant TUR 10/I13 (mit E. Erbay): Lipotoxic Stress	ca. 150 T€
2012-2015	META JTC 2011: miR-A (mit A. Schober)	ca. 1.000 T€
2017-2019	DZHK HRHV grant (mit E. Lutgens), *TRAF-STOPs*	ca. 630 T€
2019-2023	DZHK-BHF grant (mit J. Erdmann), Molecular genetics	ca. 400 T€
2023-2027	BMBF Spitzencluster C-NAT^{M} (mit S. Engelhardt)	ca. 500 T€

Industriemittel und Stiftungen **ca. 600 T€**

International

2011-2016	**ERC Advanced Investigator Grant °249929 *Atheroprotect***	**2.500 T€**
2011-2016	**NWO VICI Grant 918.10.616**	**1.500 T€**
2011-2016	**Leducq Transatlantic Network of Excellence *CVGeneF(x)***	**5.000 T€**
	(davon Koordinator C. Weber)	ca. 720 T€
2016-2022	**ERC Advanced Investigator Grant °692511 PROVASC**	**2.500 T€**
2017-2019	**NIH** grant 5R01HL122843-03 (mit D. Saleheen), CXCL12 function	ca. 200 T€
2016-2022	**ERC Advanced Investigator Grant °101200321 MONOFUN-CV**	**2.500 T€**

Gesamtvolumen (1997-2025) **> 48 Mio. €**

davon DFG Mittel **> 27 Mio. €**

Klinische Ausbildung und Tätigkeiten

- Facharzt für Innere Medizin mit Schwerpunktbezeichnung Kardiologie, insbesondere Koronare Herzkrankheit und kardiovaskuläre Prävention
- Langjährige Erfahrung in der diagnostischen Herzkatetherisierung einschließlich Herzklappendiagnostik, und Rechtsherz- und Bypasskatheterisierung
- Erfahrung in der Koronarintervention, perkutanen Angioplastie und Stentimplantation
- Mehrjährige Erfahrung in der Angiologie, Hypertonie/Nephrologie- und Stoffwechselambulanz
- Mehrjährige Erfahrung in der transthorakalen/transösophagealen Echocardiographie, Duplex-Dopplersonographie der hirnversorgenden renalen und peripheren Arterien, weiterführende angiologische Diagnostik, z.B. Segmentoszillographie und Extremitätenplethysmographie.
- Leitung einer Kardiovaskulären Präventionsambulanz

Lehrerfahrung

Currrikuläre Lehre und elektive Veranstaltungen in der Humanmedizin (seit 2001)

V1 Vorlesung Innere Medizin: Grundlagen von Atherosklerose und Myokardinfarkt

V2 Vorlesung Medizinische Propädeutik und Pathophysiologie

Ü2 Kolloquium Molekulare Medizin

Ü2 Lectures and Master Classes in Vascular Biology and Medicine

VT1 Vorlesung Molekulare Pathologie (für Biologiestudenten als nicht-biologisches Nebenfach)

S1 Molekulare Mechanismen der Atherogenese und Restenose: Basis für Prävention & Therapie

S1 Ausgewählte Kapitel und Methoden aus der vaskulären Biologie und Pathophysiologie

S1 'Molecular Imaging' und Stammzellbiologie im kardiovaskulären Kontext

S2 Immunologie, Pathobiochemie und Signalübertragung entzündlicher Erkrankungen

Ü12 Anleitung zu selbständigem, wissenschaftlichen Arbeiten (inkl. Promotion)

Methodenseminare und Vorlesung Atheroskleroseforschung im Graduiertenmodul der SFB1123

Studiengang Human Biology – Principles of Health and Disease im Elitenetzwerk Bayern (gemeinsam mit der Fakultät für Biologie)

Beteiligung am Modul Herz- und Kreislauferkrankungen

Beteiligung am/Leitung des Moduls Bioimaging

Lehrkonzept

Die Gesamtheit der Lehre sollte der Prämisse des Strebens nach wissenschaftlicher und fachlicher Exzellenz folgen, sowie mit dem Bewusstsein der humanitären und menschlichen Verpflichtung in Einklang stehen. Ein Lehrvertrag zwischen dem Studierenden und dem Lehrenden sollte die Erwartungen und Anforderungen auch in individualisierter Form definieren und die Basis für eine effective Lehre herstellen. System-bezogene Lehrinhalte können in Vorlesungen strukturiert, in Kleingruppenseminaren und -tutorien intensiviert und in Computer-basierten Modellen und Fall-studien veranschaulicht werden. Die Einführung in den wissenschaftlichen und Evidenz-basierten Goldstandard und deren Anwendung dient nicht nur einer enzyklopädischen Ausbildung, sondern befördert darüber hinaus auch die persönliche Entwicklung gemäß der Ideale der *Universitas*. Neben der intensiven und vielfältigen Betreuung zahlreicher Doktoranden, Postdoktoranden und Habilitanden als Mentor in Einzelgesprächen und Advisory Committees, habe ich mich der erfolg-reichen Karriereplanung zu berufender Professoren (siehe Auflistung) sowie standortübergreifeden Mentoraten von Wissenschaftlern z.B. im Rahmen des DZHK Mentoring-Programms verschrieben.

Betreuung von Doktoranden und Nachwuchswissenschaftlern

Naturwissenschaftliche Doktoranden/innen

- Dr. rer. hum. biol. Wolfgang Erl (‘summa cum laude’, 1996, LMU München)
- Dr. rer. nat. Georg Ostermann (‘summa cum laude’, 2002, LMU München)
- Dr. rer. nat. Line Fraemohs (‘summa cum laude’, 2007, RWTH Aachen)
- Dr. rer. medic. Elisa Liehn, M.Sc. (‘summa cum laude’, 2008, RWTH Aachen)
- Dr. rer. nat. Regina Krohn (‘summa cum laude’, 2008, RWTH Aachen)
- Dr. rer. nat. Svenja Meiler (‘summa cum laude’, 2010, RWTH Aachen)
- Dr. rer. nat. Alisina Sarabi (’magna cum laude’, 2011, RWTH Aachen)
- Dr. rer. nat. Yvonne Döring (’summa cum laude’, 2011, RWTH Aachen)
- Dr. rer. nat. Maik Drechsler (’magna cum laude’, 2011, RWTH Aachen)
- Dr. rer. nat. Sakine Simsekyilmaz (’magna cum laude’, 2012, RWTH Aachen)
- Dr. rer. nat. Sarawuth Wantha (’magna cum laude’, 2013, RWTH Aachen)
- Elena Vasina, PhD (2013, Maastricht University)
- Dr. rer. nat. Martin Schmitt (2014, RWTH Aachen & Maastricht University, PhD)
- Dr. rer. nat. Manuela Mandl (’magna cum laude’, 2017, LMU München)
- Dr. rer. nat. Carlos Neideck (‚summa cum laude‘, 2018, LMU München)
- Dr. rer.nat. Maria Aslani (LMU München, 2021)

Medizinische Doktoranden/innen

- Dr. med. Celina Wardemann (’magna cum laude’, 1998, LMU München)
- Dr. med. Philipp von Hundelshausen (‘summa cum laude’, 2003, LMU München)
- Dr. med. Tobias Weber (‘summa cum laude’, 2004, LMU München)
- Dr. med. Alma Zernecke (‘summa cum laude’, 2004, LMU München)
- Dr. med. Britta Butzbach (’magna cum laude’, 2006, RWTH Aachen)
- Dr. med. Ute Zeiffer (’summa cum laude’, 2008 RWTH Aachen)
- Dr. med. Dipl.-Chem. Thomas Baltus (’summa cum laude’, 2008 RWTH Aachen)
- Dr. med. Yassin Djalali-Talab (’summa cum laude’, 2009, RWTH Aachen)
- Dr. med. Denis Gümbel (‘summa cum laude’, 2010, RWTH Aachen)
- Dr. med. Sebastian Mause (‘summa cum laude’, 2011, RWTH Aachen)
- Dr. med. Veit Eckart (‘summa cum laude‘, 2020, LMU München)
- Dr.. med. Julian Leberzammer (‘summa cum laude‘, 2023, LMU München)
-

Nachwuchswissenschaftler/Postdoktoranden

- Dr. rer. nat. Jiri Neuzil
- Dr. rer. nat. Kiril Bidzhekov
- Dr. rer. nat. Heidi Noels
- Dr. Remco Megens, PhD
- Dr. rer. nat. Xavier Blanchet
- Dr. rer. nat. Yvonne Döring
- Dr. Emiel van der Vorst, PhD
- Dr. med. Chimge Günther
- Dr. med. Felix Vogt
- Dr. rer. nat. Otilia Postea
- Dr. med. Zuzanna Rowinska
- Dr. rer. nat. Johan Duchene
- Dr. rer. nat. Virginia Egea
- Dr. med. Donato Santovito

Habilitationen

- PD Dr. med. Andreas Schober
- PD Dr. med. Alma Zernecke
- PD Dr. ing. Rory Koenen
- PD Dr. med. Oliver Soehnlein, PhD
- PD Dr. med. Michael Hristov
- PD Dr. med. Elisa Liehn
- PD Dr. Philipp von Hundelshausen

Professuren

- Prof. Dr. Andreas Schober (W2, Aachen & LMU)
- Prof. Dr. Alma Zernecke (W3, Würzburg)
- Prof. Dr. Esther Lutgens (AMC Amsterdam)
- Prof. Dr. Oliver Söhnlein (W2, LMU)
- Prof. Dr. Norbert Gerdes (W2, Düsseldorf)
- Prof. Dr. Yvonne Döring (W2, Bern)
- Prof. Dr. Oliver Söhnlein (W3, Münster)
- Prof. Dr. Donato Santovito (W2, LMU)

Bibliographie (ORCID 0000-0003-4610-8714, WoS ID AAW-2153-2020)

10 wichtigste Originalarbeiten (Zitationen *GoogleScholar*)

1. Mohanta SK, Peng L, Li Y, Yin C, Lu S, Sun T, Carnevale L, Perrotta M, Ma Z, Förstera B, Stanic K, … **Weber C***, Lembo G*, Carnevale D*, Habenicht AJR*. Neuroimmune cardiovascular interfaces control atherosclerosis. ***Nature*** 2022;605:152-159. *equal contribution. *(198 citations)*
2. Santovito D, Egea V, Bidzhekov K, Natarelli L, Mourão A, Wichapong K, Blanchet X, Aslani M, Horckmans M, Hristov M, Lutgens E, Daemen MJAP, Hackeng T, Ries C, von Hundelshausen P, Steffens S, Duchene J, Megens RTA, Sattler M, **Weber C**. Non-canonical inhibition of caspase-3 by a nuclear microRNA confers endothelial protection by autophagy in atherosclerosis. ***Sci. Transl. Med.*** 2020;12:eaaz2994 (*133 Zitationen*).
3. von Hundelshausen P, Agten S, Eckardt V, Schmitt MMW, Blanchet X, Ippel H, Neideck C, Bidzhekov K, Wichapong K, Faussner A, Drechsler M, Grommes J, van Geffen J, Li H, Leberzammer J, Naumann R, Dijkgraf I, Nicolaes G, Döring Y, Soehnlein O, Lutgens E, Heemskerk J, Koenen R, Mayo K, Hackeng T, **Weber C**. Chemokine interactome mapping enables tailored intervention in acute and chronic inflammation. ***Sci Transl Med*** 2017;9:eaah6650 (*161 Zitationen*).
4. Schober A, Nazari-Jahantigh M, Wei Y, Bidzhekov K, Gremse F, Grommes J, Megens RTA, Heyll K, Noels H, Hristov M, Wang S, Kiessling F, Olson EN, **Weber C**. MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. ***Nat Med*** 2014;20:368-376 (*727 Zitationen*).
5. Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B, Hristov M, Köppel T, Nazari-Jahantigh M, Lutgens E, Wang S, Olson E, Schober A, **Weber C**. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. ***Sci Signal*** 2009;2:ra81 (*1663 Zitationen*).
6. Koenen RR, von Hundelshausen P, Nesmelova IV, Zernecke A, Liehn EA, Sarabi A, Kramp BK, Piccinini A, Kowalska A, Kungl AJ, Hackeng TM, Mayo KH, **Weber C**. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. ***Nat Med*** 2009;15:97-103 (*521 Zitationen*).
7. Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, Koenen RR, Dewor M, Georgiev I, Schober A, Leng L, Kooistra T, Fingerle-Rowson G, Ghezzi P, Kleemann R, McColl SR, Bucala R, Hickey MJ, **Weber C**. MIF is a non-cognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. ***Nat Med*** 2007;13:587-596 (*1547 Zitationen*).
8. Huo YQ, Schober A, Forlow SB, Smith D, Hyman M, Jung S, Littman DR, **Weber C**, Ley K. Circulating activated platelets exacerbate atherosclerosis in apolipoprotein E deficient mice. ***Nat Med*** 2003;9:61-67 (*1330 Zitationen*).
9. Ostermann G, Weber KSC, Zernecke A, Schröder A, **Weber C**. JAM-1 is a ligand for the β2 integrin LFA-1 involved in transendothelial migration of leukocytes. ***Nat Immunol*** 2002;3:151-158 (*850 Zitationen*).
10. von Hundelshausen P, Weber KSC, Huo YQ, Proudfoot A, Nelson PJ, Ley K, **Weber C**. Deposition of RANTES by platelets triggers monocyte recruitment on inflamed and atherosclerotic endothelium. ***Circulation*** 2001;103:1772-1777 (*774 Zitationen*).

Bibliometrische Parameter (Stand 10/2025)

Kumulativer Impact-Faktor (IF, 728 Original- und Übersichtsarbeiten)	6613.3
Kumulativer IF (Originalia bis #444)	4305.6
Kumulativer IF (126 Originalia als Erst- oder Letztautor)	1383.1
Kumulativer IF (Übersichtsarbeiten und Kommentare bis #284)	2307.6
Durchschnittlicher IF pro Originalarbeit	9.7
Durchschnittlicher IF pro Originalarbeit (Erst- oder Letztautor)	10.9
Gesamtzitationen seit 1996 (*Scopus*)	61.450
Gesamtzitationen (*Clarivate: InCites, Web of Science*)	59.119
Gesamtzitationen (*GoogleScholar*)	92.621
Zitationen p.a. 2020-2024 (*Scopus*)	3634-4579
Zitationen p.a. 2020-2024 (*GoogleScholar*)	5546-6772
h-Index/m-Index *Scopus*	**133 / 4.0**
h-Index Clarivate: *InCites, WoS*	**131**
h-Index *GoogleScholar* (seit 2020)	**161 (97)**
c-Index (doi: 10.17632/btchxktzyw.5)	**4.29**
c-index Rang (aller *Scopus* Autorenprofile)	**#2903**

Publikationen in *NEJM, Nature*-, *Science*- and *Cell* / *Immunity*-Familien (n=52)

1. El Bounkari O et al. & **Weber C**, Kapurniotu A, Bernhagen J (2025) An atypical atherogenic chemokine that promotes advanced atherosclerosis and hepatic lipogenesis. ***Nat. Commun.*** 16:2297.
2. Yaw A et al. & **Weber C**, Bernhagen J, Dichgans M (2025) A cis-regulatory element controls *HDAC9* expression to fine-tune inflammasome-dependent chronic inflammation. ***Immunity*** 58:555-567.e9.
3. Döring Y, van der Vorst EPC, **Weber C** (2024) Targeting immune cell recruitment in atherosclerosis. ***Nat. Rev. Cardiol.*** 21:824-840.
4. Döring Y et al. & **Weber C** (2024) Identification of a non-canonical chemokine-receptor pathway suppressing regulatory T cells to drive atherosclerosis. ***Nat. Cardiovasc. Res.*** 3:221-242.
5. Cimen I et al. & Santovito D, **Weber C** (2023) Targeting a cell-specific microRNA repressor of CXCR4 ameliorates atherosclerosis in mice. ***Sci. Transl. Med.*** 15:eadf3357.
6. Pekayvaz KA et al. & **Weber C**, … , Stark K (2023) Mural cell-derived chemokines provide a protective niche to safeguard vascular macrophages and limit chronic inflammation. ***Immunity*** 56:2325-41. ***(IF 32.4)***
7. Wagner JUG et al., **Weber C**, et al. & Zeiher AM, Brandes RP, Luxán G, Dimmeler S (2023) Ageing impairs the neurovascular interface in the heart. ***Science*** 381:897-906.
8. Wang Z et al. & **Weber C**, Habenicht A, Yin C (2023) Pairing of scRNA analysis & T-cell receptor profiling reveals breakdown of T-cell tolerance checkpoints in atherosclerosis. ***Nat. Cardiovasc. Res.*** 2:290-306.
9. Guillamat-Prats R et al. & **Weber C**, … , Hilgendorf I, Steffens S (2022) GPR55 in B cells limits atherosclerosis development and regulates plasma cell maturation. ***Nat. Cardiovasc. Res.*** 1:1056-1071.
10. Tas K et al. & **Weber C**, Megens RT, Bernhagen J, Kapurniotu A (2022) Designed peptides as nanomolar cross-amyloid inhibitors acting via supramolecular nanofiber co-assembly. ***Nat. Commun.*** 13:5004.
11. Santovito D, **Weber C** (2022) Noncanonical features of microRNAs: paradigms emerging from cardiovascular disease. ***Nat. Rev. Cardiol.*** 19:620-638.
12. Rot A et al. & **Weber C**, Duchene J (2022) Murine bone marrow macrophages and human monocytes do not express atypical chemokine receptor 1. ***Cell Stem Cell*** 29:1013-1015.
13. Mohanta SK et al. &, **Weber C***, Lembo G*, Carnevale D*, Habenicht AJR* (2022) Neuroimmune cardiovascular interfaces control atherosclerosis. ***Nature*** 605:152-159. *equal contribution.
14. **Weber C**, Siess W, von Hundelshausen P (2021) VITT after ChAdOx1 nCOV-19 vaccination. ***N. Engl. J Med.*** 385:2202-2205.
15. Lacy M et al. & **Weber C**, Gerdes N, Atzler D, Lutgens E (2021) Cell-specific and divergent roles of the CD40L-CD40 axis in atherosclerotic vascular disease. ***Nat. Commun.*** 12:3754.
16. Kontos C et al. & **Weber C**, Kapurniotu A, Bernhagen J (2020) An engineered soluble chemokine receptor that blocks atherogenic inflammation by agonist-specific targeting. ***Nat. Commun.*** 11:5981.
17. Bartelt A, **Weber C** (2020) Mitochondrial ejection for cardiac protection: the macrophage connection. ***Cell Metabol.*** 32:512-513.
18. Santovito D et al. & **Weber C** (2020) Non-canonical inhibition of caspase-3 by a nuclear microRNA confers endothelial protection by autophagy in atherosclerosis. ***Sci. Transl. Med.*** 12:eaaz2994.
19. Adrover JM et al. & **Weber C**, Torres A, Ruiz-Cabello J, Vázquez J, Hidalgo A (2020) Programmed “disarming” of the neutrophil proteome reduces the magnitude of inflammation. ***Nat. Immunol.*** 21:135-44.
20. Bianchini M, Duchêne J* et al. & **Weber C***, Megens RTA (2019) PD-L1 on non-classical monocytes reveals their origin and immuno-regulatory function. ***Sci. Immunol.*** 4:eaar3054. *corresponding author.
21. Silvestre-Roig C, Braster Q et al. & **Weber C**, Hidalgo A, Wong G, Nicolaes G, Soehnlein O (2019) Externalized histone H4 orchestrates chronic inflammation by inducing lytic cell death. ***Nature*** 569:236-240.
22. Yin C et al. & **Weber C***, Zipfel PF*, Skerka C*, Habenicht AJR* (2019) ApoE attenuates unresolvable inflammation by complex formation with activated C1q. ***Nat. Med.*** 25:496-506. *equal contribution.
23. Adrover JM et al. & **Weber C**, Ng LG, Lopez-Rodriguez C, Sancho D, Moro MA, Ibáñez B, Hidalgo A (2019) A neutrophil clock coordinates immune defense and vascular protection. ***Immunity*** 50:390-402.
24. Braza MS et al. & **Weber C**, Swirski FK, Nahrendorf M, Fisher EA, Duivenvoorden R, Fayad ZA, Netea MG, Mulder WMJ, Ochando J (2018) Inhibiting inflammation with myeloid cell-specific nanobiologics promotes organ transplant acceptance. ***Immunity*** 49:819-828.
25. Winter C et al. & **Weber C**, Viola JR, Hidalgo A, Scheiermann C, Soehnlein O (2018) Chronopharmacological targeting of the CCL2-CCR2 axis ameliorates atherosclerosis. ***Cell Metab.*** 28:175-182.

26. Soehnlein O, Steffens S, Hidalgo A, **Weber C** (2017) Neutrophils in immunity and immunopathology – protagonists and targets of chronic inflammation. ***Nat. Rev. Immunol.*** 17:248-261.

27. Krishnasamy K et al. & **Weber C**, Adams RH, Limbourg FP (2017) Blood vessel control of macrophage maturation promotes arteriogenesis in ischemia. ***Nat. Commun.*** 8:952.

28. Duchene J et al. & **Weber C***, Rot A* (2017) Atypical chemokine receptor 1 on nucleated erythroid cells regulates haematopoiesis. ***Nat. Immunol.*** 18:753-761. *corresponding authors.

29. von Hundelshausen P et al. & **Weber C** (2017) Chemokine interactome mapping enables tailored intervention in acute and chronic inflammation. ***Sci. Transl. Med.*** 9:eaah6650.

30. Gamrekelashvili J et al. & **Weber C**, Limbourg FP (2016) Regulation of monocyte cell fate by blood vessels. ***Nat. Commun.*** 7:12597.

31. Hartmann P et al. & **Weber C**, Schober A (2016) Endothelial Dicer promotes atherosclerosis and vascular inflammation by miRNA-103-mediated suppression of KLF4. ***Nat. Commun.*** 7:10521.

32. Finan B et al. & **Weber C**, Rozman J, Fuchs S, Gailus-Durner V, Hrabě de Angelis M, Hoffman SM, Gelfanov V, Yang B, Tschöp MH, DiMarchi R, Müller TD (2016) Chemical hybridization of glucagon and thyroid hormone optimizes therapeutic impact for metabolic disease. ***Cell*** 167:843-857.

33. Schober A, Nazari-Jahantigh M, **Weber C** (2015) Mechanisms of microRNAs in atherosclerosis. ***Nat. Rev. Cardiol.*** 12:361-374.

34. Alard JE et al. & **Weber C**, Soehnlein O (2015) Recruitment of classical monocytes can be inhibited by disturbing heteromers of neutrophil HNP1 and platelet CCL5. ***Sci. Transl. Med.*** 7:317ra196.

35. Hu D et al. & **Weber C**, Lehmann T, Beer M, Grabner R, Maffia P, Weih F, Habenicht AJR (2015) ATLOs control aortic immunity and protect against atherosclerosis via VSMC-LTβ receptors. ***Immunity*** 42:1100-15. (***IF 24.082***)

36. Hinkel R et al. & **Weber C**, Bock-Marquette I, Olson EN, Posern G, Deindl E, Niemann H, Kupatt C (2014) MRTF-A mediates vessel growth and maturation via CCN1 and CCN2. ***Nat. Commun.*** 5:3970.

37. Schober A et al. & **Weber C** (2014) MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. ***Nat. Med.*** 20:368-376.

38. Casanova-Acebes M et al. & **Weber C**, Nagasawa T, Frenette PS, Castrillo A, Hidalgo A (2013) Rhythmic modulation of the hematopoietic niche through neutrophil clearance. ***Cell*** 153:1025–1035

39. **Weber C**, Noels H (2011) Atherosclerosis: current pathogenesis and therapeutic options. ***Nat. Med.*** 17:1410-1422

40. Zhou Z et al. & **Weber C**, Schober A (2011) Lipoprotein-derived lysophosphatidic acid enhances atherosclerosis through the release of CXCL1 from endothelium. ***Cell Metab.*** 13:592-600.

41. Soehnlein O et al. & **Weber C** (2011) Neutrophil-derived cathelicidin protects from neointimal hyperplasia. ***Sci. Transl. Med.*** 3:103ra98.

42. **Weber C** (2010) Far from the heart: receptor cross-talk in remote conditioning. ***Nat. Med.*** 16:760-762

43. Goossens P et al. & **Weber C**, Lutgens E, de Winther MP (2010) Myeloid type I interferon signaling promotes atherosclerosis by stimulating macrophage recruitment to lesions. ***Cell Metab.*** 12:142-153.

44. Koenen RR, **Weber C** (2010) Therapeutic targeting of chemokine interactions in atherosclerosis. ***Nat. Rev. Drug Discov.*** 9:141-53.

45. Zernecke A et al. & **Weber C** (2009) Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. ***Sci. Signal.*** 2:ra81.

46. Koenen RR et al. & **Weber C** (2009) Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. ***Nat. Med.*** 15:97-103.

47. Choi EY et al. & **Weber C**, Chavakis T (2008) Del-1 is an endogenous inhibitor of leukocyte-endothelial adhesion preventing inflammatory cell recruitment. ***Science*** 322:1101-4.

48. **Weber C**, Zernecke A, Libby P (2008) The multifacetted contributions of leukocyte subsets to atherosclerosis. ***Nat. Rev. Immunol.*** 8:802-815.

49. Bernhagen J et al. & **Weber C** (2007) MIF is a non-cognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. ***Nat. Med.*** 13:587-596.

50. **Weber C**, Fraemohs L, Dejana E (2007) The role of junctional adhesion molecules in vascular inflammation. ***Nat. Rev. Immunol.*** 7:467-477.

51. Huo YQ et al. & **Weber C**, Ley K (2003) Circulating activated platelets exacerbate atherosclerosis in apolipoprotein E deficient mice. ***Nat. Med.*** 9:61-67.

52. Ostermann G, Weber KSC, Zernecke A, Schröder A, **Weber C** (2002) JAM-1 is a ligand for the β2 integrin LFA-1 involved in transendothelial migration of leukocytes. ***Nat. Immunol.*** 3:151-158.

Originalarbeiten (IF im Publikationsjahr, ° Clarivate Top 1% im Fachgebiet)

1991-1994 (IF 38.2)

1. **Weber C**, Aepfelbacher M, Lux I, Zimmer B, Weber PC (1991) Docosahexaenoic acid inhibits PAF and LTD_4 stimulated $[Ca^{2+}]_i$-increase in differentiated monocytic U937 cells. ***Biochim. Biophys. Acta.*** 1133:38-45. ***(IF 4.160***)
2. Ziegler-Heitbrock HWL, Käfferlein E, Haas JG, Meyer N, Ströbel M, **Weber C**, Flieger D (1992) Gangliosides suppress tumor necrosis factor production in human monocytes. ***J. Immunol.*** 148:1753-58. ***(IF 6.937)***
3. **Weber C**, Aepfelbacher M, Haag H, Ziegler-Heitbrock HWL, Weber PC (1993) Tumor necrosis factor induces enhanced responses to platelet activating factor and differentiation in human monocytic Mono Mac 6 cells. ***Eur. J. Immunol.*** 23:852-859. ***(IF 5.256)***
4. **Weber C**, Kruse HJ, Sellmayer A, Erl W, Weber PC (1993) Platelet activating factor enhances receptor-operated Ca^{2+}-influx and subsequent prostacyclin-synthesis in human endothelial cells. ***Biochem. Biophys. Res. Commun.*** 195:874-880. ***(IF 2.671)***
5. Ziegler-Heitbrock HWL, Sternsdorf, Liese J, Belohradsky B, **Weber C**, Wedel A, Schreck R, Baeuerle P, Ströbel M (1993) Pyrrolidine-dithiocarbamate inhibits NF-κB mobilization and TNF production in human monocytes. ***J. Immunol.*** 151:6986-6993. ***(IF 6.937)***
6. Sellmayer A, Goeßl C, Obermeier H, Volk R, Reeder E, **Weber C**, Weber PC (1994) Differential expression of eicosanoid synthesis in monocytic cells treated with retinoic acid and 1,25-dihydroxy-vitamin D_3. ***Prostaglandins.*** 47:203-220. ***(IF 0.837)***
7. Ziegler-Heitbrock HWL, Schraut W, Wendelgaß P, Ströbel M, Sternsdorf T, **Weber C**, Aepfelbacher M, Haas JG (1994) Distinct patterns of differentiation induced in the monocytic cell line Mono Mac 6. ***J. Leukoc. Biol.*** 55:73-80. (***IF 3.906)***
8. **Weber C**, Erl W, Pietsch A, Ströbel M, Ziegler-Heitbrock HWL, Weber PC (1994) Antioxidants inhibit monocyte adhesion by suppressing nuclear factor-κB mobilization and induction of vascular cell adhesion molecule 1 in endothelial cells stimulated to generate radicals. ***Arterioscler. Thromb. Vasc. Biol.*** 14:1665-1673. (***IF 5.317,*** *402 citations)*
9. Haag H, Grünberg B, **Weber C**, Vauti F, Aepfelbacher M, Siess W (1994) Lovastatin inhibits receptor-stimulated Ca^{2+}-influx of retinoic acid differentiated U937 and HL-60 cells. ***Cell. Signal.*** 7:735-742. (***IF 2.174)***

1995 (IF 33.2)

10. **Weber C**, Erl W, Weber PC (1995) Enhancement of monocyte adhesion to endothelial cells by modified low density lipoprotein is mediated via activation of CD11b. ***Biochem. Biophys. Res. Commun.*** 206:621-628. (***IF 2.671)***
11. **Weber C**, Calzada-Wack JC, Goretzki M, Pietsch A, Johnson JP, Ziegler-Heitbrock HWL (1995) Retinoic acid inhibits basal and interferon-γ induced expression of intercellular adhesion molecule 1 in monocytic cells. ***J. Leukoc. Biol.*** 57:401-406. (***IF 3.906)***
12. Erl W, **Weber C**, Wardemann C, Weber PC (1995) Adhesion properties of Mono Mac 6, a monocytic cell line with characteristics of mature human monocytes. ***Atherosclerosis*** 113:99-107. (***IF 2.889***)
13. **Weber C**, Erl W, Pietsch A, Weber PC (1995) Aspirin inhibits NF-κB mobilization and monocyte adhesion in stimulated human endothelial cells. ***Circulation.*** 91:1914-1917. (***IF 9.762,*** *346 citations)*
14. **Weber C**, Erl W, Pietsch A, Danesch U, Weber PC (1995) Docosahexaenoic acid selectively attenuates induction of vascular cell adhesion molecule 1 and subsequent monocytic cell adhesion to human endothelial cells stimulated by tumor necrosis factor-α. ***Arterioscler. Thromb. Vasc. Biol.*** 15:622-628. (***IF 5.317)***
15. **Weber C**, Negrescu E, Erl W, Pietsch A, Frankenberger M, Ziegler-Heitbrock HWL, Siess W, Weber PC (1995) Inhibitors of protein tyrosine kinase suppress TNF-stimulated induction of endothelial cell adhesion molecules. ***J. Immunol.*** 155:445-451. (***IF 6.937)***
16. Pietsch A, **Weber C**, Goretzki M, Weber PC, Lorenz RL (1995) N-3 but not n-6 fatty acids reduce the expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells. ***Cell Biochem. Funct.*** 13:211-216. (***IF 0.882)***
17. **Weber C**, Erl W, Weber PC (1995) Lovastatin induces differentiation of Mono Mac 6 cells. ***Cell Biochem. Funct.*** 13:273-277. (***IF 0.882)***

1996 (IF 30.8)

18. **Weber C**, Erl W, Weber K, Weber PC (1996) Increased adhesiveness of isolated monocytes to en-dothelium is prevented by vitamin C intake in smokers. ***Circulation*** 93:1488-492. (***IF 9.762****)*

19. **Weber C**, Alon R, Moser B, Springer TA (1996) Sequential regulation of $\alpha 4\beta 1$ and $\alpha 5\beta 1$ integrin avidity by CC chemokines in monocytes: Implications for transendothelial chemotaxis. ***J. Cell Biol.*** 134:1063-1073. (***IF 12.005,*** *292 citations)*

20. **Weber C**, Kitayama J, Springer TA (1996) Differential regulation of $\beta 1$ and $\beta 2$ integrin avidity by chemo-attractants in eosinophils. ***Proc. Natl. Acad. Sci. USA.*** 93:10939-944. (***IF 9.040****)*

1997 (IF 34.7)

21. Sellmayer A, Obermeier H, **Weber C** (1997) Intrinsic cyclooxygenase activity is not required for monocytic differentiation of U937 cells. ***Cell. Signal.*** 9:91-96. (***IF 2.174****)*

22. Erl W, **Weber C**, Wardemann C, Weber PC (1997) α-Tocopheryl succinate inhibits monocytic cell adhesion to endothelial cells by suppressing NF-κB mobilization and adhesion molecule expression. ***Am. J. Physiol.*** 273: H634-H640. (***IF 3.116****)*

23. **Weber C**, Lu CF, Casasnovas JM, Springer TA (1997) Role of $\alpha L\beta 2$ integrin avidity in transendothelial chemotaxis of mononuclear cells. ***J. Immunol.*** 159:3968-3975. (***IF 6.937****)*

24. Kupatt C, **Weber C**, Wolf DA, Becker BF, Smith TW, Kelly RA (1997) Nitric oxide attenuates reoxygenation-induced ICAM-1 expression in coronary microvascular endothelium: role of NF-κB. ***J. Mol. Cell. Cardiol.*** 29:2599-2609. ***(IF 3.255****)*

25. **Weber C**, Springer TA (1997) Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to $\alpha IIb\beta 3$ and stimulated by platelet activating factor. ***J. Clin. Invest.*** 100:2085-2093. ***(IF 9.667,*** *424 citations)*

26.° **Weber C**, Erl W, Weber KSC, Weber PC (1997) HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from hypercholesterolemic patients. ***J. Am. Coll. Cardiol.*** 30:1212-1217 (comment in *J. Am. Coll. Cardiol.* 30:1218). ***(IF 6.704,*** *557 citations)*

27. Kupatt C, Habazettl H, Zahler S, **Weber C**, Becker BF, Messmer K, Gerlach E (1997) ACE inhibition prevents leukocyte-dependent reperfusion injury by reducing coronary leukocyte adhesion. ***Cardiovasc. Res.*** 36:386-395. (***IF 2.885****)*

1998 (IF 20.9)

28. Piali L, **Weber C**, La Rosa G, Mackay CR, Springer TA, Clark-Lewis I, Moser B (1998) The chemokine receptor CXCR3 mediates rapid and shear-resistant adhesion-induction of effector T lymphocytes by the chemokines IP10 and Mig. ***Eur. J. Immunol.*** 28:961-972. ***(IF 5.438****)*

29. Erl W, Weber PC, **Weber C** (1998) Monocytic cell adhesion to endothelial cells stimulated by oxidized low density lipoprotein is mediated by distinct endothelial ligands. ***Atherosclerosis.*** 136:297-303. ***(IF 2.885****)*

30. Weber KSC, Klickstein L, Weber PC, **Weber C** (1998) Chemokine-induced monocyte transmigration requires cdc42-mediated cytoskeletal changes. ***Eur. J. Immunol.*** 28:2245-2251. ***(IF 5.438****)*

31. **Weber C**, Springer TA (1998) Interaction of VLA-4 with VCAM-1 supports transendothelial che-motaxis of monocytes by facilitating lateral migration. ***J. Immunol.*** 161:6825-834. ***(IF 7.166****)*

1999 (IF 56.9)

32. Neuzil J, Sorensen I, Weber T, **Weber C**, Brunk U (1999) Tocopheryl succinate-induced apoptosis of Jurkat T cells involves caspase-3 activation, and both lysosomal and mitochondrial destabilisation. ***FEBS Lett.*** 445:295-300. ***(IF 3.720****)*

33. Weber KSC, von Hundelshausen P, Weber PC, Clark-Lewis I, **Weber C** (1999) Differential immobilization of chemokines and hierarchical involvement of their receptors in monocyte arrest and transmigration on inflammatory endothelium. ***Eur. J. Immunol.*** 29:700-12. ***(IF 5.635****)*

34. Draude G, von Hundelshausen P, Frankenberger M, Ziegler-Heitbrock HWL, **Weber C** (1999) Distinct sca-venger receptor expression and function in the $CD14^+CD16^+$ human blood monocyte subsets. ***Am. J. Physiol.*** 276:H1144-H1149. ***(IF 2.747****)*

35. Erl W, Hansson GK, de Martin R, Draude G, Weber KSC, **Weber C** (1999) Nuclear factor-κB regulates apoptosis and inhibitor of apoptosis protein-1 expression in vascular smooth muscle cells. ***Circ. Res.*** 84:668-677. ***(IF 8.281)***

36. Weber KSC, Klickstein LB, **Weber C** (1999) Specific activation of the β2 integrins Mac-1 and LFA-1 by chemokines in mononuclear cells mediated by distinct activation pathways via the α subunit cytoplasmic domains. ***Mol. Biol. Cell.*** 10:861-873. ***(IF 7.527)***

37. Weber KSC, Draude G, Erl W, de Martin R, **Weber C** (1999) Monocyte arrest and transmigration on inflamed endothelium in shear flow is inhibited by adenoviral gene transfer of IκB-α. ***Blood*** 93:3685-3693. ***(IF 8.782)***

38. **Weber C**, Draude G, Weber KSC, Wübert J, Lorenz R, Weber PC (1999) Downregulation by tumor necrosis factor-α of monocyte CCR2 expression and MCP-1-induced transendothelial chemotaxis is antagonized by oxidized LDL: a potential mechanism of monocyte retention in atherosclerotic lesions. ***Atherosclerosis*** 145:115-123. ***(IF 2.877)***

39. Gröne HJ, **Weber C**, Weber KS, Gröne EF, Rabelink J, Klier C, Wells TN, Proudfoot A, Schlöndorff D, Nelson PJ (1999) MetRANTES reduces vascular and tubular damage during acute vascular rejection: blocking monocyte arrest and recruitment. ***FASEB J.*** 13:1371-1383. ***(IF 11.880)***

40. Weber KSC, Nelson PJ, Gröne HJ, **Weber C** (1999) Expression of CCR2 by endothelial cells: implications for MCP-1-mediated wound injury repair and in vivo inflammatory activation of endothelium. ***Arterioscler. Thromb. Vasc. Biol.*** 19:2085-2093. ***(IF 5.406,*** *338 citations)*

2000 (IF 8.4)

41. **Weber C**, Belge KU, von Hundelshausen P, Draude G, Steppich B, Mack M, Frankenberger M, Weber KSC, Ziegler-Heitbrock HWL (2000) Differential chemokine receptor expression and function in human monocyte subpopulations. ***J. Leukoc. Biol.*** 67:699-704. ***(IF 4.342,*** *507 citations)*

42. Erl W, **Weber C**, Hansson GK (2000) Susceptibility to apoptosis induced by pyrrolidine dithiocarbamate is dependent on cell type, density and copper/zinc ions. ***Am. J. Physiol. Cell Physiol.*** 278:C1116-1125. ***(IF 4.086)***

2001 (IF 102.1)

43. Neuzil J, Weber T, Gellert N, **Weber C** (2001) Selective cancer cell killing by α-tocopheryl succinate. ***Brit. J. Cancer*** 84:87-89. ***(IF 3.942)***

44. Neuzil J, Weber T, Schröder A, Lu M, Olejnicka B, Ostermann G, Gellert N, Mayne GC, Negre-Salvayre A, Sticha M, Coffey RJ, **Weber C** (2001) Induction of cancer cell apoptosis by α-tocopheryl succinate: molecular pathways and structural requirements. ***FASEB J.*** 15:403-15. ***(IF 8.817)***

45. **Weber C**, Weber KSC, Klier C, Gu H, Horuk R, Wank R, Nelson PJ (2001) Specialized roles of the chemokine receptors CCR1 and CCR5 in recruitment of monocytes and Th1-like/CD45RO$^+$ T cells. ***Blood*** 97:1144-1146 (comment in *Blood* 97:833). ***(IF 9.273)***

46. Horuk R, Clayberger C, Krensky AM, Wang Z, Gröne HJ, **Weber C**, et al. (2001) A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection. ***J. Biol. Chem.*** 276:4199-4204. ***(IF 7.258)***

47.° von Hundelshausen P, Weber KSC, Huo YQ, Proudfoot A, Nelson PJ, Ley K, **Weber C** (2001) Deposition of RANTES by platelets triggers monocyte recruitment on inflamed and atherosclerotic endothelium. ***Circulation*** 103:1772-1777 (comment in *Circulation* 103:1718). ***(IF 10.517,*** *728 citations)*

48. Neuzil J, Schröder A, von Hundelshausen P, Zernecke A, Weber T, Gellert N, **Weber C** (2001) Inhibition of endothelial inflammatory responses by subapoptotic caspase activation and p65 cleavage. ***Biochemistry*** 40:4686-4692. ***(IF 4.441)***

49. Zernecke A, Weber KSC, Erwig LP, Kluth DC, Schröppel B, Rees A, **Weber C** (2001) Combinatorial model of chemokine involvement in glomerular monocyte recruitment: role of CXCR2 in infiltration during nephrotoxic nephritis. ***J. Immunol.*** 166:5755-5762. ***(IF 7.065)***

50. **Weber C**, von Stülpnagel C, Weber KSC, Hengel H, Weber PC (2001) Association of myocardial infarction with mononuclear cell expression of the CMV chemokine receptor US28 in NIDDM patients. ***Exp. Clin. Cardiol.*** 6:105-108. ***(IF 0.756)***

51. Haritoglou C, Müller-Schunk S, **Weber C**, Hoffmann U, Ulbig MW (2001) Central retinal artery occlusion in association with an aneurysm of the internal carotid artery. ***Am. J. Ophthalmol.*** 132:270-271. ***(IF 1.828)***

52. Weber KSC, Nelson P, Röcken H, Klier C, Gu H, Proudfoot A, Wank R, **Weber C** (2001) Selective recruitment of Th2-type cells and evasion from a cytotoxic immune response mediated by viral MIP-II. ***Eur. J. Immunol.*** 31:2458-2466. *(**IF 5.103***)

53. Alleva R, Tomaselli M, Gellert N, **Weber C**, Murphy MP, Neuzil J (2001) Coenzyme Q blocks biochemical but not receptor-mediated apoptosis by increasing mitochondrial antioxidant protection. ***FEBS Lett.*** 503:46-50. *(**IF 3.644**)*

54. Erl W, Weber KSC, Weber PC, **Weber C** (2001) Transient increase in monocyte adhesion to endothelium by a single dose of simvastatin. ***Atherosclerosis*** 158:491-493. (***IF 3.469***)

55. **Weber C**, Tato F, Brandl T, Kellner W, Hoffmann U (2001) Adult moyamoya disease with peripheral artery involvement. ***J. Vasc. Surgery*** 34: 943-946. *(**IF 3.145**)*

56. Weber KSC, Ostermann G, Zernecke A, Schröder A, Klickstein LB, **Weber C** (2001) Dual role of H-ras in regulation of LFA-1 activity by SDF-1α: implications for leukocyte transmigration. ***Mol. Biol. Cell*** 12:3074-3086. *(**IF 7.700**)*

57. Huo YQ, **Weber C**, Forlow SB, Sperandio M, Thatte J, Mack M, Jung S, Littman DR, Ley K (2001) The chemokine KC but not MCP-1 triggers arrest of monocytes in carotid arteries with early atherosclerotic lesions. ***J. Clin. Invest.*** 108:1307-14 (see also *J. Clin. Invest.* 108:1269). *(**IF 14.118,** 344 citations)*

58. Zernecke A, Weber KSC, **Weber C** (2001) Combined modulation of the mesangial machinery for monocyte recruitment by inhibition of NF-κB. ***Am. J. Physiol. Cell Physiol.*** 188:C1881-88. *(**IF 3.896**)*

59. Weber KSC*, **Weber C***, Ostermann G, Nagel W, Dierks H, Kolanus W (2001) Cytohesin-1 is a dynamic regulator of distinct LFA-1 functions in arrest and transmigration triggered by chemokines during leukocyte recruitment. ***Curr. Biol***. 11:1969-1974. *equal contribution. *(**IF 7.460**)*

2002 (IF 56.5)

60. Jostarndt K, Gellert N, Rubic T, **Weber C**, Kühn H, Johansen B, Hrboticky N, Neuzil J (2002) Dissociation of apoptosis induction and CD36 upregulation by enzymatically modified LDL in monocytic cells. ***Biochem. Biophys. Res. Commun.*** 290:988-993. *(**IF 2.935**)*

61.° Ostermann G, Weber KSC, Zernecke A, Schröder A, **Weber C** (2002) JAM-1 is a ligand for the β2 integrin LFA-1 involved in transendothelial migration of leukocytes. ***Nat. Immunol.*** 3:151-158 (comment in *Nat. Immunol.* 3:116). *(**IF 27.868,** 796 citations)*

62. Neuzil J, Zhao M, Ostermann G, Kagedal K, Sticha M, Gellert M, **Weber C**, Eaton J, Brunk UT (2002) α-Tocopheryl succinate, an agent with in vivo anti-tumour activity induces apoptosis by causing lysosomal instability. ***Biochem. J.*** 362:709-715. *(**IF 4.589**)*

63. Mack M, Pfirstinger J, **Weber C**, Weber KSC, Nelson PJ, Rupp T, Maletz K, Brühl H, Schlöndorff D (2002) Chondroitin sulfate A released from platelets blocks RANTES presentation and RANTES-dependent firm adhesion of leukocytes. ***Eur. J. Immunol.*** 32:1012-20. *(**IF 4.832**)*

64. Weber T, Lu M, Andera L, Lahm H, Gellert N, Fariss MW, Korinek V, Sattler W, Ucker DS, Terman A, Schröder A, Erl W, Brunk U, Coffey RJ, **Weber C**, Neuzil J (2002) Vitamin E succinate is a potent novel anti-neoplastic agent with high selectivity and cooperativity with tumor necrosis factor-related apoptosis inducing ligand *in vivo*. ***Clin. Cancer Res.*** 8:863-869. *(**IF 5.991**)*

65. Schober A, Manka D, von Hundelshausen P, Huo YQ, Hanrath P, Sarembock IJ, Ley K, **Weber C** (2002) Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. ***Circulation*** 106:1523-1529 (comment in *Circulation* 106:1433). *(**IF 10.255,** 419 citations)*

2003 (IF 77.3)

66. Buss J, Neuzil J, Gellert N, **Weber C**, Ponka P (2003) Pyridoxal isonicotinoyl hydrazones induce apoptosis in hematopoetic cells due to their iron-chelating properties. ***Biochem. Pharmacol.*** 65:161-172. *(**IF 2.993**)*

67.° Huo YQ, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, Littman DR, **Weber C**, Ley K (2003) Circulating activated platelets exacerbate atherosclerosis in apolipoprotein E deficient mice. ***Nat. Med.*** 9:61-67. *(**IF 30.550,** 1250 citations)*

68. Schmid H, Schubert S, **Weber C**, Bogner J (2003) Isolation of a pantoea dispersa strain from a 71 year old woman with acute myeloid leukemia and multiple myeloma. ***Infection*** 31:66-67. *(**IF 1.042**)*

69. Weber T, Dalen H, Andera L, Negre-Salvayre A, Sticha M, Loret A, Terman A, Witting PK, Higuchi M, Zivny J, Gellert N, **Weber C**, Neuzil J (2003) Mitochondria play a central role in apoptosis induced by α-tocopheryl

succinate, an agent with antineoplastic activity: comparison with receptor-mediated pro-apoptotic signaling. ***Biochemistry*** 42:4277-4291. ***(IF 3.922)***

70. Zernecke A, Erl W, Fraemohs L, Lietz M, **Weber C** (2003) Suppression of endothelial adhesion molecule upregulation with cyclopentenone prostaglandins is dissociated from IκB-α kinase inhibition and cell death induction. ***FASEB J.*** 17:1099-1101. ***(IF 7.172)***

71. Ortlepp JR, Vesper K, Mevissen V, Schmitz F, Janssens U, Franke A, Hanrath P, **Weber C**, Zerres K, Hoffmann R (2003) Chemokine receptor CCR2 genotype is associated with myocardial infarction and heart failure in patients under 65 years of age. ***J. Mol. Med.*** 81:363-367. ***(IF 5.192)***

72. Baltus T, Weber KSC, Johnson Z, Proudfoot AEI, **Weber C** (2003) Oligomerization of RANTES is required for CCR1-mediated arrest but not CCR5-mediated transmigration of leukocytes. ***Blood*** 102:1085-1088. ***(IF 10.120)***

73. Ortlepp JR, Metrikat J, Vesper K, Mevissen V, Schmitz F, Albrecht M, Maya-Pelzer P, Hanrath P, **Weber C**, Zerres K, Hoffmann R (2003) The interleukin-6 promoter polymorphism is associated with elevated leukocyte, lymphocyte, and monocyte counts and reduced physical fitness in young healthy smokers. ***J. Mol. Med.*** 81:578-584. ***(IF 5.192)***

74. Schober A, Knarren S, Lin E, Lietz M, Guttenbach M, **Weber C** (2003) Crucial role of stromal cell-derived factor-1α in neointima formation after arterial injury in apolipoprotein E-deficient mice. ***Circulation*** 108:2491-2497. ***(IF 11.164)***

2004 (108.9)

75. Erl W, **Weber C**, Zernecke A, Neuzil J, Vosseler CA, Kim HJ, Weber PC (2004) Cyclopentenone prostaglandins induce endothelial cell apoptosis independent of the peroxisome proliferator-activated receptor-γ. ***Eur. J. Immunol.*** 34:241-250. ***(IF 5.005)***

76. Schober A, Bernhagen J, Thiele M, Zeiffer U, Knarren S, Roller M, Bucala R, **Weber C** (2004) Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice. ***Circulation*** 109:380-385. ***(IF 12.563)***

77. Blindt R, Bosserhoff AK, Dammers J, Krott N, Demircan L, Hoffmann R, Hanrath P, **Weber C**, Vogt F (2004) Downregulation of N-cadherin in the neointima stimulates migration of smooth muscle cells by rhoA deactivation. ***Cardiovasc. Res.*** 62:212-222 ***(IF 4.575)***

78. Ortlepp JR, Schmitz F, Mevissen V, Weiss S, Huster J, Dronskowski R, Langebartels G, Autschbach R, Zerres K, **Weber C**, Hanrath P, Hoffmann R (2004) The amount of calcium-deficient hexagonal hydroxyl-apatite in aortic valves is influenced by gender and associated with genetic polymorphisms in patients with severe calcific aortic stenosis. ***Eur. Heart J.*** 25:514-52. ***(IF 6.247)***

79. Jostarndt K, Rubic T, Kühn H, Anthosen MW, Andera L, Gellert N, Trottmann M, **Weber C**, Johansen B, Hrboticky N, Neuzil J (2004) Enzymatically modified LDL upregulates CD36 in low-differentiated monocytic cells in a PPAR-γ-dependent way. ***Biochem. Pharmacol.*** 67:841-854. ***(IF 3.436)***

80. Zeiffer U, Schober A, Lietz M, Liehn EA, Erl W, Emans N, Yan ZQ, **Weber C** (2004) Neointimal smooth muscle cells display a proinflammatory phenotype resulting in increased leukocyte recruitment mediated by P-selectin and chemokines. ***Circ. Res.*** 94:776-784. (comment in *Circ. Res.* 94:706) ***(IF 9.972***)

81. Skobel E, Schuh A, Lin E, Schwarz ER, Reffelmann T, Franke A, Breuer S, Günther K, Hanrath P, **Weber C** (2004) Transplantation of fetal cardiomyocytes into infarcted rat heart results in long-term functional improvement. ***Tissue Engineering*** 10:849-864. ***(IF 3.143)***

82. Merx MW, Lin EA, Janssens U, Lütticken R, Schrader J, Hanrath P, **Weber C** (2004) HMG-CoA-reductase inhibitor simvastatin profoundly improves survival in sepsis. ***Circulation*** 109:2560-2565. ***(IF 12.563****, 341 citations)*

83. Hoffmann R, Langenberg R, Radke PW, Franke A, Ortlepp J, **Weber C**, Hanrath P (2004) Evaluation of a high-dose dexamethasone eluting stent. ***Am. J. Cardiol.*** 94:193-5. (***IF 3.140)***

84. Vogt F, Stein A, Rettemeier G, Krott N, Hoffmann R, Bosserhoff AK, Michaeli W, **Weber C**, Blindt R (2004) A novel biodegradable coronary polymer stent with drug-delivery capacities: paclitaxel-loading inhibits neointimal hyperplasia in a porcine model of coronary restenosis. ***Eur. Heart J.*** 25:1330-40. ***(IF 6.247)***

85. Weissenbach M, Clahsen T, **Weber C**, Spitzer D, Wirth D, Vestweber D, Heinrich PC, Schaper F (2004) Interleukin-6 is a direct mediator of T cell migration. ***Eur. J. Immunol.*** 34:2895-2904. ***(IF 5.005)***

86. Liehn EA, Schober A, **Weber C** (2004) Blockade of KC inhibits re-endothelialization and enhances plaque formation after arterial injury in apolipoprotein E-deficient mice. ***Arterioscler. Thromb. Vasc. Biol.*** 24:1891-1896. ***(IF 7.432)***

87. Fraemohs L, Koenen RR, Ostermann G, Heinemann B, **Weber C** (2004). The functional interaction of the β2 integrin LFA-1 with junctional adhesion molecule-A is mediated by the I-domain. ***J. Immunol.*** 173:6259-6264 ***(IF 6.486)***

88. Koszalka P, Özüyaman B, Huo Y, Zernecke A, Flögel U, Braun N, Buchheiser A, Decking UK, Smith ML, Sévigny J, Gear A, Weber A, Molojavyi A, Ding ZP, Zimmermann H, **Weber C**, Ley K, Gödecke A, Schrader J (2004) Targeted disruption of *cd73*/ecto-5´-nucleotidase alters thrombo-regulation and augments vascular inflammatory response. ***Circ. Res.*** 95:814-821. (comment in *Circ. Res.* 95:752) ***(IF 9.972)***

89. Schober A, Zernecke A, Liehn E, von Hundelshausen P, Knarren S, Kuziel WA, **Weber C** (2004) The crucial role of the CCL2/CCR2 axis in neointimal hyperplasia after arterial injury in atherosclerosis-prone mice involves early monocyte recruitment and CCL2 presentation on platelets. ***Circ. Res.*** 95:1125-1133. (***IF 9.972***)

90. Hoffmann R, Radke PW, Ortlepp JR, Haager PK, Blindt R, Iofina E, Franke A, **Weber C**, Hanrath P (2004) Intravascular ultrasonic comparative analysis of degree of intimal hyperplasia produced by 4 different stents in the coronary arteries. ***Am. J. Cardiol.*** 94:1548-1550. ***(IF 3.140)***

2005 (IF 71.8)

91. von Hundelshausen P, Koenen RR, Sack M, Mause SF, Proudfoot AEI, Adriaens W, Hackeng TM, **Weber C** (2005) Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. ***Blood*** 105:924-930. ***(IF 10.131****, 409 citations)*

92. Furnkranz A, Schober A, Bochkov V, Kronke G, Kadl A, Binder BR, **Weber C**, Leitinger N (2005) Oxidized phospholipids trigger atherogenic inflammation in murine arteries. ***Arterioscler. Thromb. Vasc. Biol.*** 25:633-8. ***(IF 7.053)***

93. Schuh A, Breuer S, Al Dashti R, Sulemanjee N, Hanrath P, **Weber C**, Uretsky BF, Schwarz ER (2005) Administration of VEGF adjunctive to fetal cardiomyocyte transplantation and improvement of cardiac function in the rat model. ***J. Cardiovasc. Pharmacol. Ther.*** 10:55-66. ***(IF 1.000)***

94. Ostermann G, Fraemohs L, Baltus T, Schober A, Lietz M, Zernecke A, **Weber C** (2005) Involvement of junctional adhesion molecule-A (JAM-A) in mononuclear cell recruitment on inflamed or atherosclerotic endothelium: inhibition by soluble JAM-A. ***Arterioscler. Thromb. Vasc. Biol.*** 25:729-735. ***(IF 7.053)***

95. Ortlepp JR, Graf J, Vesper K, Schmitz F, Mevissen V, Sucigan S, Kersten A, **Weber C**, Janssens U (2005) Relationship of five inflammatory gene polymorphisms with morbidity and mortality in 533 patients admitted to an ICU. ***Inflammation*** 29:1-7. ***(IF 0.772)***

96. Zernecke A, Schober A, von Hundelshausen P, Liehn EA, Möpps B, Mericskay M, Gierschik P, Biessen EA, **Weber C** (2005) SDF-1α/CXCR4 axis is instrumental for neointimal hyperplasia and recruitment of smooth muscle cell progenitors. ***Circ. Res.*** 96:784-791. ***(IF 9.408,*** *456 citations)*

97. Merx M, Zernecke A, Liehn EA, Schuh A, Skobel E, Butzbach B, Hanrath P, **Weber C** (2005) Transplantation of human umbilical vein endothelial cells improves left ventricular function in a rat model of myocardial infarction. ***Basic Res. Cardiol.*** 100:208-16. ***(IF 2.806)***

98. Mause SF, von Hundelshausen P, Zernecke A, Koenen R, **Weber C** (2005) Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on inflamed and atherosclerotic endothelium. ***Arterioscler. Thromb. Vasc. Biol.*** 25:1512-18. ***(IF 7.053****, 459 citations)*

99. Merx MW, Liehn EA, Graf J, van de Sandt A, Schaltenbrand M, Schrader J, Hanrath P, **Weber C** (2005) Statin treatment after onset of sepsis in a murine model improves survival, ***Circulation*** 112:117-124. (***IF 11.632****)*

100. Baltus T, von Hundelshausen P, Mause S, Buhre W, Rossaint R, **Weber C** (2005) Differential and additive effects of platelet-derived chemokines on monocyte arrest on inflamed endothelium under flow conditions. ***J. Leukoc. Biol.*** 78:435-441. ***(IF 4.627)***

101. Schober A, Hoffmann R, Opree N, Knarren S, Iofina E, Hutschenreuter G, Hanrath P, **Weber C** (2005) Peripheral $CD34^+$ cells and the risk of restenosis after coronary stent placement. ***Am. J. Cardiol.*** 96:1116-1122. ***(IF 3.059)***

102. Merx MW, Schäfer C, Westenfeld R, Brandenburg V, Hidajat S, **Weber C**, Ketteler M, Jahnen-Dechent W (2005) Cardiac remodeling and diastolic dysfunction in fetuin-A deficient mice. ***J. Am. Soc. Nephrol.*** 16:3357-64. ***(IF 7.240)***

2006 (IF 55.9)

103. Burger-Kentischer A, Göbel H, Kleemann R, Zernecke A, Bucala R, Leng L, Finkelmeier D, Geiger G, Schaefer HE, Schober A, **Weber C**, Brunner H, Rütten H, Ihling C, Bernhagen J (2006) Reduction of the aortic inflammatory response in spontaneous atherosclerosis by blockade of macrophage migration inhibitory factor. ***Atherosclerosis*** 184:28-38. ***(IF 3.811)***

104. Koch KC, Liehn E, Rammos C, Müller D, Schröder J, Dimassi T, Stopinski T, Schäfer W, **Weber C** (2006) Effect of catheter-based transendocardial delivery of SDF-1α on left ventricular function and perfusion in a porcine model of myocardial infarction. ***Basic Res. Cardiol.*** 101:69-77 ***(IF 3.798)***

105. Zernecke A, Liehn EA, von Hundelshausen P, Fraemohs L, Krohn R, Corada M, Dejana E, **Weber C** (2006) Importance of JAM-A for neointimal lesion formation and infiltration in atherosclerosis-prone mice. ***Arterioscler. Thromb. Vasc. Biol.*** 26:e10-13. ***(IF 6.883)***

106. Hoffmann R, Suliman H, Haager P, Christott P, Lepper W, Radke PW, Ortlepp J, Blindt R, Hanrath P, **Weber C** (2006) Association of C-reactive protein and myocardial perfusion in patients with acute myocardial infarction. ***Atherosclerosis*** 186:177-183. ***(IF 3.811)***

107. Zernecke A, Bidzhekov K, Özüyaman B, Liehn EA, Fraemohs L, Firzlaff-Lüscher J, Lüscher B, Schrader J, **Weber C** (2006) CD73/ecto-5'-nucleotidase protects against vascular inflammation and neointima formation. ***Circulation*** 113:2120-27 ***(IF 10.940)***

108. Blindt R, Vogt F, Astafieva I, Fach C, Hristov M, Krott N, Seitz B, Kapurniotu A, Kwok C, Dewor M, Bosserhoff AK, Bernhagen J, Hanrath P, Hoffmann R, **Weber C** (2006) A novel drug-eluting stent coated with an integrin-binding cRGD peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells. ***J. Am. Coll. Cardiol.*** 47:1786-1795. ***(IF 9.701)***

109. Zernecke A*, Liehn EA*, Gao JL, Murphy PM, Kuziel WA, **Weber C** (2006) Deficiency in CCR5 but not in CCR1 protects from neointima formation in atherosclerosis-prone mice: involvement of IL-10. ***Blood***. 107:4240-4243. * equal contribution. ***(IF 10.370)***

110. Hristov M, Heussen N, Schober A, **Weber C** (2006) Intracoronary infusion of autologous bone marrow cells and left ventricular function after acute myocardial infarction: a meta-analysis. ***J. Cell. Mol. Med.*** 10:727-733. ***(IF 6.555)***

2007 (IF 141.1)

111. Lucerna M, Zernecke A, de Nooijer R, de Jager S, Bot I, van der Lans C, Kholova I, van Berkel TJC, Ylä-Herttuala S, **Weber C**, Biessen EAL (2007) Vascular endothelial growth factor induces plaque expansion in ApoE knockout mice by promoting *de novo* leukocyte recruitment. ***Blood*** 109:122-129. (comment in *Blood* 109:2-3) ***(IF 10.896)***

112. Hristov M , Fach C, Becker C, Heussen N, Liehn EA, Blindt R, Hanrath P, **Weber C** (2007) Reduced numbers of circulating endothelial progenitor cells in patients with coronary artery disease associated with long-term statin treatment. ***Atherosclerosis*** 192:413-420. ***(IF 4.287)***

113. Braunersreuther V, Zernecke A, Steffens S, Burger F, Pelli G, Luckow B, Mach F, **Weber C** (2007) CCR5 but not CCR1 deficiency reduces development of diet-induced atherosclerosis in mice. ***Arterioscler. Thromb. Vasc. Biol.*** 27:373-9. ***(IF 7.221**, 339 citations)*

114. Nowak B, **Weber C**, Schober A, Zeiffer U, Liehn EA, von Hundelshausen P, Reinartz P, Buell U (2007) ^{111}Indium-oxine labeling affects cellular integrity of hematopoietic progenitor cells. ***Eur. J. Nucl. Med. Mol. Imaging*** 34:715-721. ***(IF 4.101)***

115. Hristov M, Zernecke A, Bidzhekov K, Liehn EA, Shagdarsuren E, Ludwig A, **Weber C** (2007) Importance of CXCR2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury. ***Circ. Res.*** 100:590-597. ***(IF 9.721)***

116.° Bernhagen J, Krohn R, Lue H, Gregory J, Zernecke A, Koenen R, Dewor M, Georgiev I, Schober A, Leng L, Kooistra T, Fingerle-Rowson G, Ghezzi P, Kleemann R, McColl SR, Bucala R, Hickey MJ, **Weber C** (2007) MIF is a non-cognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. ***Nat. Med.*** 13:587-596. (comment in *Nat. Rev. Drug Dis.* 6:435) ***(IF 26.382,** 1384 citations)*

117. Bot I, de Jager SCA, Zernecke A, **Weber C**, van Berkel TJC, Biessen EAL (2007) Perivascular mast cell activation aggravates atherogenesis and contributes to plaque destabilization in ApoE$^{-/-}$ mice. ***Circulation*** 115:2516-2525. (comment in *Circulation* 115:2471) ***(IF 12.755,** 357 citations)*

118. Segerer S, Djafarzadeh R, Gröne HJ, Weinghart C, Kerjaschki D, **Weber C**, Regele H, Kungl AJ, Proudfoot AEI, Nelson PJ (2007) Selective binding and presentation of CCL5 by discrete tissue microenvironments during inflammation. ***J. Am. Soc. Nephrol.*** 18:1835-44. ***(IF 7.111)***

119. Hundhausen C, Schulte A, Schulz B, von Hundelshausen P, Achilles J, Winter U, Paliga K, Reiss K, **Weber C**, Ludwig A (2007) Regulated shedding of transmembrane chemokines by the metalloproteinase ADAM10 facilitates detachment of adherent leukocytes. ***J. Immunol.*** 178:8064-72. ***(IF 6.068)***

120. Schulte A, Schulz B, Hundhausen C, Andrzejewski MM, Mletzko S, Achilles J, Reiss K, Paliga K, **Weber C**, Rose-John S, Ludwig A (2007) Sequential processing of the transmembrane chemokines CX3CL1 and CXCL16 by α- and γ-secretases. ***Biochem. Biophys. Res. Commun.*** 358:233-40. ***(IF 2.749)***

121. Redondo S, Hristov M, Gümbel D, Tejerina T, **Weber C** (2007) Biphasic effect of pioglitazone on isolated human endothelial progenitor cells: involvement of PPAR-γ and TGF-β. ***Thromb. Haemost.*** 6:979-987. ***(IF 3.501)***

122. Galkina E, Harry B, Ludwig A, Liehn E, Sanders J, Bruce A, **Weber C**, Ley K (2007) CXCR6 promotes atherosclerosis by supporting T cell homing, interferon-γ production and macrophage accumulation in the aortic wall. ***Circulation*** 116:1801-1811. ***(IF 12.755)***

123. Krohn R, Raffetseder U, Bot I, Zernecke A, Shagdarsuren E, Liehn EA, van Santbrink PJ, Nelson PJ, Biessen EA, Mertens PR, **Weber C** (2007) YB-1 controls CCL5 expression in smooth muscle cells and contributes to neointima formation in atherosclerosis-prone mice. ***Circulation*** 116:1812-20. ***(IF 12.755)***

124. Dewor M, Krohn R, Steffens G, Baron J, **Weber C**, Bernhagen J (2007) Macrophage migration inhibitory factor (MIF) promotes fibroblast migration in wounded monolayers *in vitro*. ***FEBS Letters*** 581:4734-42. ***(IF 3.263)***

125. Karshovska E, Zernecke A, Sevilmis G, Millet A, Cohen C, Schmid H, Sohn HY, **Weber C**, Schober A (2007) Expression of HIF-1α in injured arteries controls SDF-1α-mediated neointima formation in apoE-deficient mice. ***Arterioscler. Thromb. Vasc. Biol.*** 27:2540-7. ***(IF 7.221)***

126. Bidzhekov K, Hautmann M, Semisch M, **Weber C**, Engelmann B, Hatzopoulos A (2007) Rafs as nodal points in the regulation of endothelial progenitor cell growth and differentiation. ***J. Cell Mol. Med.*** 11:1395-1407. ***(IF 6.807)***

127. Blindt R, Iofina K, de Taeye A, Müller R, Kiefer P, **Weber C**, Kelm M, Hoffmann R (2007) The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. ***Thromb. Haemostasis*** 98:1329-1334. ***(IF 3.501)***

2008 (IF 164.2)

128. Schuh A, Liehn EA, Sasse A, Hristov M, Sobota R, Kelm M, Merx MW, **Weber C** (2008) Transplantation of endothelial progenitor cells improves neovascularization and myocardial function in a rat model. ***Basic Res. Cardiol.*** 103:69-77. ***(IF 5.407)***

129. Shagdarsuren E, Bidzhekov K, Liehn EA, Djalali-Talab Y, Hristov M, Matthijsen RA, Buurman WA, Zernecke A, **Weber C** (2008) C1-esterase inhibitor protects against neointima formation after arterial injury in atherosclerosis-prone mice. ***Circulation*** 117:70-78. ***(IF 12.755)***

130. ° Zernecke A, Bot I, Djalali-Talab Y, Shagdarsuren E, Meiler S, Liehn EA, Schober A, Soehnlein O, Sperandio M, Tacke F, Biessen EA, **Weber C** (2008) Protective role of Cxcr4/Cxcl12 unveils the importance of neutrophils in atherosclerosis. ***Circ. Res.*** 102:209-217. (comment in *Circ. Res.* 102:154-156) ***(IF 9.721,*** *505 citations)*

131. Liehn EA, Merx MW, Postea O, Becher S, Djalali Talab Y, Shagdarsuren E, Kelm M, Zernecke A, **Weber C** (2008) Ccr1 deficiency reduces neutrophil infiltration, limits infarct size and improves left ventricular function after myocardial infarction. ***J. Cell. Mol. Med.*** 12:496-506 ***(Impact 4.499)***

132. Donners MMPC, Beckers L, Lievens D, Munnix I, Heemskerk J, Janssen BJ, Wijnands E, Cleutjens J, Zernecke A, **Weber C**, Ahonen CL, Benbow U, Newby AC, Noelle RJ, Daemen MJAP, Lutgens E (2008) The CD40-TRAF6 axis is the key regulator of the CD40/CD40L system in neointima formation and arterial remodelling. ***Blood*** 111:4596-604. ***(IF 5.114***)

133. Redondo S, Gordillo-Moscoso AA, Ruiz E, Hristov M, **Weber C**, Tejerina T (2008) High-reproducible endothelial progenitor cell determination in human peripheral blood as $CD34^+/CD144^+/CD3^-$ lymphocyte population. ***J. Immunol. Methods*** 335:21-7. ***(IF 2.120)***

134. Frommhold D, Ludwig A, Bixel G, Zarbock A, Babushkina I, Lange-Sperandio B, Ellies LG, Marth JD, Beck-Sickinger AG, Linderkamp O, Zernecke A, **Weber C**, Vestweber D, Ley K, Sperandio M (2008) Sialyltransferase ST3Gal-IV controls CXCR2-mediated firm leukocyte arrest during inflammation. ***J. Exp. Med.*** 205:1435-46. ***(IF 15.463)***

135. Lukowski R, Weinmeister P, Bernhard D, Feil S, Gotthardt M, Herz J, Massberg S, Zernecke A, **Weber C**, Hofmann F, Feil R (2008) Role of smooth muscle cGMP/cGKI signaling in murine vascular restenosis. ***Arterioscler. Thromb. Vasc. Biol.*** 28:1244-50. ***(IF 6.858)***

136. Vogt F, Zernecke A, Beckner M, Krott N, Bosserhoff AK, Hoffmann R, Jahnke T, Kelm M, **Weber C**, Blindt R (2008) Blocking of angio-associated migratory cell protein inhibits smooth muscle cell migration and neointima formation after vascular injury in hyperlipidemic apolipoprotein E knock-out mice. ***J. Am. Coll. Cardiol.*** 52:302-11. (comment in *J. Am. Coll. Cardiol.* 52:312–314) ***(IF 11.438)***

137. Schlieper G, Hristov M, Brandenburg V, Krüger T, Westenfeld R, Mahnken AH, Yagmur E, Boecker G, Heussen N, Gladziwa U, Ketteler M, **Weber C**, Floege J (2008) Predictors of low circulating endothelial progenitor cell numbers in hemodialysis patients. ***Nephrol. Dial. Transplant.*** 23:2611-8. ***(IF 3.568)***

138. Soehnlein O, Zernecke A, Eriksson EE, Rothfuchs AG, Pham CT, Herwald H, Bidzhekov K, Rottenberg ME, **Weber C**, Lindbom L (2008) Neutrophil secretion products pave the way for inflammatory monocytes. ***Blood*** 112:1461-71. ***(IF 10.432)***

139. Pluskota E, Soloviev DA, Szpak D, **Weber C**, Plow EF (2008) Neutrophil apoptosis: selective regulation by different ligands of integrin $\alpha_M\beta_2$. ***J. Immunol.*** 181:3609-19. ***(IF 6.000)***

140. Jacoby C, Böring YC, Beck A, Zernecke A, Aurich V, **Weber C**, Schrader J, Flögel U (2008) Dynamic changes in murine vessel geometry assessed by high resolution magnetic resonance angiography: a 9.4 T study. ***J. Magn. Res. Imaging*** 28:637-645. ***(IF 2.658)***

141. **Weber C**, Kraemer S, Drechsler M, Lue H, Koenen R, Kapurniotu A, Zernecke A, Bernhagen J (2008) Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte recruitment. ***Proc. Natl. Acad. Sci. USA.*** 105:16278-16283. ***(IF 9.380)***

142. Postea O, Koenen RR, Hristov M, **Weber C**, Ludwig A (2008) Homocysteine upregulates vascular transmembrane chemokine CXCL16 and induces $CXCR6^+$ lymphocyte recruitment in vitro and in vivo. ***J. Cell. Mol. Med.*** 12:1700-1708. ***(IF 5.114)***

143. Karshovska E, Zagorac D, Zernecke A, Klauss V, **Weber C**, Schober A (2008) A small molecule CXCR4 antagonist inhibits neointima formation and smooth muscle progenitor cell mobilization after arterial injury. ***J. Thromb. Haemost.*** 10:1812-1815 ***(IF 6.291)***

144. Spyridopoulos I, Fichtlscherer S, Popp R, Toennes SW, Trepels T, Zernecke A, Liehn EA, **Weber C**, Zeiher AM, Dimmeler S, Haendeler J (2008) Caffeine enhances endothelial repair by an AMPK-dependent mechanism. ***Arterioscler. Thromb. Vasc. Biol.*** 28:1967-74. ***(IF 6.858)***

145. Choi EY, Chavakis E, Czabanka MA, Langer H, Fraemohs L, Economopoulou M, Orlandi A, Kundu RK, Zheng YY, Ballantyne CM, Constant SL, Aird W, Papayannopoulou T, Gahmberg C, Udey MC, Vajkoczy P, Quertermous T, Dimmeler S, **Weber C**, Chavakis T (2008) Del-1 is an endogenous inhibitor of leukocyte-endothelial adhesion preventing inflammatory cell recruitment. ***Science*** 322:1101-4. (comment in *Nat. Rev. Immunol.* 9:6-7) ***(IF 28.103)***

146. Dragomir E, Manduteanu I, Calin M, Gan AM, Stan D, Koenen RR, **Weber C**, Simionescu M (2008) High glucose condition induces an inflammatory up-regulation of fractalkine and MCP-1 in human smooth muscle cells. ***Thromb. Haemost.*** 100:1155-65. ***(IF 6.499)***

2009 (IF 148.1)

147. ° Koenen RR, von Hundelshausen P, Nesmelova IV, Zernecke A, Liehn EA, Sarabi A, Kramp B, Piccinini A, Kowalska A, Kungl AJ, Hackeng TM, Mayo KH, **Weber C** (2009) Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. ***Nat. Med.*** 15:97-103. ***(IF 27.136,*** *493 citations)*

148. Raffetseder U, Djudjaj S, Rauen T, Frye BC, Kretzler M, Kunter U, Floege J, Nelson P, **Weber C***, Mertens PR* (2009) Differential regulation of chemokine CCL5 expression in monocytic/macrophage and renal cells is orchestrated by YB-1. ***Kidney Int.*** 75:185-196. *equal contribution. ***(IF 6.193)***

149. Wojcikiewicz EP, Koenen RR, Fraemohs L, Minkiewicz J, Azad H, **Weber C**, Moy VT (2009) LFA-1 binding destabilizes the JAM-A homophilic interaction during leukocyte transmigration. ***Biophys. J.*** 96:285-293. ***(IF 4.390)***

150. ° Landsman L*, Ber-On L*, Zernecke A*, Kim K, Krautgamer R, Shagdarsuren E, Lira SA, Weisman IL, **Weber C**, Jung S (2009) CX3CR1-mediated cell survival in monocyte homeostasis and atherogenesis. ***Blood*** 113:963-972. (comment in ***Blood*** 113:767-768) *equal contribution. ***(IF 10.555****, 530 citations)*

151. Rana OR, Saygili E, Meyer C, Schotten U, Weis J, Krüttgen A, Nolte KW, Andrzejewski MG, Ludwig A, **Weber C**, Schwinger RHG, Kelm M, Schauerte P (2009) Regulation of nerve growth factor in the heart: a central role of the calcineurin-NFAT pathway. ***J. Mol. Cell. Cardiol.*** 46:568-578. ***(IF 4.956)***

152. Matthijsen RA, de Winther MP, **Weber C**, Herias V, Gijbels MJ, Buurman WA (2009) Macrophage specific expression of mannose-binding lectin controls atherosclerosis in low-density lipoprotein receptor-deficient mice. ***Circulation*** 119:2188-95. ***(IF 14.816)***

153. Koenen RR, Pruessmeyer J, Soehnlein O, Fraemohs L, Zernecke A, Schwarz N, Reiss K, Lindbom L, **Weber C**, Ludwig A (2009) Regulated release and functional modulation of junctional adhesion molecule-A by disintegrin metalloproteinases. ***Blood*** 113:4799-809. ***(IF 10.555)***

154. Quast T, Tappertzhofen B, Schild C, Grell J, Czeloth N, Förster R, Alon R, Fraemohs L, Dreck K, **Weber C**, Lämmermann T, Sixt M, Kolanus W (2009) Cytohesin-1 controls the activation of RhoA and modulates integrin-dependent adhesion and migration of dendritic cells. ***Blood*** 113:5801-5810. ***(IF 10.555)***

155. Schuh A, Liehn EA, Sasse A, Schneider R, Neuss S, **Weber C**, Kelm M, Merx MW (2009) Improved left ventricular function after transplantation of microspheres and fibroblasts in a rat model of myocardial infarction. ***Basic Res. Cardiol.*** 104:403-11. ***(IF 5.973)***

156. Saygili E, Rana OR, Meyer C, Gemein C, Andrzejewski MG, Ludwig A, **Weber C**, Schotten U, Krüttgen A, Weis J, Schwinger RHG, Mischke K, Rassaf T, Kelm M, Schauerte P (2009) The angiotensin II-calcineurin-NFAT-pathway mediates stretch induced up-regulation of matrix metalloproteinases-2 and -9 in atrial cardiomyocytes. ***Basic Res. Cardiol.*** 104:435-48. ***(IF 5.973)***

157. ° Karlmark KR, Weiskirchen R, Henning W. Zimmermann HW, Gassler N, Ginhoux F, **Weber C**, Merad M, Luedde T Trautwein C, Tacke F (2009) Hepatic recruitment of the inflammatory Gr1^{+} monocyte subset upon liver injury promotes hepatic fibrosis. ***Hepatology*** 50:261-274. ***(IF 10.840,*** *842 citations)*

158. Shagdarsuren E, Djalali-Talab Y, Liehn EA, Bidzhekov K, Aurrand-Lions M, Imhof BA, **Weber C**, Zernecke A (2009) Importance of junctional adhesion molecule-C for neointimal hyperplasia and monocyte recruitment in atherosclerosis-prone mice. ***Arterioscler. Thromb. Vasc. Biol.*** 29:1161-1163. ***(IF 7.235)***

159. Segerer S, Johnson Z, Rek A, Baltus T, von Hundelshausen P, Kungl AJ, Proudfoot AEI, **Weber C***, Nelson PJ* (2009) The basic residue cluster 55KKWVR59 in CCL5 is required for *in vivo* biologic function. ***Mol. Immunol.*** 46:2533-8. *equal contribution. ***(IF 3.202)***

160. Schröder K, Kohnen A, Aicher A, Liehn EA, Büchse T, Stein S, **Weber C**, Dimmeler S, Brandes RP (2009) The NADPH oxidase Nox2 is required for hypoxia-induced mobilization of endothelial progenitor cells. ***Circ. Res.*** 105:537-44. ***(IF 9.214)***

161. Hristov M, Leyendecker T, Schuhmann C, von Hundelshausen P, Krötz F, Sohn HY, Nauwelaers F, **Weber C** (2009) A refined flow cytometry procedure for the analysis of circulating angiogenic monocytes and endothelial progenitor cells in coronary artery disease. ***Cytometry*** 75A:848-853. ***(IF 2.698)***

162. Schwartz V, Lue H, Kraemer S, Krohn R, Ohl K, Korbiel J, Bucala R, **Weber C**, Bernhagen J (2009) A functional heteromeric MIF receptor formed by CD74 and CXCR4. ***FEBS Letters*** 583:2749-57. ***(IF 3.541)***

163. Goetzenich A, Hatam N, Zernecke A, **Weber C**, Czarnotta T, Autschbach R, Christiansen S. Alteration of matrix metalloproteinases in selective left ventricular adriamycin-induced cardiomyopathy in the pig (2009) ***J. Heart Lung Transplant.*** 28:1087-93. ***(IF 3.541)***

164. ° Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B, Hristov M, Köppel T, Nazari Jahantigh M, Lutgens E, Wang S, Olson EN, Schober A, **Weber C** (2009) Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. ***Sci. Signal.*** 2:ra81. (comment in *Science* 326:1590) ***(IF 6.354,*** *1542 citations)*

2010 (IF 184.6)

165. Hristov M, Gümbel D, Shagdarsuren E, Lutgens E, Zernecke A, **Weber C** (2010) Soluble CD40 ligand impairs peripheral blood angiogenic outgrowth cell function and increases neointima formation after arterial injury. ***Circulation*** 121:315-324. (comment in *Circulation* 121:197-199) ***(IF 14.432)***

166. Lutgens E, Lievens D, Beckers L, Wijnands E, Soehnlein O, Zernecke A, de Winther M, Engel S, Seijkens T, Boon L, Ahonen C, Noelle R, Daemen M, Biessen EA, **Weber C** (2010) Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis and skews the immune response towards an anti-inflammatory profile. ***J. Exp. Med.*** 207:391-404. (***IF 14.776***)

167. Braunersreuther V, Pellieux C, Pelli G, Burger F, Steffens S, Montessuit C, **Weber C**, Proudfoot A, Mach F, Arnaud C (2010) Chemokine CCL5/RANTES inhibition reduces myocardial reperfusion injury in atherosclerotic mice. ***J. Mol. Cell. Cardiol.*** 48:789-98. ***(IF 5.499)***

168. Zaldivar MM, Pauels K, von Hundelshausen P, Berres ML, Schmitz P, Kowalska MA, Weiskirchen R, Trautwein C, **Weber C**, Wasmuth HE (2010) A non-redundant role of the platelet-derived chemokine CXCL4 (PF4) in experimental liver fibrosis. ***Hepatology*** 51:1345-53. ***(IF 10.885)***

169. Saygili E, Schauerte P, Küppers F, Heck L, Weis J, **Weber C**, Schwinger RH, Hoffmann R, Schröder JW, Marx N, Rana OR (2010) Electrical stimulation of sympathetic neurons induces autocrine/paracrine effects of NGF mediated by TrkA. ***J. Mol. Cell. Cardiol.*** 49:79-87. ***(IF 5.499)***

170. Subramanian P, Karshovska E, Reinhard P, Zhou Z, Megens RTA, Akhtar S, Li X, van Zandvoort M, Ludin C, **Weber C**, Schober A (2010) Lysophosphatidic acid receptors LPA_1 and LPA_3 promote CXCL12-mediated smooth muscle progenitor cell recruitment in neointima formation. ***Circ. Res.*** 107:96-105. ***(IF 9.504)***

171. Mause SF, Ritzel E, Liehn EA, Hristov M, Bidzhekov K, Mueller-Newen G, Soehnlein O, **Weber C** (2010) Platelet microparticles enhance the vasoregenerative potential of angiogenic early outgrowth cells after vascular injury. ***Circulation*** 122:495-506. ***(IF 14.432)***

172. Goossens P, Gijbels MJJ, Zernecke A, van der Made I, Beckers L, Buurman WA, Daemen MJ, Kalinke U, **Weber C**, Lutgens E, de Winther MP (2010) Myeloid type I interferon signaling promotes atherosclerosis by stimulating macrophage recruitment to lesions. ***Cell Metab.*** 12:142-153. ***(IF 18.207)***

173. Saygili E, Schauerte P, Küppers F, Heck L, Weis J, **Weber C**, Schwinger RH, Hoffmann R, Schröder JW, Marx N, Rana OR (2010) Acetylcholine as an age-dependent non-neuronal source in the heart. ***Auton. Neurosci.*** 156:82-89. ***(IF 1.671)***

174. Hristov M, Leyendecker T, Schuhmann C, von Hundelshausen P, Heussen N, Kehmeier E, Krötz F, Sohn HY, Klauss V, **Weber C** (2010) Circulating monocyte subsets and cardiovascular risk factors in coronary artery disease. ***Thromb. Haemost.*** 104:412-4. (comment in *Thromb. Haemost.* 104:191-193) ***(IF 4.701)***

175. Shagdarsuren E, Bidzhekov K, Mause S, Simsekyilmaz S, Polakowski T, Hawlisch H, Gessner JE, Zernecke A, **Weber C** (2010) C5a receptor targeting in neointima formation after arterial injury in atherosclerosis-prone mice. ***Circulation*** 122:1026-1036. ***(IF 14.432***)

176. Berres ML, Rueland A, Koenen RR, Moreno Zaldivar M, Schmitz P, Streetz KL, Gassler N, Weiskirchen R, **Weber C**, Trautwein C, Wasmuth HE (2010) Antagonism of the chemokine CCL5 (RANTES) ameliorates experimental liver fibrosis *in vivo.* ***J. Clin. Invest.*** 120:4129-40. ***(IF 14.152)***

177. ° Drechsler M, Megens R, van Zandvoort M, **Weber C**, Soehnlein O (2010) Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis in mice. ***Circulation*** 122:1837-45. ***(IF 14.432,*** *753 citations)*

178. Lievens D, Zernecke A, Seijkens T, Beckers L, Munnix ICA, Wijnands E, Flavell RA, Noelle RJ, Biessen EA, Daemen MJAP, Heemskerk JWM, **Weber C**, Lutgens E (2010) Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. ***Blood*** 116:4317-27. ***(IF 10.558)***

179. Liehn EA, Piccinini A, Koenen RR, Soehnlein O, Adage T, Fatu R, Curaj A, Popescu A, Zernecke A, Kungl A, **Weber C** (2010) A potent CCL2 antagonist suitable for combined treatment of vascular and ischemia-reperfusion injury. ***J. Am. Coll. Cardiol.*** 56:1847-57. ***(IF 14.293)***

180. Schwarz N, Pruessmeyer J, Hess MF, Pantaler E, Windoffer R, Voss M, Sarabi A, **Weber C**, Secchi AS, Uhlig S, Ludwig A (2010) Stepwise leukocyte recruitment via the transmembrane chemokine CX3CL1. ***Cell. Mol. Life Sci.*** 67:4233-48. ***(IF 7.047)***

181. Ren M, Guo Q, Guo L, Lenz M, Qian F, Koenen RR, Xu H, Schilling AB, **Weber C**, Ye RD, Dinner AR, Tang WJ (2010) Polymerization of MIP-1 chemokine (CCL3 and CCL4) and clearance of MIP-1 by insulin degrading enzyme. ***EMBO J.*** 29:3952-3966. (***IF 10.124***)

2011 (IF 126.7)

182. Sarabi A, Kramp B, **Weber C**, Koenen R, von Hundelshausen P (2011) CXCL4L1 inhibits angiogenesis and induces undirected endothelial migration without affecting proliferation or monocyte recruitment. ***J. Thromb. Haemost.*** 9:209-19. (***IF 5.731***)

183. Saygili E, Schauerte P, Pekassa M, Saygili E, Rackauskas G, Schwinger RHG, Weis J, **Weber C**, Marx N, Rana OR (2011) Sympathetic neurons express and secrete MMP-2 and MT1-MMP to control nerve sprouting via pro-NGF conversion. ***Cell. Mol. Neurobiol.*** 31:17-25. ***(IF 1.969)***

184. de Jager SC, Bermúdez B, Bot I, Koenen RR, Bot M, Kavelaars A, de Waard V, Heijnen CJ, Muriana FJ, **Weber C**, van Berkel TJ, Kuiper J, Lee SJ, Abia R, Biessen EA (2011) Growth differentiation factor-15 deficiency protects against atherosclerosis by attenuating CCR2-mediated macrophage chemotaxis. ***J. Exp. Med.*** 208:217-25. (***IF 13.853***)

185. Schober A, Hristov M, Forbrig R, Kofler S, Löhr B, Schumann U, Krötz F, Leibig M, König A, Kazcmerek I, Reichart B, Klauss V, **Weber C**, Sohn HY (2011) $CD34^+CD140b^+$ cells and CXCL12 predict the severity of cardiac allograft vasculopathy. ***Eur. Heart J.*** 32:476-84. ***(IF 10.478)***

186. Kraemer S, Lue H, Zernecke A, Kapurniotu A, Andreetto E, Frank R, Lennartz B, **Weber C**, Bernhagen J (2011) MIF-chemokine receptor interactions in atherogenesis are dependent on an N-loop-based two-site binding mechanism. ***FASEB J.*** 25:894-906. (***IF 5.712***)

187. Simons D, Grieb G, Hristov M, Pallua N, **Weber C**, Bernhagen J, Steffens G (2011) Hypoxia-induced endothelial secretion of macrophage migration inhibitory factor and role in endothelial progenitor cell recruitment. ***J. Cell. Mol. Med.*** 15:668-678. ***(IF 4.125)***

188. Zhou Z, Subramanian P, Sevilmis G, Globke B, Soehnlein O, Karshovska E, Megens R, Heyll K, Reinholz M, van Zandvoort M, **Weber C**, Schober A (2011) Lipoprotein-derived lysophosphatidic acid enhances atherosclerosis through the release of CXCL1 from endothelium. ***Cell Metab.*** 13:592-600. ***(IF 13.668)***

189. Rana OR, Saygili E, Buhr A, Saygili E, Gemein C, Mischke K, Nolte KW, Weis J, **Weber C**, Marx N, Schauerte P (2011) Chronic electrical neuronal stimulation increases cardiac parasympathetic tone by eliciting neurotrophic effects. ***Circ. Res.*** 108:1209-19. (***IF 9.489)***

190. **Weber C**, Meiler S, Döring Y, Koch M, Drechsler M, Megens R, Rowinska Z, Bidzhekov K, Fecher C, Ribechini E, van Zandvoort M, Binder C, Jelinek Y, Hristov M, Boon L, Jung S, Korn T, Lutz MB, Förster I, Zenke M, Hieronymus T, Junt T, Zernecke A (2011) CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T-cell homeostasis in mice. ***J. Clin. Invest.*** 121:2898–2910. (comment in *SciBX* 2011;648) (***IF 13.069,*** *287 citations*)

191. Poggi M, Engel D, Christ A, Beckers L, Wijnands E, Boon L, Driessen A, Cleutjens J, **Weber C**, Gerdes N, Lutgens E (2011) CD40L deficiency ameliorates adipose tissue inflammation and metabolic manifestations of obesity in mice, ***Arterioscler. Thromb. Vasc. Biol.*** 31:2251-60. ***(IF 6.368)***

192. Vasina EM, Cauwenberghs S, Feijge MAH, Heemskerk JWM, **Weber C**, Koenen RR (2011) Microparticles from apoptotic platelets promote resident monocyte subset differentiation. ***Cell Death Dis.*** 2:e233. ***(IF 5.333)***

193. Soehnlein O, Wantha S, Simsekyilmaz S, Doering Y, Megens RT, Mause SF, Drechsler M, Smeetz R, Weinandy S, Schreiber F, Gries T, Vijayan S, van Zandvoort M, Agerberth B, Pham CT, Gallo RL, Hackeng TM, Liehn EA, Hristov M, Zernecke A, Klee D, **Weber C** (2011) Neutrophil-derived cathelicidin protects from neointimal hyperplasia. ***Sci. Transl. Med.*** 3:103ra98. (comment in *Nat. Rev. Drug Discov.* 2011;11:902; *SciBX* 2011;1227) (***IF 7.804***)

194. Butoi E, Gan AM, Manduteanu I, Stan D, Calin M, Pirvulescu M, Koenen RR, **Weber C**, Simionescu M (2011) Cross talk between smooth muscle cells and monocytes/activated monocytes via CX3CL1/CX3CR1 axis augments expression of pro-atherogenic molecules. ***BBA Mol. Cell Res.*** 1813:2026-2035. ***(IF 5.269***)

195. Heinrichs D, Jung J, Offermanns C, Berres ML, Nellen A, Leng L, Schmitz P, Trautwein C, Bucala R, **Weber C**, Bernhagen J, Wasmuth HE (2011) Macrophage migration inhibitory factor (MIF) exerts anti-fibrotic effects in experimental liver fibrosis via CD74. ***Proc. Natl. Acad. Sci. USA.*** 8:17444-9. ***(IF 9.681)***

196. Liehn E, Tuchscheerer N, Kanzler I, Drechsler M, Fraemohs L, Schuh A, Koenen R, Zandler S, Soehnlein O, Hristov M, Grigorescu G, Urs A, Leabu M, Bucur I, Merx M, Zernecke A, Bernhagen J, Schober A, **Weber C** (2011) Double-edged role of the CXCL12-CXCR4 axis in experimental myocardial infarction. ***J. Am. Coll. Cardiol.*** 58:2415-23. (comment in *J. Am. Coll. Cardiol.* 58:2424-2426) (***IF 14.156***)

2012 (IF 115.0)

197. Rowinska Z, Zander S, Zernecke A, Jacobs M, Langer S, **Weber C**, Merx MW, Koeppel TA (2012) Non-invasive in vivo analysis of a murine aortic graft using high resolution ultrasound microimaging. ***Eur. J. Radiol.*** 81:244-9. (***IF 2.512***)

198. Hamesch K, Subramanian P, Li X, Dembowsky K, Chevalier E, **Weber C**, Schober A (2012) The CXCR4 antagonist POL5551 is equally effective as sirolimus in reducing neointima formation without impairing re-endothelialisation. ***Thromb. Haemost.*** 107:356-68. ***(IF 6.094)***

199. Redondo S, Gonzalez-Rocafort A, Navarro-Dorado J, Ramajo M, Hristov M, Gordillo-Moscoso A, Reguillo F, Carnero M, Martinez-Gonzalez J, Rodriguez E, **Weber C**, Tejerina T (2012) Decreased pre-surgical CD34+ $CD144^{+}$ cell number in patients undergoing coronary artery bypass grafting compared to coronary artery disease-free valvular patients. ***J. Cardiothorac. Surg.*** 7:2. ***(IF 0.900)***

200. ° Megens R, Santosh V, Lievens D, Döring Y, Zandvoort M, Grommes J, **Weber C**, Söhnlein O (2012) Presence of luminal neutrophil extracellular traps in atherosclerosis. ***Thromb. Haemost.*** 107:597-8. ***(IF 6.094)***

201. Grommes J, Alard JE, Drechsler M, Wantha S, Mörgelin M, Kuebler W, Jacobs M, von Hundelshausen P, Markart P, Preissner KT, Hackeng TM, Koenen RR, **Weber C**, Soehnlein O (2012) Disruption of platelet-derived chemokine heteromers abolishes endotoxin-induced lung injury. ***Am. J. Resp. Crit. Care Med.*** 185:628-36. ***(IF 11.041)***

202. ° Döring Y, Manthey H, Drechsler M, Lievens D, Manca M, Hartwig H, Busch M, Koenen RR, Soehnlein O, Zenke M, Daemen M, Lutgens E, **Weber C**, Zernecke A (2012) Autoantigenic protein-DNA complexes stimulate plasmacytoid dendritic cells to promote atherosclerosis. ***Circulation*** 125:1673-83. ***(IF 15.202,*** *381 citations)*

203. Bidzhekov K, Gan L, Denecke B, Hristov M, Koeppel TA, Zernecke A, **Weber C** (2012) microRNA expression signatures and parallels between monocyte subsets and atherosclerotic plaque in humans. ***Thromb. Haemost.*** 107:619-25. *(**IF 6.094**)*

204. Döring Y, Drechsler M, Wantha S, Kemmerich K, Lievens D, Vijayan S, Gallo R, **Weber C**, Söhnlein O (2012) Lack of neutrophil-derived CRAMP reduces atherosclerosis in mice. ***Circ. Res.*** 110:1052-6. (***IF 11.861***)

205. Postea O, Vasina EM, Cauwenberghs S, Projahn D, Liehn EA, Lievens D, Theelen W, Kramp BK, Butoi E, Soehnlein O, Heemskerk JWM, Ludwig A, **Weber C***, Koenen RR* (2012) Role of platelet CX3CR1 in monocyte recruitment to arterial lesions. ***Arterioscler. Thromb. Vasc. Biol.*** 32:1186-1193. *equal contribution. *(**IF 6.338**)*

206. Schwartz V, Krüttgen A, Weis J, **Weber C**, Ostendorf T, Lue H, Bernhagen J (2012) Role for CD74 and CXCR4 in clathrin-dependent endocytosis. ***Eur. J. Cell Biol.*** 91:435-49. *(**IF 3.213**)*

207. Hristov M, Schmitz S, Nauwelaers F, **Weber C** (2012) A flow cytometric protocol for enumeration of endothelial progenitor cells and monocyte subsets in human blood. ***J. Immunol. Methods*** 381:9-13. *(**IF 2.225**)*

208. Doering Y, Soehnlein O, Drechsler MD, Meiler S, Shagdarsuren E, Hartwig H, Hieronymus T, Koenen RR, Hristov M, Zenke M, **Weber C**, Zernecke A (2012) Chronic myelogenous leukemia-like disease due to hematopoietic IRF8-deficiency fuels atherosclerosis in mice. ***Arterioscler. Thromb. Vasc. Biol.*** 32:1613-23. *(**IF 6.338**)*

209. Grommes J, Vijayan S, Mörgelin M, Dembinski R, Jacobs M, Koeppel TA, Binnebösel M, **Weber C**, Soehnlein O (2012) Simvastatin ameliorates endotoxin-induced acute lung injury by reduction of neutrophil extravasation and radical formation, ***PLoS One*** 7:e38917. *(**IF 3.730**)*

210. Poti F, Costa S, Bergonzini V, Galletti M, Pignatti E, **Weber C**, Simoni M, Nofer JR. Effect of sphingosine 1-phosphate (S1p) receptor agonists Fty720 and Cym5442 on atherosclerosis development in LDL receptor deficient (LDL-R-/-) mice. ***Vascul. Pharmacol.*** 57:56-64. (***IF 3.212***)

211. Schuh A, Sasse A, Konschalla S, Kroh A, Merx MW, **Weber C**, Liehn EA (2012) Repetitive transplantation of different cell types in a rat model of myocardial infarction sequentially improves left ventricular function. ***J. Cell. Mol. Med.*** 16:1640-1647. *(**IF 4.753**)*

212. Cardilo-Reis L, Schreier SM, Gruber S, Papac-Milicevic N, **Weber C**, Wagner O, Stangl H, Soehnlein O, Binder CJ (2012) Interleukin-13 protects from atherosclerosis and modulates plaque composition by inducing a regression phenotype in mice, ***EMBO Mol. Med.*** 4:1072-1086. *(**IF 7.795**)*

213. Schuh A, Kroh A, Konschalla S, Liehn EA, Sobota RM, Biessen EA, Bot I, Sönmez T, Schober A, Marx N, **Weber C**, Sasse A (2012) Myocardial regeneration by transplantation of modified endothelial progenitor cells expressing SDF-1 in a rat model. ***J. Cell. Mol. Med*.** 16:2311-2320. *(**IF 4.753**)*

214. ° Nazari-Jahantigh M, Wei Y, Noels H, Akhtar S, Zhe Z, Koenen RR, Heyll K, Gremse F, Kiessling F, Grommes J, **Weber C**, Schober A (2012) MicroRNA-155 promotes atherosclerosis by derepressing Bcl6 in macrophages. ***J. Clin. Invest.*** 122:4190-4202. *(**IF 12.812,** 557 citations)*

2013 (IF 156.1)

215. Kanzler I, Tuchscheerer N, Steffens G, Simsekyilmaz S, Konschalla S, Kroh A, Simons D, Asare Y, Schober A, Bucala R, **Weber C**, Bernhagen J, Liehn EA (2013) Differential role of proangiogenic chemokines in endothelial progenitor cell-induced angiogenesis, ***Basic Res. Cardiol.*** 108:310. *(**IF 5.955**)*

216. Wantha S, Alard JE, Megens RTA, van der Does A, Döring Y, Drechsler M, Pham CT, Wang MW, Wang JM, Gallo RL, von Hundelshausen P, Lindbom L, Hackeng T, **Weber C**, Soehnlein O (2013) Neutrophil-derived cathelicidin promotes adhesion of classical monocytes, ***Circ. Res.*** 112:792-801. (***IF 11.089***)

217. Kumar N, Ippel H, **Weber C**, Hackeng T, Mayo KH (2013) Protein lysine N(zeta) alkylation and O-phosphorylation mediated by DTT-generated reactive oxygen species. ***Protein Sci.*** 22:327-46. (***IF 2.861***)

218. Soehnlein O, Drechsler M, Döring Y, Lievens D, Hartwig H, Kemmerich K, Ortega-Gómez A, Mandl M, Vijayan S, Projahn D, Garlichs CD, Koenen RR, Hristov M, Lutgens E, Zernecke A, **Weber C** (2013) Distinct functions of chemokine receptor axes in the atherogenic mobilization and recruitment of classical monocytes. ***EMBO Mol. Med.*** 5:471-481. *(**IF 8.245**, 224 citations)*

219. Akthar S, Gremse F, Kiessling F, **Weber C**, Schober A (2013) CXCL12 promotes the stabilization of atherosclerotic lesions mediated by smooth muscle progenitor cells in mice. ***Arterioscler. Thromb. Vasc. Biol.*** 33:679-86. *(**IF 5.533**)*

220. Wei Y, Nazari-Jahantigh M, Heyll K, Thiemann A, Chan L, **Weber C**, Schober A (2013) The microRNA-342-5p fosters inflammatory macrophage activation through an Akt1- and microRNA-155-dependent pathway during atherosclerosis. ***Circulation*** 127:1609-1619. *(**IF 14.948**)*

221. Vasina EM, Cauwenberghs S, Staudt M, Feijge MA, **Weber C**, Koenen RR, Heemskerk JWM (2013) Aging- and activation-induced platelet microparticles suppress apoptosis in monocytic cells and differentially signal to proinflammatory mediator release. ***Am. J. Blood Res.*** 3:107-23. ***(IF 1.980)***

222. ° Casanova-Acebes M, Pitaval C, Weiss LA, Nombela-Arrieta C, Chèvre R, A-González N, Kunisaki Y, Zhang D, van Rooijen N, Silberstein L, **Weber C**, Nagasawa T, Frenette PS, Castrillo A, Hidalgo A (2013) Rhythmic modulation of the hematopoietic niche through neutrophil clearance. ***Cell*** 153:1025–1035. ***(IF 33.116,*** *655 citations)*

223. Poti F, Gualtieri F, Sacchi S, Weißen-Plenz G, Varga G, Brodde M, **Weber C**, Simoni M, Nofer JR (2013) KRP203, sphingosine 1-phosphate receptor type 1 agonist, ameliorates atherosclerosis in LDL-R$^{-/-}$ mice. ***Arterioscler. Thromb. Vasc. Biol.*** 33:1505-1512. ***(IF 5.533)***

224. Asare Y, Shagdarsuren E, Schmid JA, Grommes J, El Bounkari O, **Weber C**, de Winther MPJ, Noels H, Bernhagen J (2013) Endothelial CSN5 impairs NF-κB activation and monocyte adhesion to endothelial cells and is highly expressed in human atherosclerotic lesions. ***Thromb. Haemost.*** 110:141-52. ***(IF 5.760)***

225. Oral H, Kanzler I, Tuchscheerer N, Curaj A, Simsekyilmaz S, Sönmez TT, Radu E, Postea O, **Weber C**, Schuh A, Liehn EA (2013) CXC chemokine KC fails to induce neutrophil infiltration and neoangiogenesis in a mouse model of myocardial infarction. ***J. Mol. Cell. Cardiol.*** 60:1-7. ***(IF 5.218)***

226. Ziegler T, Horstkotte J, Schwab C, Pfetsch V, Dietzel S, Rohwedder I, Hinkel R, Krieg L, Hu J, Theiss H, Franz WM, Söhnlein O, Sperandio M, Pohl U, Thomas M, **Weber C**, Augustin H, Fässler R, Deutsch U, Kupatt C (2013) Angiopoietin-2 induced pericyte loss mediates hemodynamic alterations in sepsis, ***J. Clin. Invest.*** 123:3436–3445. ***(IF 13.765)***

227. Liehn E, Kanzler I, Konschalla S, Kroh A, Simsekyilmaz S, Sönmez T, Bucala R, Bernhagen J, **Weber C** (2013) Compartmentalized protective versus detrimental effects of endogenous MIF mediated by CXCR2 in a mouse model of myocardial ischemia/reperfusion. ***Arterioscler. Thromb. Vasc. Biol.*** 33:2180-86 ***(IF 5.533)***

228. Kramp BK, Sarabi A, Projahn D, Winkler S, Megens RTA, Proudfoot AE, **Weber C**, Koenen RR, von Hundelshausen P (2013) Exchanging the extracellular domains of CCR1 and CCR5 reveals confined functions in CCL5-induced cell recruitment. ***Thromb. Haemost.*** 110:795-806. ***(IF 5.760)***

229. Ghosh M, van den Akker NMS, Wijnands KAP, **Weber C**, McQuade LE, Pluth MD, Lippard SJ, Post MJ, Molin DGM, van Zandvoort MAMJ (2013) Specific visualization of nitric oxide in the vasculature with two-photon microscopy using a novel copper based fluorescent probe. ***PLoS One*** 8:e75331. ***(IF 3.534)***

230. Manthey H, Barnsteiner S, Cochain C, Karshovska E, Koch M, Chaudhari S, Busch M, **Weber C**, Koenen RR, Zernecke A (2013) CCR6 selectively promotes monocyte-mediated inflammation and atherogenesis in mice. ***Thromb. Haemost.*** 110:1267-77. ***(IF 5.760)***

231. Wu Z, Curaj A, Fokong S, Liehn EA, **Weber C**, Lammers T, Kiessling F, van Zandvoort MAMJ (2013) Rhodamine-loaded ICAM-1-targeted microbubbles for dual-modality imaging under controlled shear stresses. ***Circ. Cardiovasc. Imaging*** 6:974-81. (***IF 6.752***)

232. Lievens D, Habets KL, Robertson AK, Laouar Y, Winkels H, Rademakers T, Beckers L, Wijnands E, Boon L, Mosaheb M, Ait-Oufella H, Mallat Z, Flavell RA, Rudling M, Binder C, Gerdes N, Biessen EAL, **Weber C**, Daemen MJAP, Kuiper J, Lutgens E (2013) Abrogated transforming growth factor-β receptor II (TGFβRII) signaling in dendritic cells promotes immune reactivity of T cells resulting in enhanced atherosclerosis. ***Eur. Heart J.*** 34:3717-27. (comment in *Eur. Heart J.* 34:3684) ***(IF 14.723)***

2014 (IF 191.7)

233. Schmitt MMN, Megens RTA, Zernecke A, Bidzhekov K, van den Akker NM, Rademakers T, van Zandvoort MA, Hackeng TM, Koenen RR, **Weber C** (2014) Endothelial JAM-A guides monocytes into flow-dependent predilection sites of atherosclerosis. ***Circulation*** 129:66-76. ***(IF 15.073)***

234. Ring L, Neth P, **Weber C**, Steffens S, Faussner A (2014) β-catenin-dependent pathway activation by both promiscuous canonical WNT3a-, and specific noncanonical WNT4- and WNT5a-FZD receptor combinations with strong differences in LRP5 and LRP6 dependency. ***Cell Signal.*** 26:260-267. ***(IF 4.315)***

235. Simsekyilmaz S, Cabrera-Fuentes HA, **Weber C**, Meiler S, Boisvert WA, Preissner KT, Zernecke A (2014) The role of extracellular RNA in atherosclerotic plaque formation in mice, ***Circulation*** 129:598-606. ***(IF 15.073)***

236. Tilstam PV, Gijbels MJ, Habbeddine M, Cudejko C, Asare Y, Theelen W, Zhou B, Döring Y, Drechsler M, Pawig L, Simsekyilmaz S, Lawrence T, Koenen RR, de Winther MPJ, Zernecke A, Bernhagen J, **Weber C**, Noels H (2014) Bone marrow-specific knock-in of a non-activatable Ikkα kinase mutant influences haematopoiesis but not atherosclerosis in Apoe-deficient mice. ***PLoS One*** 9:e87452. ***(IF 3.234)***

237. Aoqui C, Chmielewski S, Scherer E, Eißler R, Sollinger D, Heid I, Braren R, Schmaderer C, Megens RTA, **Weber C**, Heemann U, Tschöp M, Baumann M (2014) Microvascular dysfunction in the course of metabolic syndrome induced by high-fat diet. ***Cardiovasc. Diabetol.*** 13:31. ***(IF 4.015)***

238. Jaczewska J, Abdulreda M, Yau C, Schmitt M, Schubert I, Berggren PO, **Weber C**, Koenen RR, Moy C, Wojcikiewicz E (2014) TNF-α and INF-γ promote lymphocyte adhesion to endothelial junctional regions facilitating transendothelial migration. ***J. Leukoc. Biol.*** 95:265-74. (***IF 4.289***)

239. Chatzigeorgiou A, Engel D, Poggi M, van den Berg S, Seijkens T, Winkels H, Beckers L, Meiler S, Burger P, Smeets E, Driessen A, Lievens D, Kusters P, Garcia Martin R, Klotzsche von Ameln A, Chung K, Nicolaes G, **Weber C**, van Dijk KW, Renssen P, Gerdes N, Chavakis T, Lutgens E (2014) The CD40-TRAF2/3/5 and CD40-TRAF6 signaling pathways have opposing roles in mediating metabolic complications and adipose tissue inflammation in diet induced obesity. ***Proc. Natl. Acad. Sci. USA.*** 111:2686-91. ***(IF 9.674)***

240. Chèvre R, González-Granado JM, Megens RT, Sreeramkumar V, Silvestre-Roig C, Molina-Sanchez P, **Weber C**, Soehnlein O, Hidalgo A, Andrés V (2014) High-resolution imaging of intravascular atherogenic inflammation in live mice. ***Circ. Res.*** 114:770-9. (***IF 11.019***)

241. ° Hartwig H, Drechsler M, Lievens D, Kramp B, von Hundelshausen P, Lutgens E, **Weber C**, Döring Y, Soehnlein O (2014) Platelet-derived PF4 reduces neutrophil apoptosis in inflammation. ***Thromb. Haemost.*** 111:562-4. ***(IF 4.984)***

242. Döring Y, Noels H, Mandl M, Kramp B, Lievens D, Drechsler M, Megens R, Tilstam PV, Langer M, Hartwig H, Sperandio M, Soehnlein O, **Weber C** (2014) Deficiency of the sialyltransferase St3Gal4 reduces Ccl5-mediated myeloid cell recruitment and arrest. ***Circ. Res.*** 114:976-981. (comment in *Circ. Res.* 114:935-937) (***IF 11.019***)

243. Li X, Penfold M, Megens R, Koenen RR, Thiemann A, Heyll K, Akhtar S, van Zandvoort M, Schall TJ, **Weber C***, Schober A* (2014) Activation of CXCR7 limits atherosclerosis and improves hyperlipidemia by increasing cholesterol uptake in adipose tissue. ***Circulation*** 129:1244-53. *corresponding authors. ***(IF 15.073)***

244. ° Schober A, Nazari-Jahantigh M, Wei Y, Bidzhekov K, Gremse F, Grommes J, Megens RTA, Heyll K, Noels H, Hristov M, Wang S, Kiessling F, Olson EN, **Weber C** (2014) MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. ***Nat. Med.*** 20:368-376. (comment in *Sci. Transl. Med.* 6:230ec57*; Arterioscler. Thromb. Vasc. Biol.* 2014;34:e15-6; recommended in F1000 Prime, http://f1000.com/prime/718293958) ***(IF 28.223,** 648 citations)*

245. Projahn D, Simsekyilmaz S, Singh S, Kanzler I, Kramp BK, Langer M, Bernhagen J, Klee D, Zernecke A, Hackeng TM, Groll J, **Weber C**, Liehn EA, Koenen RR (2014) Intramyocardial release of engineered chemokines from biodegradable hydrogels prevents injury extension after myocardial infarction. ***J. Cell. Mol. Med.***, 18:790-800. ***(IF 4.655)***

246. Schmitt MM, Fraemohs L, Hackeng TM, **Weber C**, Koenen RR (2014) Atherogenic mononuclear cell recruitment is facilitated by oxidized lipoprotein-induced endothelial junctional adhesion molecule-A re-distribution. ***Atherosclerosis*** 234:254-264. ***(IF 3.994)***

247. Rossaint J, Herter J, van Aken H, Napirei M, Döring Y, **Weber C**, Soehnlein O, Zarbock A (2014) Synchronized integrin and chemokine activation is crucial in neutrophil extracellular trap-mediated acute lung injury. ***Blood*** 123:2573-84. ***(IF 10.452)***

248. Noels H, Zhou B, Tilstam PV, Theelen W, Li X, Akhtar S, Simsekyilmaz S, Liehn EA, Schober A, Adams RH, Bernhagen J, Döring Y, **Weber C** (2014) Deficiency of endothelial Cxcr4 reduces reendothelialization and enhances neointimal hyperplasia after vascular injury in mice. ***Arterioscler. Thromb. Vasc. Biol.*** 34:1209-20. ***(IF 6.008)***

249. Bot I, Daissormont IT, Zernecke A, Kramp B, de Jager SC, Westra MM, Bot M, van Santbrink PJ, van Berkel TJ, Su L, Aukrust P, Koenen RR, **Weber C**, Biessen EAL (2014) CXCR4 blockade induces atherosclerosis by affecting neutrophil function. ***J. Mol. Cell. Cardiol.*** 74C:44-52. ***(IF 4.655)***

250. Hinkel R, Trenkwalder T, Petersen B, Stachel G, Lee, S, Husada W, Gesenhues F, Hannappel E, DiMaio JM, Hatzopoulos AK, Theisen D, Boekstegers P, LeNoble F, Nordheim A, Reichart B, **Weber C**, Bock-Marquette I, Olson EN, Posern G, Deindl E, Niemann H, Kupatt C (2014) MRTF-A mediates vessel growth and maturation via CCN1 and CCN2. ***Nat. Commun.*** 5:3970. ***(IF 11.470)***

251. Vijayan S, Grommes J, Söhnlein O, Lutgens E, **Weber C**, Schober A, Shagdarsuren E (2014)· High expression of C5L2 correlates with high proinflammatory cytokine levels in advanced human atherosclerosis. ***Am. J. Pathol.*** 184:2123-33. ***(IF 4.591)***

252. Popp T, Steinritz D, Breit A, Deppe J, Egea V, Gudermann T, **Weber C**, Ries C (2014) Wnt5a/β-catenin signaling drives calcium-induced differentiation of human primary keratinocytes. ***J. Invest. Dermatol.*** 134: 2183–2191. ***(IF 7.216)***

253. Richter R, Jochheim-Richter A, Ciuculescu F, Kollar K, Seifried E, Forssmann U, Verzijl D, Smit M, Blanchet X, von Hundelshausen P, **Weber C**, Forssmann WG, Henschler R (2014) Identification and characterization of circulating variants of CXCL12 (SDF-1) from human plasma: effects on chemotaxis and mobilization of hematopoietic stem and progenitor cells. ***Stem Cell Dev.*** 23:1959-74. ***(IF 3.727)***

254. Mandl M, Schmitz S, **Weber C**, Hristov M (2015) Characterization of the $CD14^{++}CD16^{+}$ monocyte population in human bone marrow. ***PLoS One*** 9:e112140. ***(IF 3.234)***

255. Blanchet X, Cesarek K, Brandt J, Herwald H, Teupser D, Küchenhoff H, Karshovska E, Mause SF, Siess W, Wasmuth H, Söhnlein O, Koenen RR, **Weber C**, von Hundelshausen P (2014) Inflammatory role and prognostic value of platelet chemokines in acute coronary syndrome. ***Thromb. Haemost.*** 112:1277-1287. ***(IF 4.984)***

256. Ippel H, Miller M, Berbís M, Suylen D, André S, Hackeng T, Cañada F, **Weber C**, Gabius H, Jiménez-Barbero J, Mayo K (2015) 1H, 13C, and 15N backbone and side-chain chemical shift assignments for the 36 proline-containing full length 29 kDa human chimera-type galectin-3. ***Biomol. NMR Assign.*** 9:59-63. ***(IF 0.760)***

2015 (IF 164.2)

257. Azghandi S, Prell C, van der Laan SW, Schneider M, Malik R, Berer K, Gerdes N, Pasterkamp G, **Weber C**, Haffner C, Dichgans M (2015) Deficiency of the stroke-relevant HDAC9 gene attenuates atherosclerosis in accord with allele-specific effects at 7p21.1. ***Stroke*** 46:197-202. (***IF 5.787***)

258. von Hundelshausen P, Oexle K, Bidzhekov K, Hristov M, Schmitt MM, Kaemmerer H, Matyas G, Meitinger T, **Weber C** (2015) Recurrent spontaneous coronary dissections in a patient with a de novo fibrillin-1 mutation without Marfan syndrome. ***Thromb. Haemost.*** 113:668-70. ***(IF 5.255)***

259. Karshovska E, Zhao Z, Blanchet X, Schmitt M, Bidzhekov K, Soehnlein O, von Hundelshausen P, Mattheij NJA, Cosemans JM, Megens RTA, Koeppel TA, Schober A, Hackeng TM, **Weber C**, Koenen RR (2015) Hyperreactivity of junctional adhesion molecule A-deficient platelets accelerates atherosclerosis in hyperlipidemic mice. ***Circ. Res.*** 116:587-99. (***IF 11.551***)

260. Drechsler M, de Jong R, Rossaint J, Viola JR, Leoni G, Wang JM, Grommes J, Hinkel R, Kupatt C, **Weber C**, Döring Y, Zarbock A, Soehnlein O (2015) Annexin A1 counteracts chemokine-induced arterial myeloid cell recruitment. ***Circ. Res.*** 116:827-35. (***IF 11.551***)

261. Kornmann LM, Zernecke A, Curfs DM, Janssen BJ, **Weber C**, de Winther MP, Reneman RS, Hoeks AP, Reesink KD (2015) Echogenic perfluorohexane-loaded macrophages adhere in vivo to activated vascular endothelium in mice. ***Cardiovasc. Ultrasound*** 13:1. ***(IF 1.463)***

262. Zarzycka B, Seijkens T, Nabuurs S, Ritschel T, Grommes J, Soehnlein O, Schrijver R, van Tiel C, Hackeng T, **Weber C**, Giehler F, Kieser A, Lutgens E, Vriend G, Nicolaes G (2015) Discovery of small molecule CD40-TRAF6 inhibitors. ***J. Chem. Inform. Model.*** 55:294-307. ***(IF 3.657)***

263. Wei Y, Zhu M, Corbalan-Campos J, Heyll K, **Weber C**, Schober A (2015) Regulation of Csf1r and Bcl6 in macrophages mediates the stage-specific effects of miR-155 on atherosclerosis. ***Arterioscler. Thromb. Vasc. Biol.*** 35:796-803. ***(IF 5.969)***

264. van den Berg S, Seijkens T, Kusters P, Zarzycka B, Beckers L, den Toom M, Gijbels M, Chatzigeorgiou A, **Weber C**, de Winther M, Chavakis T, Nicolaes G, Lutgens E (2015) Blocking CD40-Traf6 interactions by small molecule inhibitor 6860766 ameliorates the complications of diet induced obesity in mice. ***Int. J. Obesity*** 39:782-90. (***IF 5.337***)

265. Curaj A, Wu Z, Fokong S, Liehn EA, **Weber C**, Lammers T, van Zandvoort MA, Kiessling F (2015) Non-invasive molecular ultrasound monitoring of vessel healing following intravascular surgical procedures. ***Arterioscler. Thromb. Vasc. Biol.*** 35:1366-73. ***(IF 5.969)***

266. Jamasbi, J, Megens R, Münch G, Ungerer M, Faussner A, Lorenz R, Sherman S, Walker A, Gojal P, **Weber C**, Brandl R, Jung S, Farndale R, Elia N, Siess W (2015) Inhibition of platelet activation in blood exposed to atherosclerotic plaques by GPVI-Fc and anti-GPVI antibodies: functional and imaging studies. ***J. Am. Coll. Cardiol.*** 65:2404-15. (***IF 17.759***)

267. Hu D, Mohanta SK, Peng L, Yin C, Srikakulapu P, Grassia G, MacRitchie N, Dever G, Gordon P, Burton FL, Ialenti A, Sabir SR, McInnes IB, Brewer JM, Garside P, **Weber C**, Lehmann T, Beer M, Grabner R, Maffia P, Weih F, Habenicht AJR (2015) ATLOs control aortic immunity and protect against atherosclerosis via VSMC-LTβ receptors. ***Immunity*** 42:1100-15. (***IF 24.082***)

268. Medina I, Cougole C, Drechsler M, Bermudez B, Koenen RR, Wolfs I, Doering Y, Herias V, Gijbels M, Bot I, de Jager S, Moscai A, **Weber C**, Cleutjens J, van Berkel TJC, Maridonneau-Parini I, Soehnlein O, Biessen EAL (2015) Hck/Fgr kinase deficiency reduces plaque growth and stability by blunting monocyte recruitment and intraplaque motility. ***Circulation*** 132:490-501. ***(IF 17.202)***

269. Mandl M, Drechsler M, Jansen Y, Neideck C, Noels H, Faussner A, Soehnlein O, **Weber C**, Döring Y (2015) Evaluation of the BDCA2-DTR transgenic mouse model in chronic and acute inflammation. ***PLoS One*** 10:e0134176. ***(IF 3.057)***

270. Selle J, Asare Y, Köhncke J, Alampour-Rajabi S, Shagdarsuren G, Klos A, **Weber C**, Jankowski J, Shagdarsuren E (2015) Atheroprotective role of C5ar2 deficiency in apolipoprotein E-deficient mice. ***Thromb. Haemost.*** 114:848-58. ***(IF 5.255)***

271. ° Soehnlein O, Ortega-Gómez A, Döring Y, **Weber C** (2015) Neutrophil-macrophage interplay in atherosclerosis: protease-mediated cytokine processing versus NET release. ***Thromb. Haemost.*** 114:866-867. ***(IF 5.255)***

272. Stoppe C, Rex S, Goetzenich A, Kraemer S, Emontzpohl C, Soppert J, Sun Y, Rossaint R, Lue H, Leng L, Bucala R, **Weber C**, Bernhagen J (2015) Interaction of MIF family proteins in myocardial ischemia/reperfusion damage and their influence on clinical outcome of cardiac surgery patients. ***Antioxid. Redox Signal.*** 23:865-79. ***(IF 7.093)***

273. Alampour-Rajabi, El Bounkari O, Rot A, Müller-Newen G, Bachelerie F, Chatterjee M, Gawaz M, **Weber C**, Schober A, Bernhagen J (2015) MIF interacts with CXCR7 to promote receptor internalization, ERK1/2 signaling and lymphocyte chemotaxis. ***FASEB J.*** 29:4497-511. ***(IF 5.299)***

274. Akhtar S, Hartmann P, Karshovska E, Subramanian, Gremse F, Grommes J, Jacobs M, Kiessling F, **Weber C**, Steffens S, Schober A (2015) Endothelial hypoxia-inducible factor-1α promotes atherosclerosis and monocyte recruitment by upregulating miRNA-19a. ***Hypertension*** 66:1220-6. ***(IF 6.350)***

275. Alard JE, Ortega-Gomez A, Wichapong K, Bongiovani D, Horckmanns M, Megens RTA, Leoni G, Ferraro B, Rossaint J, Paulin N, Hinkel R, Blanchet X, Gaillard F D'Amico M, von Hundelshausen P, Zarbock A, Scheiermann C, Hackeng TM, Steffens S, Kupatt C, Nicolaes GAF, **Weber C**, Soehnlein O (2015) Recruitment of classical monocytes can be inhibited by disturbing heteromers of neutrophil HNP1 and platelet CCL5. ***Sci. Transl. Med.*** 7:317ra196. (***IF 16.264***)

2016 (IF 200.4)

276. Deppe J, Steinritz D, Santovito D, Egea V, Schmidt A, **Weber C**, Ries C (2016) Upregulation of miR-203 and miR-210 affect growth and differentiation of keratinocytes after exposure to sulfur mustard in normoxia and hypoxia. ***Toxicol. Lett.*** 244:81-7. ***(Impact 3.858)***

277. Hartmann P, Zhou Z, Natarelli L, Nazari-Jahantigh M, Wei Y, Zhu M, Grommes J, Steffens S, **Weber C**, Schober A (2016) Endothelial Dicer promotes atherosclerosis and vascular inflammation by miRNA-103-mediated suppression of KLF4. ***Nat. Commun.*** 7:10521. ***(IF 12.124)***

278. Gerdes N, Seijkens T, Lievens D, Kuijpers MJE, Winkels H, Projahn D, Hartwig H, Beckers L, Megens RTA, Boon L, Noelle RJ, Soehnlein O, Heemskerk JWM, **Weber C**, Lutgens E (2016) Platelet CD40 exacerbates atherosclerosis by transcellular activation of endothelial cells and leukocytes. ***Arterioscler. Thromb. Vasc. Biol.*** 36:482-90. ***(IF 6.607)***

279. Mahl C, Egea V, Megens RTA, Pitsch T, Santovito D, **Weber C**, Ries C (2016) RECK (reversion-inducing cysteine-rich protein with Kazal motifs) regulates migration, differentiation and Wnt/β-catenin signaling in human mesenchymal stem cells. ***Cell. Mol. Life Sci.*** 73:1489-501. ***(IF 5.788)***

280. Simsekyilmaz S, Liehn EA, Weinandy S, Schreiber F, Megens RT, Theelen W, Smeets R, Jockenhövel S, Gries T, Möller M, Klee D, **Weber C***, Zernecke A* (2016) Targeting in-stent-stenosis with RGD- and CXCL1-coated mini-stents in mice. ***PLoS One.*** 11:e0155829. *equal contribution. ***(IF 2.806)***

281. Deppe J, Popp T, Egea V, Steinritz D, Schmidt A, Thiermann H, **Weber C**, Ries C (2015) Impairment of hypoxia-induced HIF-1α signaling in keratinocytes and fibroblasts by sulfur mustard is counteracted by a selective PHD-2 inhibitor. ***Arch. Toxicol.*** 90:1141-50. ***(IF 5.901)***

282. Li J, McArdle S, Gholami A, Kimura T, Wolf D, Gerhardt T, Miller J, **Weber C**, Ley K (2016) CCR5+T-bet+ FoxP3+ effector CD4 T cells drive atherosclerosis. ***Circ. Res.*** 118:1540-52. (***IF 13.965***)

283. Wichapong K, Alard J, Ortega-Gomez A, **Weber C**, Hackeng TM, Soehnlein O, Nicolaes GA (2016) Structure-based design of peptidic inhibitors of the interaction between the CC chemokine ligand 5 (CCL5) and human neutrophil protein 1 (HNP1). ***J. Med. Chem.*** 59:4289-301. ***(IF 6.259)***

284. Schmohl J, Santovito D, Guenther T, Sutanto W, Kroell T, Salih H, Pitsch T, Egea V, **Weber C**, Schmetzer H, Ries C (2016) Expression of surface-associated 82kDa-proMMP-9 in primary acute leukemia blast cells inversely correlates with patients' risk. ***Exp. Hematol.*** 44:358-362. ***(IF 2.820)***

285. Braster Q, Silvestre Roig C, Hartwig H, Kusters P, Aarts S, den Toom M, Gallo RL, **Weber C**, Lutgens E, Soehnlein O (2016) Cathelicidin regulates myeloid cell accumulation in adipose tissue and promotes insulin resistance during obesity. ***Thromb. Haemost.*** 115:1237-9. ***(IF 5.627)***

286. Srikakulapu P, Hu D, Yin C, Vineela Bontha S, Mohanta SK, Peng L, Beer M, **Weber C**, McNamara CA, Manz RA, Habenicht AJR (2016) Artery tertiary lymphoid organs control multi-layered territorialized B cell responses in aged ApoE-/- mice. ***Arterioscler. Thromb. Vasc. Biol.*** 36:1174-85. ***(IF 6.607)***

287. Rajasekaran D, Gröning S, Schmitz C, Zierow S, Drucker N, Bakou M, Kohl K, Mertens A, Lue H, **Weber C**, Xiao A, Luker G, Kapurniotu A, Lolis EJ, Bernhagen J (2016) Macrophage migration inhibitory factor-CXCR4 receptor interactions: evidence for partial allosteric agonism in comparison to CXCL12. ***J. Biol. Chem.*** 291:15881-95. ***(IF 4.125)***

288. Schloss MJ, Horckmans M, Nitz K, Bidzhekov K, Duchene J, **Weber C**, Soehnlein O, Steffens S (2016) The time-of-day of ischemia onset affects myocardial infarction healing and heart function through oscillations in neutrophil mobilization. ***EMBO Mol. Med.*** 8:937-48. ***(IF 9.249)***

289. Gamrekelashvili J, Giagnorio R, Jussofie J, Soehnlein O, Duchene J, Briseño CG, Ramasamy SK, Krishnasamy K, Limbourg A, Kapanadze T, Ishifune C, Hinkel R, Radtke F, Strobl LJ, Zimber-Strobl U, Napp LC, Bauersachs J, Haller H, Yasutomo K, Kupatt C, Murphy KM, Adams RH, **Weber C**, Limbourg FP (2016) Regulation of monocyte cell fate by blood vessels. ***Nat. Commun.*** 7:12597. ***(IF 12.124)***

290. Meiler S, Smeets E, Winkels H, Shami A, Nolte M, Beckers L, **Weber C**, Gerdes N, Lutgens E (2016) Constitutive GITR activation reduces atherosclerosis by promoting regulatory CD4+ T cell responses. ***Arterioscler. Thromb. Vasc. Biol.*** 36:1748-52. ***(IF 6.607)***

291. Jamasbi J, Megens RTA, Bianchini M, Münch G, Ungerer M, Sherman S, Faussner A, Brandl R, John C, Buchner J, **Weber C**, Lorenz R, Elia N, Siess W (2016) Substantial enhancement of GPVI-Fc inhibition of human atherosclerotic plaque- and collagen-induced platelet activation by anti-Fc antibody cross-linking**.** ***JACC: Basic to Translational Research*** 1:142-13. ***(IF 0.500)***

292. Viola, JR, Lemnitzer P, Jansen Y, Winter C, Neideck C, Silvestre-Roig C, Döring Y, Drechsler M, **Weber C**, Cenac N, Soehnlein O (2016) Resolving lipid mediators maresin 1 and resolvin D2 prevent atheroprogresion in mice. ***Circ. Res.*** 119:1030-1038. (***IF 13.965***)

293. Ortega-Gomez A, Salvermoser M, Rossaint J, Pick R, Brauner J, Lemnitzer P, Tilgner J, de Jong R, Megens R, Jamasbi J, Döring Y, Pham C, Scheiermann C, Siess W, Drechsler M, **Weber C**, Grommes J, Zarbock A, Walzog B, Soehnlein O (2016) Cathepsin G controls arterial but not venular myeloid cell recruitment. ***Circulation*** 134:1176-1188. ***(IF 19.309)***

294. Finan B, Clemmensen C, Zhu Z, Vanacker K, Müller L, Moreth K, Neff F, Perez-Tilve D, Fischer K, Lutter D, Sánchez-Garrido MA, Flamant D, Biebermann H, Döring Y, **Weber C**, Rozman J, Fuchs S, Gailus-Durner V, Hrabě de Angelis M, Hoffman SM, Gelfanov V, Yang B, Tschöp MH, DiMarchi R, Müller TD (2016) Chemical hybridization of glucagon and thyroid hormone optimizes therapeutic impact for metabolic disease. ***Cell*** 167:843-857. ***(IF 30.410)***

295. Chong SZ, Evrard M, Devi S, Chen J, Lim YJ, See P, Zhang Y, Adrover JM, Lee B, Tan L, Li JLY, Liong KH, Phua C, Balachander A, Boey A, Liebl D, Tan SM, Chan JKY, Balabanian K, Harris JE, Bianchini M, Duchene J, **Weber C**, Lum J, Poidinger M, Chen Q, Renia L, Wang CI, Larbi A, Randolph GJ, Weninger W, Looney MR, Krummel MF, Biswas SK, Ginhoux F, Hidalgo A, Bachelerie F, Ng LG (2016) CXCR4 identifies transitional bone marrow pre-monocytes that replenish the mature monocyte pool for peripheral responses. ***J. Exp. Med.*** 213:2293-2314. ***(IF 11.991)***

296. Agten SM, Koenen RR, Ippel H, Eckardt V, von Hundelshausen P, Mayo KH, **Weber C**, Hackeng TM (2016) Probing functional heteromeric chemokine protein-protein interactions through conformation-assisted oxime-linkage. ***Angew. Chem. Int. Ed. Engl.*** 55:14963-14966. ***(IF 11.994)***

297. Chubanov V, Ferioli S, Wisnowsky A, Simmons D, Leitzinger C, Einer C, Jonas W, Shymkiv Y, Braun A, Akdogan B, Mittermeier L, Sytik L, Torben F, Jurinovic V, van der Vorst EP, **Weber C**, Yildirim ÖA, Sotlar K, Bartsch H, Schürmann A, Zierler S, Zischka H, Ryazanov AG, Gudermann T (2016) Epithelial magnesium transport by TRPM6 is essential for prenatal development and adult survival. ***eLife*** 5:e20914. ***(IF 7.725)***

2017 (IF 257.0)

298. Zahedi F, Nazari-Jahantigh M, Zhou Z, Subramanian P, Wei Y, Grommes J, Offermanns S, Steffens S, **Weber C**, Schober A (2017) Dicer generates a regulatory microRNA network in smooth muscle cells that limits neointima formation during vascular repair. ***Cell. Mol. Life Sci.*** 74:359-372. ***(IF 6.721)***

299. Bamberg F, Hetterich H, Rospleszcz S, Lorbeer R, Auweter SD, Schlett CL, Schafnitzel A, Bayerl C, Schindler A, Saam T, Müller-Peltzer K, Sommer W, Zitzelsberger T, Machann J, Ingrisch M, Selder S, Rathmann W, Heier M, Linkohr B, Meisinger C, **Weber C**, Ertl-Wagner B, Massberg S, Reiser MF, Peters A (2017) Subclinical disease burden as assessed by whole-body MRI in subjects with prediabetes, subjects with diabetes, and normal control subjects from the general population: the KORA-MRI study. ***Diabetes*** 66:158-169. ***(IF 7.273)***

300. Winkels H, Meiler S, Smeets E, Lievens D, Engel D, Spitz C, Bürger C, Rinne P, Beckers L, Dandl A, Reim S, Ahmadsei M, van den Bossche J, Holdt L, Megens RTA, Schmitt MMN, de Winther MPJ, Biessen EAL, Borst J, Faussner A, **Weber C**, Lutgens E, Gerdes N (2017) CD70 limits atherosclerosis and promotes macrophage function. ***Thromb. Haemost.*** 117:164-175. ***(IF 4.952)***

301. ° Horckmans M, Ring L, Duchene J, Santovito D, Schloss M, Drechsler M, **Weber C**, Soehnlein O, Steffens S (2017) Neutrophils orchestrate post-myocardial infarction healing by polarizing macrophages towards a reparative phenotype. ***Eur. Heart J.*** 38:187-197. ***(IF 23.425,*** *623 citations)*

302. Wolf D, Bukosza N, Engel D, Poggi M, Jehle F, Michel AN, Chen Y, Colberg C, Hoppe N, Dufner B, Boon L, Blankenbach H, Hilgendorf I, von zur Mühlen C, Reinohl J, Sommer B, Marchini T, Febbraio MA, **Weber C**, Bode C, Peter KH, Lutgens E, Zirlik A (2017) Inflammation, but not recruitment, of adipose tissue macrophages requires signaling through Mac-1 (CD11b/CD18) in diet-induced obesity (DIO). ***Thromb. Haemost.*** 117:325-338. ***(IF 4.952)***

303. Nicolaou A, Zhao Z, Northoff BH, Sass K, Herbst A, **Weber C**, Steffens S, Rose-John S, Teupser D, Holdt LM (2017) Adam17-deficiency promotes atherosclerosis through enhanced TNFR2 signaling. ***Arterioscler. Thromb. Vasc. Biol.*** 37:247-257. ***(IF 6.086)***

304. de Jong R , Paulin N, Lemnitzer P, Viola J, Winter C, Ferraro B, **Weber C**, Reutelingsperger C, Drechsler M, Soehnlein O (2017) The protective aptitude of annexin A1 in arterial neointima formation in atherosclerosis-porne mice. ***Arterioscler. Thromb. Vasc. Biol.*** 37:312-315. (***IF 6.086***)

305. Paulin N, Döring Y, Kooijman S, Blanchet X, Viola JR, de Jong R, Mandl M, Hendrikse J, Schiener M, von Hundelshausen P, Vogt A, **Weber C**, Bdeir K, Hofmann SM, Rensen PC, Drechsler M, Soehnlein O (2017) Human neutrophil peptide 1 limits hypercholesterolemia-induced atherosclerosis by increasing hepatic LDL clearance. ***EBioMedicine*** 16:204-211. (***IF 6.183***)

306. Tufanli O, Telkoparan P, Acosta-Alvear D, Hamid SM, Onat UI, Kocaturk B, Cimen I, Walter P, **Weber C**, Erbay E (2017) Targeting IRE1 with small molecules counteracts progression of atherosclerosis. ***Proc. Natl. Acad. Sci. USA.*** 114:E1395-E1404. (***IF 9.504***)

307. van der Vorst EPC, Zhao Z, Rami M, Holdt LM, Teupser D, Steffens S, **Weber C** (2017) Contrasting effects of myeloid and endothelial ADAM17 on atherosclerosis development. ***Thromb. Haemost.*** 117:644-646. ***(IF 4.952)***

308. Rowinska Z, Koeppel TA, Sanati M, Schelzig H, Jankowski J, **Weber C**, Zernecke A, Liehn EA (2017) Role of the CX3C chemokine receptor CX3CR1 in the pathogenesis of atherosclerosis after aortic transplantation. ***PLoS One*** 12:e0170644. ***(IF 2.766)***

309. Hyafil F, Pelisek J, Laitinen L, Schottelius M, Mohring M; Döring Y, van der Vorst EPC, Kallmayer M, Steiger K, Poschenrieder A, Notni J, Fischer J, Baumgartner C, Rischpler C, Nekolla SG, **Weber C**, Eckstein HH, Wester HJ, Schwaiger M (2017) Imaging the cytokine receptor CXCR4 in atherosclerotic plaques with the radiotracer 68Ga-pentixafor for positron emission tomography. ***J. Nucl. Med.*** 58:499-506. (***IF 7.439***)

310. Asare Y, Azombo FA, Schmitz C, Lue H, Tilstam PV, Gessner A, Lange D, **Weber C**, Dichgans M, Jankowski J, Pardi R, de Winther MPJ, Noels H, Bernhagen J (2017) Inhibition of atherogenesis by the COP9 signalosome subunit 5 in vivo. ***Proc. Natl. Acad. Sci. USA.*** 114:E2766-E2775. (***IF 9.504***)

311. von Hundelshausen P, Agten S, Eckardt V, Schmitt MMW, Blanchet X, Ippel H, Neideck C, Bidzhekov K, Wichapong K, Faussner A, Drechsler M, Grommes J, van Geffen J, Li H, Leberzammer J, Naumann R, Dijkgraf I, Nicolaes G, Döring Y, Soehnlein O, Lutgens E, Heemskerk J, Koenen R, Mayo K, Hackeng T, **Weber C** (2017) Chemokine interactome mapping enables tailored intervention in acute and chronic inflammation. ***Sci. Transl. Med.*** 9:eaah6650. (***IF 16.710***)

312. Aarts SABM, Seijkens TTP, Kusters PJH, van der Pol SMA, Zarzycka B, Heijnen BDAM, Beckers L, den Toom SM, Gijbels MJJ, Boon L, **Weber C**, de Vries HE, Nicolaes GAF, Dijkstra CD, Kooij G, Lutgens E (2017) Inhibition of CD40-TRAF6 interactions by the small molecule inhibitor 6877002 reduces neuroinflammation. ***J. Neuroinflammation*** 14:105. (***IF 5.193***)

313. Duchene J, Novitzky-Basso I, Casanova-Acebes M, Bianchini M, Etheridge SL, Hub E, Nitz K, Thiriot A, Ulvmar MH, Bacon A, Bidzhekov K, Ruelicke T, Caamano J, Moss PAH, Megens R, von Andrian UH, Hidalgo A, **Weber C***, Rot A* (2017) Atypical chemokine receptor 1 on nucleated erythroid cells regulates haematopoiesis. ***Nat. Immunol.*** 18:753-761. *corresponding authors. ***(IF 21.809)***

314. Rinne P, Rami M, Nuutinen S, Lyytikäinen LP, Raitoharju E, Oksala N, Ring L, Cai M, Hruby VJ, Lehtimäki T, **Weber C**, Steffens S (2017) Melanocortin 1 receptor signaling regulates cholesterol transport in macrophages. ***Circulation*** 136:83-97. ***(IF 18.881)***

315. Döring Y, Noels H, van der Vorst EPC, Egea V, Drechsler M, Mandl M, Neideck C, Pawig L, Jansen J, Schröder K, Bidzhekov K, Megens R, Theelen W, Klinkhammer BM, Boor P, Schurgers L, van Gorp R, Ries C, Kusters PJH, van der Wal A, Hackeng T, Gäbel G, Brandes RP, Soehnlein O, Lutgens E, Vestweber D,

Teupser D, Holdt LM, Rader DJ, Saleheen D, **Weber C** (2017) Vascular CXCR4 limits atherosclerosis by maintaining arterial integrity. ***Circulation*** 136:388-403. ***(IF 18.881)***

316. Mojica Muñoz AK, Jamasbi J, Uhland K, Degen H, Münch G, Ungerer M, Brandl R, Megens R, **Weber C**, Lorenz R, Siess W (2017) Recombinant GPVI-Fc added to single or dual antiplatelet therapy in vitro prevents plaque-induced platelet thrombus formation. ***Thromb. Haemost.*** 117:1651-1659. ***(IF 4.952)***

317. Zhao Z, Karshovska E, Schmitt MMN, Megens R, von Hundelshausen P, Koeppel T, Hackeng T, **Weber C**, Koenen RR (2017) Deletion of junctional adhesion molecule A from platelets increases early stage neointima formation after wire injury in hyperlipidemic mice. ***J. Cell. Mol. Med.*** 21:1523-1531. ***(IF 4.302)***

318. Schloss MJ, Hilby M, Nitz K, Guillamat Prats R, Ferraro B, Leoni G, Soehnlein O, Kessler T, He W, Luckow B, Horckmans M, **Weber C**, Duchene J, Steffens S (2017) Ly6Chigh monocytes oscillate in the heart during homeostasis and after myocardial infarction. ***Arterioscler. Thromb. Vasc. Biol.*** 37:1640-1645. ***(IF 6.086)***

319. Xu Y, Yan S, Yang Q, Wang Y, An X, Zeng X, Zhou Y, Fulton DJ, Weintraub NL, Caldwell R, Bagi Z, Dong Z, Hoda N, Dong Y, Boison D, Li Q, **Weber C**, Jiang X, Wu C, Huo Y (2017) Intracellular adenosine regulates epigenetic programming in endothelial cells to promote angiogenesis. ***EMBO Mol. Med.*** 9:1263-1278. ***(IF 10.293)***

320. Theodorou K, van der Vorst EPC, Gijbels MJ, Wolfs IMJ, Jeurissen M, Theelen TL, Sluimer J, Wijnands E, Cleutjens JP Jansen Y, **Weber C**, Ludwig A, Bentzon JF, Bartsch JW, Biessen EAL, Donners MMPC (2017) Whole body and hematopoietic ADAM8 deficiency does not influence advanced atherosclerotic lesion development, despite its association with human plaque progression. ***Sci. Rep.*** 7:11670. ***(IF 4.122)***

321. Krishnasamy K, Limbourg A, Kapanadze T, Gamrekelashvili J, Beger C, Häger C, Falk C, Napp LC, Bauersachs J, Mack M, Haller H, **Weber C**, Adams RH, Limbourg FP (2017) Blood vessel control of macrophage maturation promotes arteriogenesis in ischemia. ***Nat. Commun.*** 8:952. ***(IF 12.353)***

322. Feng S, Bowden N, Fragiadaki M, Hsiao S, Mahmoud M, Allen S, Thompson AA, **Weber C**, Ridger V, Schober A, Evans P (2017) Mechanical activation of hypoxia-inducible factor 1α drives endothelial dysfunction at atheroprone sites. ***Arterioscler. Thromb. Vasc. Biol.*** 37:2087-2101. ***(IF 6.086)***

323. Winkels H, Meiler S, Smeets E, Lievens D, Engel D, Spitz C, Bürger C, Beckers L, Dandl A, Reim S, Ahmadsei M, Hartwig H, Holdt L, Hristov M, Megens RTA, Schmitt MM, Biessen EA, Borst J, Faussner A, **Weber C**, Lutgens E, Gerdes N (2017) CD27 co-stimulation increases frequency of regulatory T cells and reduces atherosclerosis in hyperlipidemic mice. ***Eur. Heart J.*** 38:3590-3599. ***(IF 23.425)***

324. Kusters P, Seijkens T, Bürger C, Legein B, Winkels H, Gijbels M, Barthels C, Bennett R, Beckers L, Atzler D, Biessen E, Brocker T, **Weber C**, Gerdes N, Lutgens E (2017) Constitutive CD40-signaling in dendritic cells limits atherosclerosis by provoking inflammatory bowel disease and ensuing cholesterol malabsorption. ***Am. J. Pathol.*** 187:2912-2919. ***(IF 4.069)***

2018 (IF 225.9)

325. Merckelbach S, van der Vorst E, Kallmayer M, Rischpler C, Burgkart R, Döring Y, de Borst J, Schwaiger M, Eckstein HH, **Weber C**, Pelisek J (2018) Expression and cellular localization of CXCR4 and CXCL12 in human carotid atherosclerotic plaques. ***Thromb. Haemost.*** 118:195-206. ***(IF 4.773)***

326. Nicolaou A, Northoff Bernd, Zhao Z, Kohlmaier A, Sass K, Rose-John S, Steffens S, **Weber C**, Teupser D, Holdt LM (2018) The ADAM17 metalloproteinase maintains arterial elasticity. ***Thromb. Haemost.*** 118:210-213. ***(IF 4.773)***

327. Curaj A, Wu Z, van Zandvoort M, Gresch O, **Weber C**, Lammers T, Liehn EA, Kiessling F (2018) Molecular ultrasound imaging of junctional adhesion molecule-A depicts acute changes in blood flow and its effect on endothelial activation. ***Arterioscler. Thromb. Vasc. Biol.*** 38:40-48. ***(IF 6.618)***

328. Ebrahim M, Jamasbi J, Adler K, Megens RTA, M'Bengue Y, Blanchet X, Uhland K, Ungerer M, Brandl R, **Weber C**, Elia N, Lorenz R, Münch G, Siess W(2018) Dimeric glycoprotein VI binds to collagen but not to fibrin. ***Thromb. Haemost.*** 118:351-361. ***(IF 4.773)***

329. Seijkens TTP, van Tiel CM, Atzler D, Kusters PJ, Zarzycka B, Lameijer M, Soehnlein O, Hoeksema M, Gijbels MJ, Beckers L, den Toom M, Schrijver R, Boon L, Fay F, Jongejan A, Moerland PD, Vriend G, Bleijlevens B, Fisher EA, Duivenvoorden R, Gerdes N, de Winther MP, Nicholaes GA, Mulder WJ, **Weber C**, Lutgens E (2018) Targeting CD40-induced TRAF6 signaling in macrophages reduces atherosclerosis. ***J. Am. Coll. Cardiol.*** 71:527-542. (***IF 18.639***)

330. Horckmans M, Bianchini M, Santovito D, Megens R, Springael JY, Vacca M, Di Eusanio M, Moschetta A, **Weber C**, Duchene J, Steffens S (2018) Pericardial adipose tissue regulates granulopoiesis, fibrosis, and cardiac function after myocardial infarction. ***Circulation*** 137:948-960. ***(IF 23.054)***

331. Lacy M, Kontos C, Brandhofer M, Hille K, Gröning S, Sinitski D, Bourilhon P, Rosenberg E, Krammer C, Thavayogarajah T, Pantouris G, Bakou M, **Weber C**, Lolis E, Bernhagen J, Kapurniotu A (2018) Identification of an Arg-Leu-Arg tripeptide that contributes to the binding interface between the cytokine MIF and the chemokine receptor CXCR4. ***Sci. Rep.*** 8:5171. ***(IF 4.011)***

332. Rami M, Guillamat-Prats R, Rinne P, Salvermoser M, Ring L, Bianchini M, Blanchet X, Megens R, Döring Y, Walzog B, Soehnlein O, **Weber C**, Faussner A, Steffens S (2018). Chronic intake of the selective serotonin reuptake inhibitor fluoxetine enhances atherosclerosis. ***Arterioscler. Thromb. Vasc. Biol.*** 38:1007-1019. ***(IF 6.618)***

333. Busygina K, Jamasbi J, Seiler T, Deckmyn H, **Weber C**, Brandl R, Lorenz R, Siess W (2018) Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation. ***Blood*** 131:2605-2616. ***(IF 16.562)***

334. Winter C, Silvestre-Roig C, Ortega-Gomez A, Lemnitzer P, Poelmann H, Schumski A, Winter J, Drechsler M, de Jong R, Immler R, Sperandio M, Hristov M, Zeller T, Nicolaes GAF, **Weber C**, Viola JR, Hidalgo A, Scheiermann C, Soehnlein O (2018) Chrono-pharmacological targeting of the CCL2-CCR2 axis ameliorates atherosclerosis. ***Cell Metab.*** 28:175-182. ***(IF 22.415)***

335. Viola JR, Lemnitzer P, Paulin N, Drechsler M, Nazari-Jahantigh M, Maas S, de Jong R, Winter J, Schober A, **Weber C**, Atabai K, Soehnlein O (2018) Deletion of MFGE8 inhibits neointima formation upon arterial damage. ***Thromb. Haemost.*** 118:1340-1342. ***(IF 4.773)***

336. Ziegler T, Bähr A, Howe A, Klett K, Jusada W, **Weber C**, Laugwitz KL, Kupatt C, Hinkel R (2018) Tβ4 increases neovascularization and cardiac function in chronic myocardial ischemia of normo- and hypercholesterolemic pigs.. ***Mol. Ther.*** 26:1706-1714. ***(IF 8.402)***

337. Vajen T, Koenen RR, Kanzler I, Projahn D, Curaj A, Sönmez TT, Simsekyilmaz S, Schumacher D, Möllmann J, Hackeng TM, von Hundelshausen P, **Weber C***, Liehn EA* (2018) Blocking CCL5-CXCL4 heteromerization preserves heart function after myocardial infarction by attenuating leukocyte recruitment and NETosis. ***Sci. Rep.*** 8:10647. *equal contribution. ***(IF 4.011)***

338. Domschke G, Linden F, Pawig L, Hafner A, Akhavanpoor M, Reymann J, Doesch A, Erbel C, **Weber C**, Katus H, Noels H, Erfle H, Gleissner C, Runz H (2018) Systematic RNA-interference in primary human monocyte-derived macrophages: A high-throughput platform to study foam cell formation. ***Sci. Rep.*** 8:10516. ***(IF 4.011)***

339. ° Paulin N, Viola JR, Maas SL, de Jong R, Fernandes-Alnemri T, **Weber C**, Drechsler M, Döring Y, Soehnlein O (2018) Double-strand DNA sensing Aim2 inflammasome regulates atherosclerotic plaque vulnerability. ***Circulation*** 138:321-323. ***(IF 23.054)***

340. Schmitz C, Noels H, El Bounkari O, Straußfeld E, Megens RTA, Sternkopf M, Alampour-Rajabi S, Krammer C, Tilstam PV, Gerdes N, Bürger C, Kapurniotu A, Bucala R, Jankowski J, **Weber C**, Bernhagen J (2018) Mif-deficiency favors an atheroprotective autoantibody phenotype in atherosclerosis ***FASEB J.*** 32:4428-4443. ***(IF 5.391)***

341. Rinne P, Guillamat-Prats R, Rami M, Bindila L, Ring L, Lyytikäinen LP, Raitoharju E, Oksala N, Lehtimäki T, **Weber C**, van der Vorst EPC, Steffens S (2018) Palmitoylethanolamide promotes a pro-resolving macrophage phenotype and attenuates atherosclerotic plaque formation. ***Arterioscler. Thromb. Vasc. Biol.*** 38:2562-2575. ***(IF 6.618)***

342. ° Casanova-Acebes M, Nicolás-Ávila JA, Weiss LA, Adrover JM, A-González N, Devi S, Mortha A, Quintana J, Crainiciuc J, Leiva MN, **Weber C**, Nagasawa T, Soehnlein O, Merad M, Ng L, Hidalgo A (2018) Neutrophils instruct homeostatic and pathological states in naïve tissues. ***J. Exp. Med.*** 215:2778-95. ***(IF 10.892)***

343. Braza MS, van Leent MMT, Lameijer M, Sanchez-Gaytan BL, Arts RJW, Pérez-Medina C, Conde P, Garcia MR, Gonzalez-Perez M , Brahmachary M, Fay F, Kluza E, Kossatz S,Dress RJ, Salem F, Rialdi A, Reiner T, Boros P, Strijkers GJ, Calcagno CC, Ginhoux F, Marazzi I, Lutgens E, Nicolaes GAF, **Weber C**, Swirski FK, Nahrendorf M, Fisher EA, Duivenvoorden R, Fayad ZA, Netea MG, Mulder WMJ, Ochando J (2018) Inhibiting inflammation with myeloid cell-specific nanobiologics promotes organ transplant acceptance. ***Immunity*** 49:819-828. (***IF 21.522***)

344. Stocker T, Pircher J, Skenderi A, Ehrlich A, Eberle C, Megens R, Petzold T, Zhang S, Walzog B, Müller-Taubenberger A, **Weber C**, Massberg S, Ishikawa-Ankerhold H, Schulz, C (2019) The actin regulator Coronin1A modulates platelet shape change and consolidates arterial thrombosis. ***Thromb. Haemost.*** 118:2098-2111. ***(IF 4.773)***

345. Baaten CCF, Meacham S, de Witt SM, Feijge MAH, Adams DJ, Akkerman JW, Cosemans JM, Jupe S, Kostadima M, Mattheij NJA, Prins MH, Ramirez-Solis R, Soehnlein O, **Weber C**, White JK, Ouwehand WH, Heemskerk JWM (2018) A synthesis approach of mouse studies to identify genes and proteins in arterial thrombosis and bleeding. ***Blood*** 132:e35-e46. ***(IF 16.562)***

346. Ziegler T, Kraus M, Husada W, Gesenhues F, Jiang Q, Pinkenburg O, Trenkwalder T, Laugwitz KL, le Noble F, **Weber C**, Kupatt C, Hinkel R (2018) Steerable induction of the Thymosin ß4/MRTF-A pathway via AAV-based overexpression induces therapeutic neovascularization. ***Hum. Gene Ther.*** 28:1407–1415. ***(IF 3.855)***

2019 (IF 251.9)

347. Guillamat Prats R, Rami M, Ring L, Rinne P, Lauer E, Lenglet S, Thomas A, Cravatt BF, **Weber C**, Faussner A, Steffens S (2019) Deficiency of monoacylglycerol lipase enhances IgM plasma levels and limits atherogenesis in a CB2-dependent manner. ***Thromb. Haemost.*** 119:348-351. ***(IF 4.379)***

348. Seijkens TTP, Poels K, Meiler S, van Tiel CM, Kusters PJH, Reiche M, Atzler D, Winkels H, Tjwa M, Poelman H, Slütter B, Kuiper J, Gijbels M, Kuivenhoven JA, Perisic Matic L, Paulsson-Berne G, Hedin U, Hansson GK, Nicolaes GA, Daemen MAJP, **Weber C**, Gerdes N, de Winther M, Lutgens E (2019) Deficiency of the T cell regulator CBL-B aggravates atherosclerosis by inducing CD8+ T cell-mediated macrophage death. ***Eur. Heart J.*** 40:372-382. ***(IF 22.673)***

349. Pfeiler S, Thakur M, Grünauer P, Megens R, Joshi U, Coletti R, Samara V, Müller-Stoy G, Ishikawa-Ankerhold H, Stark K, Klingl A, Fröhlich T, Arnold G, Wörmann S, Bruns C, Algül H, **Weber C**, Massberg S, Engelmann B (2019) CD36-triggered cell invasion and persistent tissue colonization by tumor microvesicles during metastasis. ***FASEB J.*** 33:1860-1872. ***(IF 4.966)***

350. ° Adrover JM, Del Fresno C, Crainiciuc G, Cuartero MI, Casanova-Acebes M, Weiss LA, Huerga-Encabo H, Silvestre-Roig C, Rossaint J, Cossío I, Lechuga-Vieco AV, García-Prieto J, Gómez-Parrizas M, Quintana JA, Ballesteros I, Martin-Salamanca S, Aroca-Crevillen A, Chong SZ, Evrard M, Balabanian K, López J, Bidzhekov K, Bachelerie F, Abad-Santos F, Muñoz-Calleja C, Zarbock A, Soehnlein O, **Weber C**, Ng LG, Lopez-Rodriguez C, Sancho D, Moro MA, Ibáñez B, Hidalgo A (2019) A neutrophil timer coordinates immune defense and vascular protection. ***Immunity*** 50:390-402. (***IF 22.553***)

351. Schloss MJ, Horckmans M, Guillamat Prats R, Hering D, Lauer E, Lenglet S, **Weber C**, Thomas A, Steffens S (2019) 2-arachidonoylglycerol mobilizes myeloid cells and worsens heart function after myocardial infarction. ***Cardiovasc. Res.*** 115:602-613. ***(IF 8.168)***

352. ° Cremer S, Michalik K, Pfisterer L, Winter C, Boon R, Fischer A, Jaé N, Muhly-Reinholz M, John D, Uchida S, **Weber C**, Poller W, Günther S, Braun T, Li Y, Maegdefessel L, Perisic Matic L, Hedin U, Soehnlein O, Zeiher A, Dimmeler S (2019) Hematopoietic deficiency of the long non-coding RNA MALAT1 promotes atherosclerosis and plaque inflammation. ***Circulation*** 139:1320-1334. ***(IF 23.603)***

353. ° Döring Y, van der Vorst EPC, Duchene J, Jansen Y, Gencer S, Bidzhekov K, Atzler D, Santovito D, Rader DJ, Saleheen D, **Weber C** (2019) CXCL12 derived from endothelial cells promotes atherosclerosis to drive coronary artery disease. ***Circulation*** 139:1338–1340. ***(IF 23.603)***

354. ° Yin C*, Ackermann S*, Mohanta SK, Ma Z, Nietzsche S, Westermann M, Peng L, Bontha SV, Srikakulapu P, Beer M, Megens RTA, Steffens S, Hildner M, Eckstein HH, Pelisek J, Herms J, Röber S, Arzberger T, Habenicht L, Binder C, **Weber C***, Zipfel PF*, Skerka C*, Habenicht AJR* (2019) ApoE attenuates unresolvable inflammation by complex formation with activated C1q. ***Nat. Med.*** 25:496-506. *equal contribution. ***(IF 36.130**, 220 citations)*

355. Denzinger V, Busygina K, Jamasbi J, Pekrul I, Spannagl M, **Weber C**, Lorenz R, Siess W (2019) Optimizing platelet GPVI inhibition versus hemostatic impairment by the Btk-inhibitors ibrutinib, acalabrutinib,ONO/GS-4059, BGB-3111 and evobrutinib. ***Thromb. Haemost.*** 119:397-406. ***(IF 4.379)***

356. van der Vorst EPC, Mandl M, Neideck C, Jansen Y, Hristov M, Meiler S, Noels H, Söhnlein O, Drechsler M, **Weber C**, Döring Y (2019) Hematopoietic ChemR23 fuels atherosclerosis by sustaining a M1 macrophage-phenotype and guidance of plasmacytoid dendritic cells to murine lesions. ***Arterioscler. Thromb. Vasc. Biol.*** 39:685-693. ***(IF 6.604)***

357. ° Silvestre-Roig C, Braster Q, Wichapong K, Ernest Y, Lee E, Teulon JM, Berrebeh N, Winter J, Adrover JM, Santos GS, Froese A, Lemnitzer P, Ortega-Gómez A, Chevre R, Marschner J, Schmuski A, Winter C, Perez-Olivares, Chang P, Paulin N, Schoufour T, Hartwig H, González Ramos S, Kamp F, Megens RTA, Mowen KA, Gunzer M, Maegdefessel L, Hackeng T, Lutgens E, Daemen M, von Blume J, Anders HJ, Nikolaev V, Pellequer JL, **Weber C**, Hidalgo A*, Wong G*, Nicolaes G*, Soehnlein O (2019) Externalized histone H4 orchestrates chronic inflammation by inducing lytic cell death. ***Nature*** 569:236-240. ***(IF 42.778**, 293 citations)*

358. Vila-Caballera MA, González-Granado JM, Zoritab V, Abu Nabah YN, Silvestre-Roig C, Molina-Sánchez P, Ait-Oufella H, Andrés-Manzano MJ, Sanz MJ, **Weber C**, Kremeri L, Gutiérrez J, Mallat Z, Andrés V (2019) Disruption of the CCL1-CCR8 axis inhibits vascular Treg recruitment and function and promotes atherosclerosis in mice. ***J. Mol. Cell. Cardiol.*** 132:154-163. ***(IF 4.133)***

359. Bianchini M, Duchêne J*, Santovito D, Schloss MJ, Evrard M, Winkels H, Aslani M, Mohanta SK, Horckmans M, Blanchet X, Lacy M, von Hundelshausen P, Atzler D, Habenicht A, Gerdes N, Pelisek J, Ng LG, Steffens

S, **Weber C***, Megens RTA (2019) PD-L1 on non-classical monocytes reveals their origin and immuno-regulatory function. ***Sci. Immunol.*** 4(36). pii: eaar3054. *corresponding author. ***(IF 13.440)***

360. Cimen I, Yildirim Z, Dogan AE, Yildirim AD, Tufanlı Ö, Watkins SM, **Weber C**, Hotamışlıgil GS, Erbay E (2019) Double bond configuration of palmtioleate is critical for atheroprotection. ***Mol. Metab.*** 28:58-72. ***(IF 6.448)***

361. Kiouptsi K, Jäckel S, Grill, Kuijpers M, Wilms E, **Weber C**, Sommer F, Nagy M, Neideck C, Ascher S, Formes H, Karwot C, Jansen J, Subramaniam S, Rosenstiel P, Walter U, Jurk K, Heemskerk JW, van der Vorst E, Döring Y*, Reinhardt C* (2019) The microbiota promotes thrombogenicity but does affect late atherosclerotic lesion size of atherosclerotic Ldlr-/- mice. ***mBio*** 10(5). pii: e02298-19. ***(IF 6.784)***

362. Joppich M, **Weber C**, Zimmer R (2019) Using context-sensitive text mining to identify miRNAs in different stages of atherosclerosis (2019) ***Thromb. Haemost.*** 119:1247-1264. ***(IF 4.379)***

363. Bongiovanni D, Santamaria G, Klug M, Santovito D, Felicetta A, Hristov M, von Scheidt M, Aslani M, Cibella J, **Weber C**, Moretti A, Condorelli G, Laugwitz KL, Peano C, Bernlochner I (2019) Transcriptome analysis of reticulated platelets reveals a prothrombotic profile. ***Thromb. Haemost.*** 119:1795-1806. ***(IF 4.379)***

364. ° Varasteh Z, Mohanta S, Robu S, Braeuer M, Li Y, Omidvari N, Topping G, Sun T, Nekolla SG, Richter A, **Weber C**, Habenicht A, Haberkorn UA, Weber WA (2019) Molecular imaging of fibroblast activity after myocardial infarction using a 68Ga-labelled fibroblast activation protein inhibitor FAPI-04. ***J. Nucl. Med.*** 60:1743-1749. (***IF 7.887***)

365. Goldmann L, Duan R, Kragh T, Wittmann G, **Weber C**, Lorenz R, von Hundelshausen P, Spannagl M, Siess W (2020) Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc-receptor CD32 (FcγRIIA): a new option in HIT? ***Blood Adv.*** 3:4021-4033. ***(IF 4.584)***

2020 (IF 188.1)

366. Tilstam PV, Soppert J, Hemmers C, Harlacher E, Döring Y, van der Vorst EPC, Schulte C, Alampour-Rajabi S, Theelen W, Asare Y, de Winther MPJ, Lawrence T, Bernhagen J, Schober A, Zernecke A, Jankowski J, **Weber C**, Noels H (2020) Non-activatable mutant of the Inhibitor of Kappa B Kinase α (IKKα) kinase exerts site-specific effects on atherosclerosis in Apoe-deficient mice. ***Atherosclerosis*** 292:23-30. ***(IF 5.162)***

367. Occhiuzzi U, Natarelli L, Affaitati G, De Blasis G, Santovito D, Giamberardino MA, Mandolini C, Bucci M, Stellin L, De Nardis V, Paganelli C, Pinelli M, **Weber C**, Mastroiacovo D, De Cesare D, Marcantonio P, Desideri G, Cipollone F (2020) High-dose rosuvastatin increases ABCA1 transporter in human atherosclerotic plaques in a cholesterol-independent fashion. ***Int. J. Cardiol.*** 299:249-253. ***(IF 4.164)***

368. van der Vorst EPC, Daissormont I, Aslani M, Seijkens T, Wijnands E, Lutgens E, Duchene J, Santovito D, Döring Y, Halvorsen B, Aukrust P, **Weber C**, Höpken UE, Biessen EAL (2020) Interruption of the CXCL13/CXCR5 chemokine axis enhances plasma IgM levels and attenuates atherosclerosis development. ***Thromb. Haemost.*** 120:344-347. ***(IF 5.723)***

369. ° Adrover JM, Aroca-Crevillén A, Crainiciuc G, Ostos F, Rojas-Vega Y, Rubio-Ponce A, Cilloniz C, Bonzón-Kulichenko E, Calvo E, Rico D, Moro MA, **Weber C**, Lizasoaín I, Torres A, Ruiz-Cabello J, Vázquez J, Hidalgo A (2020) Programmed “disarming” of the neutrophil proteome reduces the magnitude of inflammation. ***Nat. Immunol.*** 21:135-144. ***(IF 25.606)***

370. Bernlochner I, Klug Melissa, von Scheidt M, Santovito D, Hristov M, **Weber C,** Laugwitz KL, Bongiovanni D (2020) Sorting and magnetic based isolation of reticulated platelets from peripheral blood. ***Platelets*** 11:1-7. ***(IF 3.862)***

371. Butt E, Stempfle K, Lister L, Wolf F, Kraft M, Hermann AB, Viciano CP, **Weber C**, Hochhaus A, Ernst T, Hoffmann C, Zernecke A, Frietsch JJ (2020) CXCR4-LASP1-AKT1 Interaction - differences between breast cancer and CML. ***Cells*** 9. pii: E444. ***(IF 6.600)***

372. Döring Y, Cimen I, Jansen Y, Aslani M, Gencer S, Peters LJF, Duchene J, **Weber C***, van der Vorst EPC* (2020) B-cell specific CXCR4 protects against atherosclerosis development and increases plasma IgM levels. ***Circ. Res.*** 126:787-788. ***(IF 17.367)*** *equal contribution.

373. Eckardt V, Miller MC, Blanchet X, Leberzammer J, Duchene J, Söhnlein O, Megens RTA, Ludwig AK, Dregni A, Faussner A, Wichapong K, Ippel H, Dijkgraaf I, Hackeng TM, **Weber C**, Gabius HJ, Mayo KH, von Hundelshausen P (2020) Chemokines and galectins form heterodimers to modulate inflammation. ***EMBO Reports*** 21:e47852. ***(IF 8.807)***

374. Hinkel R, Ramanujam D, Kazcmarek V, Howe A, Klett K, Beck C, Dueck A, Thum T, Laugwitz KL, Maegdefessel L, **Weber C**, Kupatt C, Engelhardt S (2020) Inhibition of microRNA-21 prevents myocardial remodelling and dysfunction in a pig model of ischemia/reperfusion injury-induced heart failure. ***J. Am. Coll. Cardiol.*** 75:1788-1800. (***IF 24.094***)

375. Zhang D, Ebrahim M, Adler K, Jamasbi J, Remco M, Uhland K, Ungerer M, Münch G, Deckmyn H, **Weber C**, Elia N, Lorenz R, Siess W (2020) Glycoprotein VI is not a functional platelet receptor for fibrin formed in plasma or blood. ***Thromb. Haemost.*** 120:977-993. ***(IF 5.723)***

376. Santovito D*, Egea V*, Bidzhekov K*, Natarelli L*, Mourão A, Wichapong K, Blanchet X, Aslani M, Horckmans M, Hristov M, Lutgens E, Daemen MJAP, Hackeng T, Ries C, von Hundelshausen P, Steffens S, Duchene J, Megens RTA, Sattler M, **Weber C** (2020) Non-canonical inhibition of caspase-3 by a nuclear microRNA confers endothelial protection by autophagy in atherosclerosis. ***Sci. Transl. Med.*** 12:eaaz2994. ***(IF 17.956***, *83 citations)*

377. Kiouptsi K, Pontarollo G, Todorov H, Jäckel S, Karwot C, Gerber S, Jansen Y, **Weber C**, Döring Y, Reinhardt C (2020) Germ-free housing conditions do not affect aortic root and aortic arch lesion size of late atherosclerotic low-density lipoprotein receptor-deficient mice. ***Gut Microbes*** 11:1809-1823. ***(IF 10.245)***

378. Shami A, Atzler D, Bosmans L, Winkels H, Meiler S, Lacy M, van Tiel C, Megens R, Nitz K, Baardman J, Buerger C, Janjic A, Riccardi C, Edsfeldt A, Monaco C, Daemen M, de Winther M, Nilsson J, **Weber C**, Gerdes N, Gonçalves I, Lutgens E (2020) Glucocorticoid-induced tumour necrosis factor receptor family-related protein (GITR) drives atherosclerosis in mice and is associated with an unstable plaque phenotype and cerebrovascular events in humans. ***Eur. Heart J.*** 41:2938-2948. ***(IF 29.983)***

379. Hamid SM, Citir M, Terzi E, Cimen I, Yildirim Z, Dogan AE, **Weber C**, Traynor-Kaplan A, Schultz C, Erbay E (2020) Mammalian inositol-requiring enzyme-1 regulates phosphoinositide signaling lipids and cell growth. ***EMBO Reports*** e51462. ***(IF 8.807)***

380. Kontos C, El Bounkari O, Krammer C, Sinitski D, Hille K, Zan C, Guangyao Y, Wang S, Brandhofer M, Bourilhon P, Megens RTA, Hoffmann A, Asare Y, Gao Y, Leng L, Mägdefessel L, Eckstein HH, Pelisek J, Gokce O, Bucala R, Dichgans M, **Weber C**, Kapurniotu A, Bernhagen J (2020) An engineered soluble chemokine receptor that blocks atherogenic inflammation by agonist-specific targeting. ***Nat. Commun.*** 11:5981. ***(IF 14.919)***

2021 (IF 362.4)

381. Krammer C, Kontos C, Dewor M, Hille K, El Bounkari O, Tas K, Sinitski D, Brandhofer M, Megens RTA, **Weber C**, Schultz JR, Bernhagen J, Kapurniotu A (2021) A MIF-derived cyclopeptide that inhibits MIF binding and atherogenic signaling via the chemokine receptor CXCR2. ***Chembiochem.*** 22:1012-19. ***(IF 3.461)***

382. Santovito D, Toto L, De Nardis V, Marcantonio P, D'Aloisio R, Mastropasqua A, De Cesare D, Bucci M, Paganelli C, Natarelli L, **Weber C**, Consoli A, Mastropasqua R, Cipollone F (2021) Plasma microRNA signature associated with retinopathy in patients with type 2 diabetes. ***Sci. Rep.*** 11:4136. ***(IF 4.996)***

383. Natarelli L, Parca L, Mazza T, **Weber C***, Virgili F, Fratantonio D (2021) MicroRNAs and long non-coding RNAs as potential candidates to target specific motifs of SARS-CoV-2. ***Non-coding RNA*** 7:14. ***(IF 6.840)*** *corresponding author.

384. Gencer S, Döring Y, Jansen Y, Bayasgalan S, Schengel O, Müller M, Peters L, **Weber C**, van der Vorst EPC (2021) Adipocyte-specific ACKR3 regulates lipid levels in adipose tissue. ***Biomedicines*** 9:394. ***(IF 4.757)***

385. Gissler M, Scherrer P, Anto-Michel N, Pennig J, Hoppe N, Füner L, Härdtner C, Stachon P, Hilgendorf I, Bode C, **Weber C**, Lutgens E, Wolf D, Gerdes N, Zirlik A, Willecke F (2021) Deficiency of endothelial CD40 induces a stable plaque phenotype and limits inflammatory cell recruitment to atherosclerotic lesions in mice. ***Thromb. Haemost.*** 121:1530-1540. ***(IF 6.681)***

386. Sundararaman SS, Peters LJF, Jansen Y, Gencer S, Yan Y, Nazir S, Biessen EAL, Jankowski J, **Weber C**, Döring Y, van der Vorst EPC (2021) Adipocyte calcium sensing receptor is not involved in in-vivo adipocyte inflammation or atherosclerosis development. ***Sci. Rep.*** 11:10409. ***(IF 4.996)***

387. Egea V, Kessenbrock K, Lawson D, Bartelt A, **Weber C**, Ries C (2021) Let-7f miRNA regulates CXCL12- and hypoxia-promoted migration of mesenchymal stem cells and attenuates tumor growth upon exosomal release. ***Cell Death Dis.*** 12:516. ***(IF 9.705)***

388. Hinkel R, Baktai S, Baehr A, Bozoglu T, Straub S, Borchert T, Viereck J, Howe A, Hornaschewitz N, Jurisch V, Kozlik-Feldmann R, Freudenthal F, Ziegler T, **Weber C**, Sperandio M, Engelhardt S. Laugwitz KL, Moretti A, Klymiuk N, Thum T, Kupatt C (2021) AntimiR-132 inhibits transition to pathologic hypertrophy in a large animal model of percutaneous aortic constriction. ***J. Am. Coll. Cardiol.*** 77:2923-2935. (***IF 27.203***)

389. Lacy M, Bürger C, Ahmadsei M, Winkels H, Nitz K, van Tiel C, Seijkens T, Kusters P, Karshovka E, Reim S, Kuipers M, Reiche M, Megens RTA, Heemskerk J, **Weber C**, Gerdes N, Atzler D, Lutgens E (2021) Cell-specific and divergent roles of the CD40L-CD40 axis in atherosclerotic vascular disease. ***Nat. Commun.*** 12:3754. ***(IF 17.694)***

390. van der Vorst EPC, Pepe MA, Peters LJ, Haberbosch M, Jansen Y, Nauman R, Stathopoulos GT, **Weber C**, Bidzhekov K (2021) Transcriptome signature of miRNA-26b KO mouse model suggests novel interactions. ***BMC Genom. Data*** 22:23 ***(IF 3.969)***

391. Schober A, Blay RM, Saboor Maleki S, Zahedi F, Winkelmaier A, Kakar M, Baatsch I, Zhu M, Geissler C, Fusco A, Eberlein A, Li N, Megens RTA, Banafsche R, Kumbrink J, **Weber C**, Nazari-Jahantigh (2021) MicroRNA-21 controls the circadian regulation of apoptosis in atherosclerotic lesions. ***Circulation*** 144:1059-1073. ***(IF 39.918)***

392. Hinterdobler J, Schott S, Meesmann A, Steinsiek AL, Zimmermann AS, Wobst J, Vilne B, Jin H, Baecklund A, Chen CS, Moggio A, Braster Q, Molitor S, Hristov M, **Weber C**, Wenzel P, Scheiermann C, Maegdefessel L, Soehnlein O, Libby P, Nahrendorf M, Schunkert H, Kessler T, Sager HB (2021) Acute mental stress promotes inflammatory leukocyte migration to tissues. ***Eur. Heart J.*** 42:4077-4088. ***(IF 35.855)***

393. Duan R, Goldmann L, Brandl R, Spannagl M, **Weber C**, Siess W, von Hundelshausen P (2021) Effects of the Btk-inhibitors remibrutinib (LOU064) and rilzabrutinib (PRN1008) with varying Btk selectivity over Tec on platelet aggregation and in vitro bleeding time. ***Trends Cardiovasc. Med.*** 8:749022. ***(IF 8.049)***

394. He Y, Xie X, Zhang H, Ye J, Gencer S, van der Vorst EPC, Döring Y, Weber C, Pang X, Jing Z, Yan Y, HanZ (2021) Identification of hypoxia induced metabolism associated genes in pulmonary hypertension. ***Front. Pharmacol.*** 12:753727. ***(IF 5.988)***

395. **Weber C**, von Hundelshausen P, Siess W (2021) VITT after ChAdOx1 nCOV-19 vaccination. ***N. Engl. J Med.*** 385:2202-2205. ***(IF 176.079)***

396. Duan R, Goldmann L, Li Y, **Weber C**, Siess W, von Hundelshausen P (2021) Spontaneous platelet aggregation in blood is mediated by FcγRIIA stimulation of Bruton's tyrosine kinase ***Int. J. Mol. Sci.*** 23:67. ***(IF 6.208)***

2022 (IF 237.1)

397. Bozoglu T, Lee S, Ziegler T, Jurisch V, Maas S, Bähr A, Hinkel R, Hoenig A, Hariharan A, Decker S, Sami H, Koppara T, Oellinger R, Müller OJ, Frank D, Megens R, Nelson P, **Weber C**, Schnieke A, Sperandio M, Santamaria G, Rad R, Moretti A, Laugwitz KL, Soehnlein O, Ogris M, Kupatt C (2022) Endothelial retargeting of AAV9 in vivo. ***Adv. Sci.*** 9:e2103867. ***(IF 17.521)***

398. Leberzammer J, Agten S, Blanchet X, Duan R, Ippel H, Megens RTA, Schulz C, Aslani M, Duchene J, Schmitt M, Stark K, Siess W, Heemskerk J, Hackeng T, Mayo K, **Weber C***, von Hundelshausen P* (2022) Targeting platelet-derived CXCL12 inhibits arterial thrombosis. ***Blood*** 139:2691-2705. ***(IF 25.476)*** *equal contribution.

399. ° Mohanta SK, Peng L, Li Y, Yin C, Lu S, Sun T, Carnevale L, Perrotta M, Ma Z, Förstera B, Stanic K, Zhang C, Zhang X, Szczepaniak P, Bianchini M, Saeed B, Carnevale R, Hu D, Nosalski R, Pallante F, Beer M, Santovito D, Ertürk A, Mettenleiter TC, Klupp BG, Megens RTA, Steffens S, Pelisek J, Eckstein HH, Kleemann R, Habenicht L, Mallat Z, Michel J, Bernhagen J, Dichgans M, D´Agostino G, Guzik T, Olofsson P, **Weber C***, Lembo G*, Carnevale D*, Habenicht AJR* (2022) Neuroimmune cardiovascular interfaces control atherosclerosis. ***Nature*** 605:152-159. *equal contribution. ***(IF 69.504***, *135 citations)*

400. Rot A, Biswas A, Hub E, Guthjar J, Aslani M, Thiriot A, von Andrian U, Megens RTA, **Weber C**, Duchene J (2022) Murine bone marrow macrophages and human monocytes do not express atypical chemokine receptor 1. ***Cell Stem Cell*** 29:1013-1015. ***(IF 25.269)***

401. Faussner A, Deininger M, **Weber C**, Steffens S (2022) Poly-lysine and poly-ethylenimine promoted cell adherence: a simple alternative to plate pre-coating. ***PLoS One*** 17:e0260173. ***(IF 3.752)***

402. Liu Y, Shi JZ, Jiang R, Liu SF, He YY, van der Vorst EPC, **Weber C**, Döring Y, Yan Y (2022) Regulatory T cell-related gene indicators in pulmonary hypertension. ***Front. Pharmacol.*** 13:908783. ***(IF 6.353)***

403. Peters LJF, Baaten CCF, Maas SL, Lu C, Nagy M, Jooss N, Bidzhekov K, Moreno-Andres D, Jankowski J, Biessen EAL, Döring J, Heemskerk JWM, **Weber C**, Kuijpers MEJ, van der Vorst EPC (2022) MicroRNA-26b attenuates platelet adhesion and aggregation in mice. ***Biomedicines*** 10:983. ***(IF 4.757)***

404. Gencer S, Jansen Y, Bayasgalan S, Yan Y, Cimen I, Müller M, Peters LJF, Megens RTA, Lemnitzer P, Soehnlein O, **Weber C**, Döring Y, van der Vorst EPC (2022) Endothelial ACKR3 drives atherosclerosis by promoting immune cell adhesion to vascular endothelium. ***Basic Res. Cardiol.*** 117:30. ***(IF 12.416)***

405. Abedi Kichi Z, Natarelli L, Sadeghian S, Behmanesh M, **Weber C** (2022) Orphan GPR26 counteracts early phases of hyperglycemia-mediated monocyte activation and is suppressed in diabetic patients. ***Biomedicines*** 10:1376. ***(IF 4.757)***

406. Tas K, Dalla Volta B, Lindner C, El Bounkari O, Hille K, Tian Y, Puig Bosch X, Ortner M, Prem S, Rammes G, **Weber C**, Megens RTA, Bernhagen J, Kapurniotu A (2022) Designed peptides as nanomolar cross-amyloid inhibitors acting via supramolecular nanofiber co-assembly. ***Nat. Commun.*** 13:5004. ***(IF 17.694)***

407. Brandhofer M, Hoffmann A, Blanchet X, Siminkovitch E, Rohlfing AK, El Bounkari O, Nestele JA, Bild A, Kontos C, Hille K, Rohde V, Fröhlich A, Golemi J, Gokce O, Scheiermann P, Tsilimparis N, Kempf W, Mägdefessel L, Megens RTA, Ippel H, Koenen RR, Mayo KH, Gawaz M, Kapurniotu A, **Weber C**, von Hundelshausen P, Bernhagen J (2022) Heterocomplexes between the atypical chemokine MIF and the CXC-motif chemokine CXCL4L1 regulate inflammation and thrombus formation. ***Cell. Mol. Life Sci.*** 79:512 ***(IF 9.237)***

408. Asare Y, Shnipova M, Živković L, Schlegl C, Tosato F, Aronova A, **Weber C**, Bernhagen J, Dichgans M (2022) IKKβ binds NLRP3 to regulate gasdermin D-mediated pyroptosis in macrophages. ***Signal Transduct. Target. Ther.*** 7:355. ***(IF 18.187)***

409. Hettwer J, Hinterdobler J, Miritsch B, Deutsch MA, Li X, Mauersberger C, Moggio A, Braster Q, Gram H, Groß O, Krane M, **Weber C**, Koenig W, Soehnlein O, Nahrendorf M, Libby P, Schunkert H, Kessler T, Sager HB (2022) Interleukin-1β suppression dampens inflammatory leukocyte production and uptake in atherosclerosis. ***Cardiovasc. Res.*** 118:2778-2791. ***(IF 13.081)***

410. Nitz K*, Lacy M*, Wu Y, Preischl C, Bianchini M, Li Y, Forné I, Ammer C, Schwedhelm E, Huveneers S, Zimmer R, Imhof A, **Weber C**, Lutgens E, Atzler D (2022) Homoarginine supplementation ameliorates atherogenesis by modulating T-cell function. ***Circ. Res.*** 131:701-712. *equal contribution. ***(IF 23.213)***

411. Habenicht LK, Wang Z, Zhang X, Li Y, Mohanta SK, Mogler C, Huspenina JS, Schmid RM, **Weber C**, Ma Z, Yin C (2022) The C1q-ApoE complex: a new hallmark pathology of virus hepatitis and nonalcoholic fatty liver disease. ***Front. Immunol.*** 13:970938. ***(IF 8.786)***

412. Guillamat-Prats R, Hering D, Rami M, Härdtner C, Santovito D, Rinne P, Bindila L, Hristov M, Pagano S, Vuilleumier N, Schmid S, Janjic A, Enard W, **Weber C**, Maegdefessel L, Faussner A, Hilgendorf I, Steffens S (2022) GPR55 in B cells limits atherosclerosis development and regulates plasma cell maturation. ***Nat. Cardiovasc. Res.*** 1:1056-1071.

2023 (IF 168.5)

413. Egea V, Megens RT, Santovito D, Wantha S, Brandl R, Siess W, Khani S, Soehnlein O, Bartelt A, **Weber C**, Ries C (2023) Properties and fate of human mesenchymal stem cells upon miRNA let-7f-promoted recruitment to atherosclerotic plaques. ***Cardiovasc. Res.*** 119:155-166. ***(IF 10.8)***

414. van der Vorst EPC, Theodorou K, Peters LJF, Rademakers T, Gijbels MJ, Rousch M, Jansen Y, **Weber C**, Lehrke M, Lebherz C, Yildiz D, Ludwig A, Bentzon JF, Biessen EAL, Donners MMPC (2023) Endothelial ADAM10 controls cellular response to oxLDL and exacerbates atherosclerosis with intraplaque hemorrhage and neovascularization in mice. ***Front. Cardiovasc. Med.*** 10:974918 ***(IF 3.6)***

415. Krammer C, Yang B, Reichl S, Besson-Girard S, Ji H, Bolini V, Schulte C, Noels H, Schlepckow K, Jocher G, El Bounkari O, Kapurniotu A, Gokce O, **Weber C**, Mohanta S, Bernhagen J (2023) Pathways linking aging and atheroprotection in Mif-deficient atherosclerotic mice. ***FASEB J.*** 37:e22752. ***(IF 4.8)***

416. van Os BW, Vos WG, Bosmans LA, van Tiel CM, Lith SC, den Toom M, Beckers L, Levels JHM, van Wouw SAE, Zelcer N, Zaal EA, Berkers CR, van de Lest CHA, Helms JB, **Weber C**, Atzler D, de Winther MPJ, Baardman J, Lutgens E (2023) Hyperlipidemia elicits an atypical, Th1 like CD4+ T cell response: a key role for VLDL. ***Eur Heart J Open*** oead013.

417. ° Wang Z, Zhang X, Zhang C, Ma Z, Lu S, Li Y, Sun T, Li Y, Hristov M, Steffens S, Santovito D, Mohanta S, Dornmair K, Ley K, **Weber C**, Habenicht A, Yin C (2023) Pairing of single-cell RNA analysis and T-cell receptor profiling reveals breakdown of T-cell tolerance checkpoints in atherosclerosis. ***Nat. Cardiovasc. Res.*** 2:290-306. ***(IF 9.4)***

418. Bosmans LA, van Tiel C, Aarts S, Willemsen L, Baardman J, den Toom M, Beckers L, Ahern D, Levels JHM, Jongejan A, Moerland PD, de Winther M, **Weber C**, Atzler D, Monaco C, Gerdes N, Shami A, Lutgens E (2023) Myeloid CD40 deficiency reduces atherosclerosis by impairing macrophages' transition into a pro-inflammatory state. ***Cardiovasc. Res.*** 119:1146–1160. ***(IF 10.8)***

419. Reiche ME, Poelsa K, Bosmans LA, van Tiel CM, Aarts SA, den Toom M, Beckers L, **Weber C**, Atzler D, Rensen PCN, Kooijman S, Lutgens E (2023) Adipose tissue controls haematopoiesis and inflammation through CD40 signaling. ***Haematologica*** 108:1873-1885. ***(IF 10.1)***

420. ° Wagner JUG, Tombor LS, Malacarne PF, Kettenhausen LM, Panthel J, Kujundzic H, Manickam N, Schmitz K, Cipca M, Stilz KA, Fischer A, Muhly-Reinholz M, Abplanalp WT, John D, Mohanta SK, **Weber C**, Habenicht AJR, Buchmann GK, Angendohr S, Amin E, Scherschel K, Klöcker N, Kelm M, Schüttler D, Clauss S, Guenther S, Boettger T, Braun T, Bär C, Pham MD, Krishnan J, Hille S, Müller OJ, Bozoglu T, Kupatt C, Nardini E, Osmanagic-Myers S, Meyer C, Zeiher AM, Brandes RP, Luxán G, Dimmeler S (2023) Ageing impairs the neuro-vascular interface in the heart. ***Science*** 381:897-906. ***(IF 56.9)***

421. Bianchini M, Möller-Ramon Z, **Weber C**, Megens RTA, Duchêne J (2023) Short-term western diet causes rapid and lasting alterations of bone marrow physiology. ***Thromb. Haemost.*** 123:1100-1104. ***(IF 6.7)***

422. Sachs S, Götz A, Finan B, DiMarchi RD, Döring Y, **Weber C**, Tschöp MH, Müller TD, Hofmann SM (2023) GIP receptor agonism improves dyslipidemia & atherosclerosis independently of body weight in obese mice. ***Cardiovasc. Diabetol.*** 22:217. ***(IF 9.3)***

423. Ebert S, Zang L, Ismail N, Otabil M, Fröhlich A, Egea V, Ács S, Hoeberg M, Berres ML, **Weber C**, Moreira JMA, Ries C, Bernhagen J,.El Bounkari O (2023) Tissue inhibitor of metalloproteinases-1 (TIMP-1) interacts with CD74 to promote AKT signaling, monocyte recruitment responses, and vascular smooth muscle cell proliferation. ***Cells*** 12:1899. ***(IF 6.0)***

424. Pekayvaz KA, Gold G, Hoseinpour P, Engel A, Coletti R, Joppich M, Janjic A, Knott M, Mehari F, Polewka V, Eivers L, Kirschner M, Martinez-Navarro A, Boda A, Nicolai L, Schulz H, Fingerle-Rowson G, Titova A, Kilani B, Lorenz M, Bucala R, Enard W, Zimmer R, Schulz C, **Weber C**, Libby P, Massberg S, Stark K (2023) Mural cell-derived chemokines provide a protective niche to safeguard vascular macrophages and limit chronic inflammation. ***Immunity*** 56:2325-2341. ***(IF 32.4)***

425. Cimen I, Natarelli L, Kichi ZA, Herndersen JM, Farina FM, Briem E, Aslani M, Megens RTA, Jansen Y, Mann-Fallenbuchel E, Gencer S, Duchene J, Nazari-Jahantigh M, van der Vorst EPC, Enard W, Döring Y, Schober A, Santovito D, **Weber C** (2023) Targeting a cell-specific microRNA repressor of CXCR4 ameliorates atherosclerosis in mice. ***Sci. Transl. Med.*** 15:eadf3357. ***(IF 17.1)***

2024 (IF 113.7)

426. Döring Y, van der Vorst EPC, Yan Y, Neideck C, Blanchet X, Jansen Y, Kemmerich M, Bayasgalan S, Peters LJF, Hristov M, Bidzhekov K, Yin C, Zhang X, Leberzammer J Park Y, Gencer S, Habenicht A, Faussner A, Teupser D, Monaco C, Holdt L, Santovito D, von Hundelshausen P, **Weber C** (2024) Identification of a non-canonical chemokine-receptor pathway suppressing regulatory T cells to drive atherosclerosis. ***Nat. Cardiovasc. Res.*** 3:221–242. ***(IF 10.8)***

427. Vos WG, van Os BW, den Toom M, Beckers L, van Roomen C, van Tiel C, Band H, Nitz K, **Weber C**, Atzler D, de Winther MP, Bosmans LA, Lutgens E, Seijkens TT (2024) T cell specific deletion of Casitas B lineage lymphoma-b reduces atherosclerosis by enhancing T cell exhaustion. ***Front. Immunol.*** 15:1297893. (***IF 5.9***)

428. Atomwise AIMS Program (2024) AI is a viable alternative to high throughput screening: a 318-target study. ***Sci. Rep.*** 14:7526. ***(IF 3.9)***

429. Strohm L, Daiber A, Ubbens H, Krishnankutty R, Oelze M, Kuntic M, Hahad O, Klein V, Hoefer IE, von Kriegsheim A, Kleinert H, Atzler D, **Weber C**, Wild P, Münzel T, Knosalla C, Lutgens E, Daub S (2024) Role of inflammatory signaling pathways involving the CD40-CD40L-TRAF cascade in animal models of diabetes and hypertension as well as coronary artery disease patients with one or two of these comorbidities. ***Basic Res. Cardiol.*** 119:1-18. ***(IF 8.0)***

430. Mueller TT, Thakur M, Wohlrab M, Meister S, Karaj F, Garcia Perez L, Öllinger R, Engleitner T, Langheinrich T, Völkl M, Zhang X, Tersteeg C, Mack M, Koedel U, Zigman Kohlmaier A, Teupser D, von Hundelshausen P, **Weber C**, Schulz C, Bortoluzzi S, Bernhagen J, Preissner KT, Rad R, Schmidt-Supprian M, Huber S, Massberg S, Ishikawa-Ankerhold H, Engelmann B (2024) Mutual regulation of $CD4^+$T cells and intravascular fibrin in infections. ***Haematologica*** 109:2487-2499. ***(IF 7.9)***

431. Wang Y, Li G, Chen B, Shakir G, Volz M, van der Vorst EPC, Maas SL, Muley C, Bartelt A, Li Z, Sachs N, Maegdefessel L, Nazari-Jahantigh M, Hristov M, Lacy M, Enard W, Lutz B, **Weber C**, Herzig S, Guillamat Prats R, Steffens S (2024) Loss of myeloid cannabinoid receptor CB1 confers atheroprotection by reducing macrophage proliferation and immunometabolic reprogramming. ***Cardiovasc. Res.*** 120:1411-1426. ***(IF 13.3)***

432. Egea V, Lutterberg K, Caca J, Bartelt A, Steinritz D, Rothmiller S, Worek F, Thiermann H, Steinestel K, Nerlich A, Blum H, Reschke S, Khani S, **Weber C**, Ries C. Targeting miR-497-5p rescues human keratinocyte dysfunction upon skin exposure to sulfur mustard. ***Cell Death Differ.*** 15:585. ***(IF 9.6***)

433. Santovito D, Henderson J, Bidzhekov K, Triantafyllidou V, Jansen Y, Chen Z, Farina F, Diagel A, Aslani M, Blanchet X, Schunkert H, Megens R, Döring Y, Sattler M, **Weber C** (2024) Mex3a protects against atherosclerosis: evidence from mice and humans. ***Circulation*** 150:1213-1216. ***(IF 38.6***)

434. Zhao D, Han C, Mammadova-Bach E, Watanabe-Kusunoki K, Bandeira Honda TS, Li Y, Li C, Li Q, Long H, Lyubenov L, Shi C, Boor P, Droste P, Parikh S, Shapiro J, de Chiara L, Carangelo G, Romagnani P, **Weber C**, Klussmann S, Vater A, Anders HJ (2024) Inhibition of complement factor C5a or C5aR for cholesterol crystal embolism-related microvascular thrombosis and its consequences. ***Kidney Int.*** 106:819-825. ***(IF 12.6)***

435. Möller-Ramon Z, Aslani M, Sobczak N, Hristov M, **Weber C**, Rot A, Duchene J (2025) The 129 strain-derived passenger mutations in ACKR1-deficient mice alter the expression of PYHIN and Fc-gamma receptor genes. ***J. Leukoc. Biol.*** 117:qiae208. ***(IF 3.1***)

2025

436. Parma L, Sachs N, Sobczak N, Li Z, Merchant K, Pauli J, Depuydt MAC, Wezel A, Smeets HJ, Bot I, Slütter B, Maegdefessel L, **Weber C**, Duchene J, Megens RTA (2025) CXCL12 derived from ACKR1^{+} intraplaque neovessels mediates CD8^{+} T cell recruitment in human atherosclerosis. ***Circulation*** 151:581-584. ***(IF 38.6)***

437. Strohm L, Ubbens H, Mihalikova D, Czarnowski A, Stamm, Molitor M, Finger S, Oelze M, Wenzel P, Lurz P, **Weber C**, Münzel T, Lutgens E, Daiber A, Daub S (2025) TRAF6 inhibition is a potential therapeutic target to suppress cardiovascular inflammation and complications in a mouse model of arterial hypertension. ***Redox Biol.*** 80:103520. ***(IF 11.9***)

438. Bonfiglio CA, Lacy M, Triantafyllidou V, Farina FM, Janjic A, Nitz K, Wu Y, Bazioti V, Avcilar-Kucukgoze I, Freire Soares Marques Y, Joppich M, Kumkum M, Röß K, Esteban Wange L, Venkatasubramani AV, Imhof A, Enard W, Maegdefessel L, de Winther M, **Weber C**, Santovito D, Lutgens E, Atzler D (2025) Ezh2 shapes T cell plasticity to drive atherosclerosis. ***Circulation*** 151:1391-1408. ***(IF 38.6)***

439. Yaw A, Yan G, Schlegl C, Prestel M, van der Vorst EPC, Teunissen AJP, Aronova A, Tosato F, Prevot G, Azzun A, Wefers B, Wurst W, Schneider M, Forne I, Bidzhekov K, Naumann R, van der Laan SW, Brandhofer M, Cao J, Roth S, Malik R, Mulder WJM, Imhof A, Liesz A, **Weber C**, Bernhagen J, Dichgans M (2025) A cis-regulatory element controls *HDAC9* expression to fine-tune inflammasome-dependent chronic inflammation. ***Immunity*** 58:555-567.e9. ***(IF 26.3***)

440. El Bounkari O, Zan C, Yang B, Ebert S, Wagner J, Bugar E, Kramer N, Bourilhon P, Kontos C, Zarwel M, Sinitski D, Milic J, Jansen Y, Kempf WE, Sachs N, Mägdefessel L, Ji H, Gokce O, Riols F, Haid M, Gerra S, Hoffmann A, Brandhofer M, Avdic M, Bucala R, Megens RTA, Willemsen N, Messerer D, Schulz C, Bartelt A, Harm T, Rath D, Gawaz M, **Weber C**, Kapurniotu A, Bernhagen J (2025) An atypical atherogenic chemokine that promotes advanced atherosclerosis and hepatic lipogenesis. ***Nat. Commun.*** 16:2297. ***(IF 15.7***)

441. Nageswaran V, Carreras A, Reinshagen L, Beck K, Steinfeldt J, Stahlman M, Ramezani Rad P, Peters L, Strässler E, Verhaar B, Döring Y, **Weber C**, König M, Steinhagen-Thiessen E, Demuth I, Kränkel N, Leistner DM, Nieuwdorp M, Knaus P, Kübler WM, Ferrell M, Hazen SL, Landmesser U, Bäckhed F, Haghikia A (2025) Gut microbial metabolite imidazole propionate impairs endothelial cell function and promotes the development of atherosclerosis. ***Arterioscler. Thromb. Vasc. Biol.*** 45:823-839. ***(IF 7.4***)

442. Peters LJF, Rakateli L, Huchzermeier R, Bonnin-Marquez A, Maas SL, Lin C, Jans A, Geng Y, Gijbels MJ, Rensen S, Olinga P, Hendrikx T, Krawczyk M, Brisbois M, Jankowski J, Bidzhekov K, **Weber C**, Biessen EA, Shiri-Sverdlov R, Houben T, Döring Y, Bartneck M, van der Vorst EPC (2025) MicroRNA-26b protects against MASH development and can be efficiently targeted with lipid nanoparticles. ***Elife*** 13:RP97165. ***(IF 6.4***)

443. Scherrer P, Marchini T, Li X, Al Hadi El Rabih A, Pennig J, Sol Mitre L, Gissler MC, Pisani G, Anto-Michel N, Mwinyella T, Abogunloko T, Hoppe N, Spiga L, Horstmann H, Siegel PM, Hansen S, Hilgendorf I, Lutgens E, **Weber C**, Gerdes N, Zirlik A, Westermann D, Willecke F, Wolf D (2025) Endothelial CD40L serves as a pro-atherogenic adhesion receptor in the inflamed vasculature. ***Atherosclerosis***, in press. ***(IF 5.7***)

444. Peters LJ, Bidzhekov K, Bonnin-Marquez A, Sahana Sundararaman S; Huchzermeier R, Maas S, Abschlag K, Jans A, Lin C, Haberbosch M, Jansen Y, Yu B, Sluimer J, Gijbels M, Jankowski J, Bartneck M, Biessen E, **Weber C**, Doering Y, van der Vorst E (2025) Lack of microRNA-26b augments atherosclerosis, while microRNA-26b mimic loaded lipid nanoparticles reduce atherogenesis. ***Cardiovasc. Res.***, in press. ***(IF 13.3)***

445. Evans BR, Schulz J, Yerly A, Thakur M, Angliker N, Siegrist M, Jansen Y, Yan Y, Triantafyllidou V, **Weber C**, Wettich J, Maegdefessel L, Sachs N, Schindewolf M, Kotelis D, Santovito D, van der Vorst EPC, Döring Y (2025) ChemR23 prevents phenotypic switching of vascular smooth muscle cells into macrophage like foam cells in atherosclerosis. ***Cardiovasc. Res.***, in revision. ***(IF 13.3***)

446. Schelemei P, Ruben Picard FS, Park Y, Wollnitzke P, Semleit N, Nemade H, Mehrkens D, Arkenberg P, Rappenecker AC, Wrobel J, Martinez Lagunas K, Wagner E, Guthoff H, Lindquist Liljeqvist RJM, Ibing W, Wagenhäuser M, Schelzig H, Levkau B, Flögel U, Gerdes N, Karimpour M, Hillmer AM, Sengle G, Megens RTA, **Weber C**, Orecchioni M, Ley K, Baldus S, Mollenhauer M, Winkels H (2025) Olfactory receptor 2 drives abdominal aortic aneurysm by promoting CX3CR1-mediated monocyte recruitment. ***Circ. Res.***, in revision. ***(IF 16.2)***

Übersichtsartikel, Kommentare und Protokolle (°Clarivate Top 1% im Fachgebiet)

1993-2000 (IF 14.4)

1. Sellmayer A, Obermeier H, **Weber C**, Weber PC (1993) Modulation of cell activation by n-3 fatty acids. In ***n-3 Fatty Acids and Vascular Disease***, Springer Verlag, pp. 21-30. ***(IF 0.500)***
2. **Weber C** (1996) Involvement of tyrosine phosphorylation in endothelial adhesion molecule induction. ***Immunol. Res.*** 15:30-37. ***(IF 1.935)***
3. **Weber C**, Erl W, Weber KSC, Weber PC (1999) Effects of oxidzied LDL, lipid mediators and statins on vascular cell interactions. ***Clin. Chem. Lab. Med.*** 37:243-251. ***(IF 1.084)***
4. Gröne HJ, **Weber C**, Weber KS, Grone EF, Klier CM, Wells TN, Proudfoot AE, Schlöndorff D, Nelson PJ (1999) Reduction of acute kidney transplantation rejection by the chemokine receptor antagonist Met-RANTES. ***Verh. Dtsch. Ges. Pathol.*** 1999;83:205-11. ***(IF 0.500)***
5. **Weber C**, Erl W (2000) Modulation of vascular cell activation, function and apoptosis by antioxidants. ***Curr. Top. Cell Reg.*** 36:217-235. ***(IF 4.364)***
6. Hengel H, **Weber C** (2000) Driving cells into atherosclerotic lesions: a deleterious role of viral chemokine receptors? ***Trends Microbiol.*** 8:294-296. ***(IF 6.006)***

2001-2003 (IF 13.6)

7. Neuzil J, **Weber C**, Kontusch A (2001) Vitamin E in atherosclerosis: linking the chemical, biological and clinical aspects of the disease. ***Atherosclerosis*** 157:257-283. ***(IF 3.469)***
8. Neuzil J, Terman A, **Weber C**, Brunk U (2001) Vitamin E analogs as inducers of apoptosis: implications for their potential antineoplastic role. ***Redox Report*** 6:143-151. ***(IF 1.017)***
9. Zernecke A, Weber C (2001) Glomeruläre Verkehrskontrolle: sequentielle Regulation der glomerulären Infiltration mit Monozyten durch spezialisierte Chemokine. ***Immunologie Aktuell*** 2:30-31. ***(IF 0.500)***
10. Neuzil J, Kagedal K, Andera L, **Weber C**, Brunk U (2002) Vitamin E analogues: a novel class of multiple action agents with anti-neoplastic and anti-atherogenic activity. ***Apoptosis*** 7:177-185. ***(IF 3.421)***
11. **Weber C** (2003) Novel mechanistic concepts for the control of leukocyte transmigration; spezialisation of integrins, chemokines and junctional molecules. ***J. Mol. Med.*** 81:4-19. ***(IF 5.192)***

2004 (IF 27.5)

12. Radke P*, **Weber C***, Kaiser A, Schober A, Hoffmann R (2004) Dexamethasone and related compounds for local drug delivery using coated stents: new indications for an old drug. ***Curr. Pharm. Des.***10:349-355 * equal contribution. ***(IF 5.385)***
13. **Weber C**, Zernecke A, Schober A (2004) Chemokines: key regulators of mononuclear cell recruitment in atherosclerotic vascular disease. ***Arterioscler. Thromb. Vasc. Biol.*** 24:1997-2008. ***(IF 7.432)***
14. Merx MW, Lin E, Janssens U, Lütticken R, Schrader J, Hanrath P, **Weber C** (2004) Simvastatin and survival in sepsis. ***Circulation*** 110:e315. ***(IF 12.563)***
15. Hristov M, **Weber C** (2004) Endothelial progenitor cells: pathophysiological aspects and possible clinical relevance. ***J. Cell. Mol. Med.*** 8:498-508. ***(IF 2.153,*** *654 citations)*

2005 (IF 23.5)

16. °Zernecke A, **Weber C** (2005) Inflammatory mediators of atherosclerotic vascular disease. ***Basic Res. Cardiol.*** 100:93-101. ***(IF 2.806)***
17. **Weber C** (2005) Plalelets and chemokines in atherosclerosis: partners in crime. ***Circ. Res.*** 96:612-616. ***(IF 9.408)***
18. Schober A, **Weber C** (2005) Mechanisms of monocyte recruitment in vascular repair after injury. ***Antioxid. Redox Signal.*** 7:1249-57. ***(IF 4.232)***
19. **Weber C** (2005) Killing two birds with one stone: targeting chemokine receptors in atherosclerosis and HIV. ***Arterioscler. Thromb. Vasc. Biol.*** 25:2448-2450. ***(IF 7.053)***

2006 (IF 64.1)

20. Hristov M, **Weber C** (2006) The therapeutic potential of progenitor cells in ischemic heart disease: past, present and future. ***Basic Res. Cardiol.*** 101:1-7. ***(IF 3.798)***
21. Merx M, **Weber C** (2006) Statins: a preventive strike against infection-related mortality in patients with cardiovascular disease? ***Lancet*** 367:372-373. ***(IF 25.800)***
22. Radke PW, Hoffmann R, Zernecke A, Kaiser A, Schunkert H, **Weber C** (2006) Thienopyridines in percutaneous coronary interventions: bare metal stents, drug eluting stents and brachytherapy. ***Curr. Pharm. Des.*** 12:1281-1286. (***IF 5.270***)
23. Hristov M, Keymel S, **Weber C** (2006) The therapeutic effect of autologous bone marrow cells in ischemic heart disease. ***Med. Klinik*** 101:186-189. ***(IF 0.289)***
24. Bidzhekov K, Zernecke A, **Weber C** (2006) MCP-1 induces a novel transcription factor with proapoptotic activities. ***Circ Res.*** 98:1107-1109. ***(IF 9.854)***
25. Schober A, Karshovska E, Zernecke A, **Weber C** (2006) SDF-1α-mediated tissue repair by stem cells: a promising tool in cardiovascular medicine? ***Trends Cardiovasc. Med.*** 16:103-108. ***(IF 4.724)***
26. **Weber C**, Koenen R (2006) Fine-tuning leukocyte responses: towards a chemokine interactome. ***Trends Immunol.*** 27:268-73. ***(IF 10.213)***
27. Merx M, **Weber C** (2006) Statins in the intensive care unit. ***Curr. Opin. Crit. Care*** 12:309-14. ***(IF 3.318)***
28. Liehn EA, Zernecke A, Postea O, **Weber C** (2006) Chemokines: inflammatory mediators of atherosclerosis. ***Arch. Physiol. Biochem.*** 112:229-238. ***(IF 0.841)***

2007 (IF 76.2)

29. von Hundelshausen P, **Weber C** (2007) Platelets as immune cells: bridging inflammation and vascular disease. ***Circ. Res.*** 100:27-40. ***(IF 9.721,*** *859 citations)*
30. **Weber C**, Schober A (2007) MIF and atherosclerosis. In ***MIF: A Most Interesting Factor***, edited by R. Bucala, World Scientific Publishing, p. 217-228. (***IF 0.500***)
31. Koenen RR, von Hundelshausen P, **Weber C** (2007) Inflammatory blues turns velvet skin into rawhide: monocyte rolling on modified endothelial PSGL-1. ***Arterioscler. Thromb. Vasc. Biol.*** 27:990-992. ***(IF 7.221)***
32. **Weber C** (2007) Chemokines take centre stage in vascular biology. ***Thromb. Haemostasis*** 97:685-687. ***(IF 3.501)***
33. Ludwig A, **Weber C** (2007) Transmembrane chemokines: versatile special agents in vascular inflammation. ***Thromb. Haemostasis*** 97:694-703. ***(IF 3.501)***
34. **Weber C**, Fraemohs L, Dejana E (2007) The role of junctional adhesion molecules in vascular inflammation. ***Nat. Rev. Immunol.*** 7:467-477. ***(IF 28.300,*** *616 citations)*
35. Merx MW, **Weber C** (2007) Sepsis and the heart. ***Circulation*** 116:782-792. ***(IF 12.755****, 627 citations)*
36. Hristov M, Zernecke A, Liehn EA, **Weber C** (2007) Mechanisms of endothelial regeneration after arterial injury. ***Thromb. Haemostasis*** 98:274-277. ***(IF 3.501)***
37. Krohn R, **Weber C**, Bernhagen J (2007) Flow chamber adhesion assay for measuring arrest function of chemokines. ***Nature Protocols*** DOI:10.1038/nprot.2007.189 ***(IF 1.671)***
38. Krohn R, Koenen RR, **Weber C**, Bernhagen J (2007) Alpha-L beta-2 integrin activation on MonoMac6 cells. ***Nat. Protocols*** DOI:10.1038/nprot.2007.190 ***(IF 1.671)***
39. Krohn R, Koenen RR, Bernhagen J, Hristov M, Georgiev IT, **Weber C** (2007) FACS-based calcium mobilization assay. ***Nat. Protocols*** DOI:10.1038/nprot.2007.212. ***(IF 1.671)***
40. Lue H, Dewor M, **Weber C**, Bernhagen J (2007) Receptor internalization assay to probe for agonist binding to CXCR2. ***Nat. Protocols*** doi:10.1038/nprot.2007.213. ***(IF 1.671)***
41. Koenen RR, von Hundelshausen P, **Weber C** (2007) Antagonism of chemokine receptors as a novel therapeutic approach in the combined treatment of viral and atherosclerotic disease. ***J. Viral Entry*** 3:20-25. ***(IF 0.500)***

2008 (IF 113.4)

42. **Weber C** (2008) Cell-cell interactions in the vascular wall. ***Nova Acta Leopoldina*** 351:83-7. (***IF 0.500***)

43. Zernecke A, Bernhagen J, **Weber C** (2008) Macrophage migration inhibitory factor in cardiovascular disease. ***Circulation*** 117:1594-1602. ***(IF 14.595)***

44. Schober A, Bernhagen J, **Weber C** (2008) Chemokine-like functions of MIF in atherosclerosis. ***J. Mol. Med.*** 86:761-70. ***(IF 5.192)***

45. Krohn R, Bernhagen J, **Weber C** (2008) MIF – ein neuer Protagonist in der Atherosklerose. ***Laborwelt*** 9:6-9. ***(Impact 0.500)***

46. Hristov M, Zernecke A, Schober A, **Weber C** (2008) Adult progenitor cells in vascular remodeling during atherosclerosis. ***Biol. Chem.*** 398:837-844. ***(IF 3.035)***

47. Schober A, **Weber C** (2008) Leptin and EPCs: yes, we can. ***Circ. Res.*** 103:447-449. ***(IF 9.989)***

48. Hristov M, **Weber C** (2008) Ambivalence of progenitor cells in vascular repair and plaque stability. ***Curr. Opin. Lipidol.*** 19:491-497. ***(IF 6.629)***

49. **Weber C**, Zernecke A, Libby P (2008) The multifacetted contributions of leukocyte subsets to atherosclerosis. ***Nat. Rev. Immunol.*** 8:802-815. ***(IF 30.006,*** *970 citations)*

50. Hristov M, **Weber C** (2008) Endothelial progenitor cells in vascular repair and remodeling. ***Pharmacol. Res.*** 58:148-51. ***(IF 3.287)***

51. **Weber C** (2008) Chemokines in Atherosclerosis, Thrombosis & Vascular Biology: Introduction to the Weber series. ***Arterioscler. Thromb. Vasc. Biol.*** 28:1896. ***(IF 6.858)***

52. Zernecke A, Shagdarsuren E, **Weber C** (2008) Chemokines in atherosclerosis: an update. ***Arterioscler. Thromb. Vasc. Biol.*** 28:1897-1908. ***(IF 6.858,*** *740 citations)*

53. **Weber C** (2008) Frontiers and novel targets in molecular cardiology. ***Drug Discov. Today Dis. Mech.*** 5:e265-266 ***(IF 6.369)***

54. Hristov M, **Weber C** (2008) Endothelial progenitor cells: cellular biomarkers in vascular disease. ***Drug Discov. Today Dis. Mech.*** 5:e267-271. ***(IF 6.369)***

55. Shagdarsuren E, Müller D**, Weber C,** Zernecke A (2008) Complement activation in vascular remodeling and organ damage. ***Drug Discov. Today Dis. Mech.*** 5:e299-306. ***(IF 6.369)***

56. Merx MW, **Weber C** (2008) Benefits of statins beyond lipid lowering. ***Drug Discov. Today Dis. Mech.*** 5:e325-331. ***(IF 6.369)***

57. **Weber C** (2008) Chemokin-artige Funktionen von MIF in der Atherosklerose. In ***Neue Aspekte der Arterioskleroseforschung***, ISBN 978-3-936423-07-5, edited by: H. Heinle et al., p. 1-6 ***(IF 0.500)***

2009 (IF 114.3)

58. von Hundelshausen P, **Weber C** (2009) Platelet-mediated enhancement of monocyte and leukocyte adhesion. ***Microcirculation*** 16:84-96. ***(IF 2.368)***

59. Mause S, **Weber C** (2009) Intrusion through the fragile back door – immature plaque microvessels as entry portals for leukocytes and erythrocytes in atherosclerosis. ***J. Am. Coll. Cardiol.*** 53:1528-31. ***(IF 12.640)***

60. Taylor J, **Weber C** (2009) Spotlight: Christian Weber, MD, FESC. ***Circulation*** 119:f139-f141. ***(IF 14.816)***

61. Taylor J, **Weber C** (2009) Team 2009: Institute for Molecular Cardiovascular Research, Aachen, Germany. ***Circulation*** 119:f142-f143. ***(IF 14.816)***

62. Taylor J, **Weber C** (2009) Initiatives in Cardiovascular Research: The Euregio Cardiovascular Research School. ***Circulation*** 119:f144. ***(IF 14.816)***

63. Soehnlein O, **Weber C** (2009) Myeloid cells in atherosclerosis: initiators and decision shapers. ***Semin. Immunopathol.*** 31:35-47. ***(IF 5.479)***

64. Koenen RR, **Weber C** (2009) Co-immunoprecipitation of platelet factor 4 and RANTES from human platelets. ***Nat. Protocols*** 10.1038/nprot.2009.132. ***(IF 6.335)***

65. Hristov M, **Weber C** (2009) Progenitor cell trafficking in the vascular wall. ***J. Thromb. Haemost.*** 7:31-34. ***(IF 4.451)***

66. Noels H, Bernhagen J, **Weber C** (2009) MIF: a non-canonical chemokine important in atherosclerosis. ***Trends Cardiovas. Med.*** 19:76-86. ***(IF 4.367***)

67. **Weber C** (2009) Frontiers in vascular biology: mechanisms of inflammation and immunoregulation in arterial remodelling. ***Thromb. Haemost.*** 102:188-90. ***(IF 4.451)***

68. Soehnlein O, Zernecke A, **Weber C** (2009) Neutrophils launch monocyte extravasation by release of granule proteins. ***Thromb. Haemost.*** 102:198-205. ***(IF 4.451)***

69. Soehnlein O, **Weber C**, Lindbom L (2009) Neutrophil granule proteins tune monocytic cell function. ***Trends Immunol.*** 30:538-46. ***(IF 8.768)***

70. Soehnlein O, Lindbom L, **Weber C** (2009) Neutrophils and the control of monocyte extravasation. ***Blood*** 114:4613-23. ***(IF 10.555)***

71. **Weber C** (2009) Monozyten und Leukozyten. In ***Hämostaseologie***, Springer Verlag (ISBN: 978-3-642-01543-4) page 105-112. ***(IF 0.780)***

72. Soehnlein O, Drechsler M, Hristov M, **Weber C** (2009) Functional alterations of myeloid cell subsets in hyperlipidaemia: relevance for atherosclerosis. ***J. Cell. Mol. Med.*** 13:4293-4303. ***(IF 5.228)***

2010 (IF 114.1)

73. **Weber C**, Lip GYH (2010) Moving forwards with a new Editorial team for Thrombosis and Haemostasis. ***Thromb. Haemost.*** 103:1-2. ***(IF 4.701)***

74. Lip GY, Preissner KT, **Weber C** (2010) Editor's choice articles. ***Thromb. Haemost.*** 103:3-6. ***(IF 4.701)***

75. Koenen RR, **Weber C** (2010) Therapeutic targeting of chemokine interactions in atherosclerosis. ***Nat. Rev. Drug Discov.*** 9:141-53. ***(IF 28.712)***

76. Lutgens E, Poggi M, **Weber C** (2010) CD40-CD40L fuel ignites obesity. ***Thromb. Haemost.*** 103:694-5. ***(IF 4.701)***

77. Koenen RR, **Weber C** (2010) Manipulating the chemokine system: Therapeutic perspectives for atherosclerosis. ***Curr. Opin. Investig. Drugs*** 11:265-72. ***(IF 3.395)***

78. Noels H, Weber C (2010) Fractalkine as an important target of aspirin in the prevention of atherogenesis. ***Cardiovasc. Drugs Ther.*** 24:1-3. ***(IF 3.098)***

79. Koenen RR, **Weber C** (2010) Platelet-derived chemokines in vascular remodeling and atherosclerosis. ***Semin. Thromb. Hemost.*** 36:163-9. ***(IF 4.169)***

80. Zernecke A, **Weber C** (2010) Chemokines in the vascular inflammatory response of atherosclerosis. ***Cardiovasc. Res.*** 86:192-201. ***(IF 6.051)***

81. **Weber C** (2010) Obstacles and options in cardiovascular drug development. ***Thromb. Haemost.*** 104:1-3. ***(IF 4.701)***

82. Lievens D, Gerdes N, Schober A, **Weber C** (2010) Atherosclerosis: cell biology and lipoproteins. ***Curr. Opin. Lipidol.*** 21:284-285. ***(IF 6.636)***

83. **Weber C**, Schober A, Zernecke A (2010) MicroRNAs in arterial remodelling, inflammation and atherosclerosis. ***Curr. Drug Targets*** 11:950-6. ***(IF 3.061)***

84. Mause SF, Sampol J, **Weber C**, Dignat-George F (2010). New horizons in vascular biology and thrombosis: Highlights from EMVBM 2009. ***Thromb. Haemost.*** 104:421-3. ***(IF 4.701)***

85. **Weber C** (2010) Far from the heart: receptor cross-talk in remote conditioning. ***Nat. Med.*** 16:760-762. ***(IF 25.430)***

86. ° Mause SF, **Weber C** (2010) Microparticles - protagonists of a novel communication network for intercellular information exchange. ***Circ. Res.*** 107:1047-57. ***(IF 9.504**, 995 citations)*

87. Vasina E, Heemskerk JW, **Weber C**, Koenen RR (2010) Platelets and platelet-derived microparticles in vascular inflammatory disease. ***Inflamm Allergy Drug Targets.*** 9:346-54. ***(IF 0.500)***

2011 (IF 84.6)

88. **Weber C**, Lip GYH (2011) Commencing 2011 with Thrombosis and Haemostasis - and looking to the future***. Thromb. Haemost.*** 105:1-2. ***(IF 5.044)***

89. Lip GYH, **Weber C** (2011) Clinical and basic science articles from Thrombosis and Hameostasis. ***Thromb. Haemost.*** 105:202-5. ***(IF 5.044)***

90. Kramp B, Sarabi A, Koenen RR, **Weber C** (2011) Heterophilic chemokine receptor interactions in chemokine signaling and biology. ***Exp. Cell Res.*** 317:655-663. ***(IF 3.580)***

91. Noels H, **Weber C** (2011) Catching up with important players in atherosclerosis: type I interferons and neutrophils. ***Curr. Opin. Lipidol.*** 22:144-5. ***(IF 6.086)***

92. Megens R, Kemmrich K, Pyta J, **Weber C**, Soehnlein O (2011) Intravital imaging of phagocyte recruitment. ***Thromb. Haemost.*** 105:802-10. ***(IF 5.044)***

93. Schober A, **Weber C** (2011) Bone marrow-derived smooth muscle cells are breaking bad in atherogenesis. ***Arterioscler. Thromb. Vasc. Biol.*** 31:1258-9. ***(IF 6.368)***

94. Ylä-Herttuala S, Bentzon JF, Daemen MJAP, Falk E, Garcia HM, Herrmann J, Hoefer I, Jukema JW, Krams R, Kwak B, Marx N, Naruszewicz M, Newby A, Pasterkamp G, Serruys PWJC, Waltenberger J, **Weber C**, Tokgözoglu L (2011) Stabilisation of atherosclerotic plaques. ***Thromb. Haemost.*** 106:1-19. ***(IF 5.044)***

95. **Weber C**, Soehnlein O (2011) ApoE controls the interface linking lipids and inflammation in atherosclerosis. ***J. Clin. Invest.*** 121:3825–3827. ***(IF 13.069)***

96. **° Weber C**, Noels H (2011) Atherosclerosis: current pathogenesis and therapeutic options. ***Nat. Med.*** 17:1410-1422. ***(IF 22.462**, 2465 citations)*

97. Hristov M, **Weber C** (2011) Differential role of monocyte subsets in atherosclerosis. ***Thromb. Haemost.*** 106:757-62. ***(IF 5.044)***

98. Koenen RR, **Weber C** (2011) Chemokines: new targets in atherosclerosis. ***EMBO Mol. Med.*** 3:713-25. ***(IF 7.795)***

2012 (IF 73.1)

99. Raffetseder U, Liehn EA, **Weber C**, Mertens PR (2012) Role of cold shock Y-box protein-1 in inflammation, atherosclerosis and organ transplant rejection. ***Eur. J. Cell Biol.*** 91:567-75. ***(IF 3.213)***

100. Lip GYH, **Weber C** (2012) Welcome to a new year in Thrombosis and Haemostasis. ***Thromb. Haemost.*** 107:1-2. ***(IF 6.094)***

101. Lutgens E, Leiner T, **Weber C** (2012) RANK(L)-ing biomarkers as surrogates for coronary calcium score. ***Thromb. Haemost.*** 107:3. ***(IF 6.094)***

102. **Weber C**, Lip GYH (2012) Editors' Choice: Highlights and hot topics from 2011 in Thrombosis and Haemostasis. ***Thromb. Haemost.*** 107:196-199. ***(IF 6.094)***

103. Doering Y, Noels H, **Weber C** (2012) The use of high-throughput technologies to investigate inflammatory pathways in vascular cells. ***Arterioscler. Thromb. Vasc. Biol.*** 32:182-195. ***(IF 6.338)***

104. Kanzler I, Liehn EA, Koenen RR, **Weber C** (2012) Anti-inflammatory therapeutic approaches to reduce acute atherosclerotic complications. ***Curr. Pharmaceut. Biotechnol.*** 13:37-45. ***(IF 2.690)***

105. Krämer S, **Weber C**, Bernhagen J (2012) MIF and the chemokine axis. In ***The MIF Handbook***, pp. 23-53, edited by R. Bucala, World Scientific Publishing. ISBN: 978-981-4335-35-5 ***(IF 0.500)***

106. Noels H, Bernhagen J, **Weber C** (2012) MIF in atherosclerosis. In ***The MIF Handbook***, pp. 321-345, edited by R. Bucala, World Scientific Publishing. ISBN: 978-981-4335-35-5 ***(IF 0.500)***

107. Karshovska E, **Weber C** (2012) New mechanistic links in atherosclerosis: chemokines mediating the effects of lipids, platelets, and dendritic cells. ***Curr. Opin. Lipidol.*** 23:400-1. ***(IF 5.839)***

108. Schober A, Zhou Z, **Weber C** (2012) Smooth muscle progenitor cells: A novel target for the treatment of vascular disease? In ***Muscle: Fundamental biology and mechanisms of disease***. ISBN: 978-012-3815-10-1, 1391-1400 ***(IF 0.500)***

109. Liehn EA, Bucur O, **Weber C**. The role of microparticles as messangers enhancing stem cell activity after genetic engineering. ***Circ. Res.*** 111:265-267. ***(IF 11.861)***

110. Zernecke A, **Weber C** (2012) Molecular mechanisms of inflammation in atherosclerosis. ***Heart*** 98:1600-6. ***(IF 5.014)***

111. Blanchet X, Langer M, **Weber C**, Koenen RR, von Hundelshausen P (2012) Touch of chemokines. ***Frontiers Immunol.*** 3:175. ***(IF 5.695)***

112. Matusik P, Guzik B, **Weber C**, Guzik TJ (2012) Do we know enough about the immune pathogenesis of acute coronary syndromes to improve clinical practice? ***Thromb. Haemost.*** 108:443-56 ***(IF 6.094)***

113. Egea V, Schober A, **Weber C**. Circulating miRNAs: messangers on the move in cardiovascular disease. ***Thromb. Haemost.*** 108:590-91. ***(IF 6.094)***

114. Koenen RR, **Weber C** (2013) Chemokines as therapeutic targets of atherosclerosis. In ***Atherosclerosis: Treatment and Prevention***, edited by C. Weber & O. Söhnlein, Pan Stanford Publishing. ISBN: 978-981-4316-26-2. ***(IF 0.500)***

115. Soehnlein O, **Weber C** (2013) Neutrophils and their granule proteins in the treatment of atherosclerosis. In ***Atherosclerosis: Treatment and Prevention***, edited by C. Weber & O. Söhnlein, Pan Stanford Publishing ISBN: 978-981-4316-26-2. ***(IF 0.500)***

2013 (IF 79.2)

116. **Weber C**, Lip G (2013) A Happy New Year 2013 for Thrombosis and Haemostasis… ***Thromb. Haemost.*** 190:1-2. ***(IF 5.760)***

117. **Weber C**, Lip G (2013) Editors' Choice papers in Thrombosis and Haemostasis. ***Thromb. Haemost.*** 109: 170-173. ***(IF 5.760)***

118. **Weber C** (2013) MicroRNAs - from basic mechanisms to clinical application in cardiovascular medicine. ***Arterioscler. Thromb. Vasc. Biol.*** 33:168-169. ***(IF 5.333)***

119. Wei Y, Nazari-Yahantigh M, Neth P, **Weber C**, Schober A (2013) MicroRNA-126, miR-145, and miR-155: A therapeutic triad in atherosclerosis? ***Arterioscler. Thromb. Vasc. Biol.*** 33:449-54 ***(IF 5.333)***

120. Gerdes N, Winkels H, **Weber C** (2013) Atherosclerosis: cell biology and lipoproteins - focus on anti-inflammatory mechanisms as therapeutic options. ***Curr. Opin. Lipidol.*** 24:187-8. ***(IF 5.803)***

121. Preissner KT, **Weber C** (2013) Go with the flow: the passion for vascular biology research. ***Thromb. Haemost.*** 109:366-7. ***(IF 5.760)***

122. Wei Y, Schober A, **Weber C** (2013) Pathogenic arterial remodeling: the good and bad in microRNAs. ***Am. J. Physiol. - Heart C.*** 304:H1050-9. ***(IF 4.012)***

123. Drechsler M, Soehnlein O, **Weber C** (2013) Nitric oxide-donating statins upgrade the benefits of lipid lowering in vascular inflammation by desensitizing neutrophil activation. ***Cardiovasc. Drugs Ther.*** 27:183-5. ***(IF 2.952)***

124. Neth P, Nazari-Jahantigh M, Schober A, **Weber C** (2013) MicroRNAs in flow-dependent vascular remodelling. ***Cardiovasc. Res.*** 99:294-303. ***(IF 5.808)***

125. Döring Y, **Weber C**, Söhnlein O (2013) Footprints of neutrophil extracellular traps as predictors of cardiovascular risk. ***Arterioscler. Thromb. Vasc. Biol.*** 33:1735-6. ***(IF 5.333)***

126. von Hundelshausen P, **Weber C** (2013) Chronic inflammation and atherosclerosis. ***Dtsch. Med. Wochenschr.*** 138:1839-44. ***(IF 0.550)***

127. Langer H, **Weber C**, Gawaz M (2013) The platelet – thrombosis and beyond. ***Thromb. Haemost.*** 110:857-858. ***(IF 5.760)***

128. Karshovska E, **Weber C**, von Hundelshausen P (2013) Platelet chemokines in health and disease. ***Thromb. Haemost.*** 110:894-902. ***(IF 5.760)***

129. Ylä-Herttuala S, Bentzon J, Daemen M, Falk E, Garcia H, Herrmann J, Hoefer I, Jukema J, Krams R, Kwak B, Marx N, Naruszewicz M, Newby A, Pasterkamp G, Serruys P, Waltenberger J, **Weber C**, Tokgözoglu L (2013) Stabilising atherosclerotic plaques: an update. ***Eur. Heart J.*** 34:3251-8. ***(IF 14.723)***

2014 (IF 109.8)

130. Silvestre-Roig C, de Winther MPJ, **Weber C**, Daemen MJ, Lutgens E, Soehnlein O (2014) Atherosclerotic plaque destabilization: mechanisms, models and therapeutic strategies. ***Circ. Res.*** 114:214-26. ***(IF 11.019)***

131. Lip G, **Weber C** (2014) A very happy New Year 2014 from Thrombosis and Haemostasis: reflections on the past, the present and the future… ***Thromb. Haemost.*** 111:1-2 ***(IF 4.984)***

132. **Weber C**, Lip G (2014) Editors' choice papers in Thrombosis and Haemostasis. ***Thromb. Haemost.*** 111: 181-183 ***(IF 4.984)***

133. Döring Y, Soehnlein O, **Weber C** (2014) Neutrophils cast NETs in atherosclerosis: employing PAD as a therapeutic target. ***Circ. Res.*** 114:931-934. ***(IF 11.019)***

134. Schiener M, Hossann M, Viola JR, Ortega-Gomez A, **Weber C**, Lauber K, Lindner LH, Soehnlein O (2014) Nanomedicine-based strategies for treatment of atherosclerosis. ***Trends Mol. Med.*** 20:271-281. ***(IF 9.453)***

135. Zernecke A, **Weber C** (2014) Chemokines in atherosclerosis: proceedings resumed. ***Arterioscler. Thromb. Vasc. Biol.*** 34:742-50. ***(IF 6.008)***

136. Rassaf T, **Weber C**, Bernhagen J (2014) Macrophage migration inhibitory factor in myocardial infarction. ***Cardiovasc. Res.*** 102:321-328. (***IF 5.940***)

137. Mohanta SK, Yin C, Peng L, Srikakulapu P, Bontha V, Hu D, Weih F, **Weber C**, Gerdes N, Habenicht AJR (2014) Artery tertiary lymphoid organs control innate and adaptive immune responses in advanced mouse atherosclerosis during aging. ***Circ. Res.*** 114:1772-1787. ***(IF 11.019)***

138. Hartmann P, Schober A, **Weber C** (2014) microRNA-155 and macrophages: a fatty liaison. ***Cardiovasc. Res.*** 103:5-6. ***(IF 5.940)***

139. Döring Y, Pawig L, **Weber C**, Noels H (2014) The chemokine receptor CXCR4 in cardiovascular disease. ***Front. Physiol.*** 5:212. ***(IF 3.534)***

140. Winkels H, **Weber C**, Lutgens E, Gerdes N (2014) Atherosclerosis: cell biology and lipoproteins-focus on iNKT cells and CD40/CD40L in atherosclerosis and metabolic disorders. ***Curr. Opin. Lipidol.*** 25:408-9. ***(IF 5.656)***

141. Simsekyilmaz S, Cabrera-Fuentes HA, **Weber C**, Meiler S, Boisvert WA, Preissner KT, Zernecke A (2014) Response to letter regarding article "Role of extracellular RNA in atherosclerotic plaque formation in mice". ***Circulation*** 130:e144-5. (***IF 15.073***)

142. Kwak B, Back M, Bochaton-Piallat ML, Caligiuri G, Daemen MAJ, Davies P, Hoefer I, Holvoet P, Krams R, Monaco C, Steffens S, Virmani R, **Weber C**, Wentzel J, Evans PC (2014) Biomechanical factors in atherosclerosis: mechanisms and clinical implications. ***Eur. Heart J.*** 35:3013-3020. ***(IF 15.203)***

2015 (IF 133.7)

143. Yin C, Mohanta S, Ma Z, **Weber C**, Hu D, Weih F, Habenicht A (2015) Generation of aorta transcript atlases of wild-type and Apoe-/- mice by laser capture microdissection-based mRNA expression microarrays. ***Methods Mol. Biol.***, 1339:297-308. ***(IF 0.500)***

144. Lip GY, **Weber C** (2015) A Happy New Year from Thrombosis and Haemostasis. A 5 year reflection from the Editorial team. ***Thromb. Haemost.*** 113:1-2. ***(IF 5.255)***

145. **Weber C**, Lip GY (2015) Editors' Choice papers in Thrombosis and Haemostasis. ***Thromb. Haemost.*** 113:217-20. ***(IF 5.255)***

146. Döring Y, Drechsler M, Soehnlein O, **Weber C** (2015) Neutrophils in atherosclerosis. ***Arterioscler. Thromb. Vasc. Biol.*** 35:288-95. ***(IF 5.969)***

147. Hristov M, **Weber C** (2015) Myocardial infarction and inflammation: lost in the biomarker labyrinth. ***Circ. Res.*** 116:781-3. ***(IF 11.551)***

148. Nazari-Jahantigh M, Egea V, Schober A, **Weber C** (2015) Regulatory mechanisms of miRNAs in atherosclerosis. ***J. Mol. Cell. Cardiol.*** 89(A):35-41. ***(IF 4.874)***

149. Santovito D, Egea V, **Weber C** (2015) DNA methylation and epigenetics: exploring the terra incognita of the atherosclerotic landscape. ***Eur. Heart J.*** 36:956-8. ***(IF 15.064)***

150. Bürger C, **Weber C**, Lutgens E, Gerdes N (2015) Atherosclerosis: cell biology and lipoproteins-focus on CD40 signaling, PCSK9, and novel animal models. ***Curr. Opin. Lipidol.*** 26:245-246. ***(IF 5.336)***

151. **Weber C** (2015) Professor Christian Weber on the inflammation in cardiovascular diseases. ***Discoveries*** 3:e36. ***(IF 0.500)***

152. Schober A, Nazari-Jahantigh M, **Weber C** (2015) Mechanisms of microRNAs in atherosclerosis. ***Nat. Rev. Cardiol.*** 12:361-374. ***(IF 10.533)***

153. Megens RTA, Bianchini M, Schmitt MMN, **Weber C** (2015) Optical imaging innovations for atherosclerosis research: multiphoton microscopy and optical nanoscopy. ***Arterioscler. Thromb. Vasc. Biol.*** 35:1339-46. ***(IF 5.969)***

154. **Weber C,** Hristov M (2015) Atherogenesis and inflammation. From cellular mediators to regulatory mechanisms of inflammation in atherosclerosis. ***Hämostaseologie*** 35:99-101. ***(IF 1.547)***

155. Hartmann P, Schober A, **Weber C** (2015) Chemokines and miRNAs in atherosclerosis. ***Cell. Mol. Life Sci.*** 72:3253-66. ***(IF 5.694)***

156. Santovito D, **Weber C** (2015) Fibronectin extradomain A: balancing atherosclerotic plaque burden and stability. ***Thromb. Haemost.*** 114:4. ***(IF 5.255)***

157. Ahmadsei M, Lievens D, **Weber C**, von Hundelshausen P, Gerdes N (2015) Immune-mediated and lipid-mediated platelet function in atherosclerosis. ***Curr. Opin. Lipidol.*** 26:438-48. ***(IF 5.336)***

158. van der Vorst E, Döring Y, **Weber C** (2015) MIF and CXCL12 in cardiovascular disease: functional differences and similarities. ***Front. Immunol.*** 6:373. ***(IF 5.695)***

159. Pawig L, Klasen C, **Weber C**, Bernhagen J, Noels H (2015) Diversity and inter-connections in the CXCR4 chemokine receptor/ligand family: molecular perspectives. ***Front. Immunol.*** 6:429. ***(IF 5.695)***

160. Bäck M, **Weber C**, Lutgens E (2015) Regulation of atherosclerotic plaque inflammation. ***J. Intern. Med.*** 278:462-82. ***(IF 7.803)***

161. Hoefer IE, Steffens S, Ala-Korpela M, Bäck M, Badimon L, Bochaton-Piallat ML, Boulanger CM, Caligiuri G,

Dimmeler S, Egido J, Evans PC, Guzik T, Kwak BR, Landmesser U, Mayr M, Monaco C, Pasterkamp G, Tuñón J, **Weber C** (2015) Novel methodologies for biomarker discovery in atherosclerosis. ***Eur. Heart J.*** 36:2635-42. ***(IF 15.064)***

162. van der Vorst E, Döring Y, **Weber C** (2015) Chemokines and their receptors in atherosclerosis. ***J. Mol. Med.*** 93:963-71. ***(IF 4.855)***
163. van der Vorst E, Döring Y, **Weber C** (2015) Recent highlights in ATVB: Chemokines. ***Arterioscler. Thromb. Vasc. Biol.*** 35:e52-6. ***(IF 5.969)***

2016 (IF 116.0)

164. Lip G, **Weber C** (2016) May your New Year be a happy and prosperous one with “Thrombosis & Haemostasis”. ***Thromb. Haemost.*** 115:1-2 ***(IF 5.627)***
165. **Weber C**, Lip G (2016) Editors’ choice 2015 papers in Thrombosis and Haemstasis. ***Thromb. Haemost.*** 115:230-2. ***(IF 5.627)***
166. Spitz C, Winkels H, Bürger C, **Weber C**, Lutgens E, Hansson GK, Gerdes N (2016) Regulatory T cells in atherosclerosis: Critical immune regulatory function and therapeutic potential. ***Cell. Mol. Life Sci.*** 73:901-922. ***(IF 5.788)***
167. Schober A, **Weber C** (2016) Mechanisms of microRNAs in atherosclerosis. ***Ann. Rev. Pathol.*** 11:583-616. ***(IF 26.853)***
168. **Weber C**, Döring Y, Noels H (2016) Potential cell-specific functions of CXCR4 in atherosclerosis. ***Hämostaseologie*** 36:97-102. ***(IF 1.828)***
169. Egea V, Nazari-Jahantigh M, Schober A, **Weber C** (2017) Regulation of atherosclerosis by microRNAs. In ***Non-coding RNAs in the vasculature***, edited by T. Thum & S. Dimmeler, Springer. ISBN 978-3-319-52945-5 ***(IF 0.500)***
170. Santovito D, Egea V, **Weber C** (2016) Small but smart: microRNAs orchestrate atherosclerosis development and progression. ***BBA - Molecular and Cell Biology of Lipids*** 1861:2075-2086. ***(IF 5.547***)
171. Hoefer I, Steffens S, **Weber C** (2016) Response to: Atherosclerosis and biomarkers: closer to solve the enigmatic puzzle… ***Eur. Heart J.*** 37:e698272/ehv236. (***IF 20.212***)
172. Meiler S, Lutgens E, **Weber C**, Gerdes N (2016) Atherosclerosis: cell biology and lipoproteins - focus on IL-18 signaling, chemotactic heteromers and microRNAs. ***Curr. Opin. Lipidol.*** 27:308-9. ***(IF 4.096)***
173. Daugherty A, Hegele RA, Mackman N, Rader DJ, Schmidt AM, **Weber C** (2016) Complying with the NIH guidelines and principles for rigor and reproducibility: refutations. ***Arterioscler. Thromb. Vasc. Biol.*** 35:e52-6. (***IF 6.607***)
174. Hu D, Yin C, Mohanta SK, **Weber C**, Habenicht AJ (2016) Preparation of single cell suspensions from mouse aorta. ***Bio Protoc.*** 6. pii: e1832. ***(IF 0.500)***
175. Mohanta S, Yin C, **Weber C**, Hu D, Habenicht AJ (2016) Aorta atherosclerosis lesion analysis in hyperlipidemic mice. ***Bio Protoc.*** 6. pii: e1833. ***(IF 0.500)***
176. Santovito D, **Weber C** (2016) Zooming in on microRNAs for refining cardiovascular risk prediction in secondary prevention. ***Eur. Heart J.*** pii:ehw259. (***IF 20.212***)
177. **Weber C**, Shantsila E, Hristov M, Caligiuri G, Guzik T, Heine GH, Hoefer I, Monaco C, Peter K, Rainger E, Siegbahn A, Steffens S, Woyta J, Ziegler-Heitbrock L, Lip GYHL (2016) Role and analysis of monocyte subsets in cardiovascular disease: joint position paper of the ESC WG on Atherosclerosis & Vascular Biology and the ESC WG on Thrombosis. ***Thromb. Haemost.*** 116:626-37. ***(IF 5.627)***
178. Yin C, Mohanta S, Srikakulapu P, Hu D, **Weber C**, Habenicht A (2016) Artery tertiary lymphoid organs: powerhouses of atherosclerosis immunity. ***Front. Immunol.*** 7:387. ***(IF 6.429)***

2017 (**IF 126.6)**

179. Lip GYH, **Weber C** (2017) A happy and prosperous New Year 2017 with “Thrombosis and Haemostasis”…. and our 60th anniversary!". ***Thromb. Haemost.*** 117:1-2. ***(IF 4.952)***
180. **Weber C**, Lip GYH (2017) Editors’ choice 2016 papers in “Thrombosis and Haemostasis”. ***Thromb. Haemost.***, 117:204-206. (***IF 4.952)***
181. Lutgens E, Bochaton-Piallat ML, **Weber C** (2017) Atherosclerosis: cellular mechanisms. ESC Textbook Vascular Biology, Chapter 13, Oxford University Press. ISBN: 9780198755777 ***(IF 0.500)***

182. Santovito D, **Weber C** (2017) Atherosclerosis revisited from a clinical perspective: still an inflammatory disease? ***Thromb. Haemost.*** 117:231-237. ***(IF 4.952)***

183. Doering Y, Soehnlein O, **Weber C** (2017) Neutrophil extracellular traps in atherosclerosis and atherothrombsis. ***Circ. Res.*** 120:736-743. ***(IF 15.211)***

184. Ferrara E, Lutgens E, **Weber C**, Gerdes N (2017) Atherosclerosis: cell biology and lipoproteins - focus on epigenetic modification and macrophage biology. ***Curr. Opin. Lipidol.*** 28:220-221. ***(IF 3.853)***

185. Soehnlein O, Steffens S, Hidalgo A, **Weber C** (2017) Neutrophils as protagonists and targets in chronic inflammation. ***Nat. Rev. Immunol.*** 17:248-261. ***(IF 41.982**, 477 citations)*

186. Steffens S, Winter C, Schloss MJ, Hidalgo A, **Weber C**, Soehnlein O (2017) Circadian control of inflammatory processes in atherosclerosis and its complications. ***Arterioscler. Thromb. Vasc. Biol.*** 37:1022-1028. (***IF 6.686***)

187. **Weber C,** Badimon L, Mach F van der Vorst E (2017) Therapeutic strategies for atherosclerosis and atherothrombosis: Past, present and future. ***Thromb. Haemost.*** 117:1258-1264. (***IF 4.952***)

188. Ridger V, Boulanger CM, Angelillo-Scherrer A, Badimon L, Blanc-Brude O, Bochaton-Piallat M, Boilard E, Buzas E, Caporali A, Dignat-George F, Evans P, Lacroix R, Lutgens E, Ketelhuth DF, Nieuwland R, Toti F, Tuñon J, **Weber C**, Hoefer IE (2017) Position paper of the ESC WG on Atherosclerosis & Vascular Biology on Microvesicles in vascular homeostasis and diseases. ***Thromb. Haemost.*** 117:1296-1316. (***IF 4.952***)

189. Lip GYH, **Weber C** (2017) Thrombosis and Haemostasis: past, present and future. ***Thromb. Haemost.*** 117:1217–1218. (***IF 4.952***)

190. Lip GY, **Weber C** (2017) Introducing our new offspring journal: TH Open. ***TH Open*** 1:e1-2. ***(IF 0.500)***

191. van der Vorst EPC, Maas SL, Ortega-Gomez A, Hameleers JMM, Bianchini M, Asare Y, Söhnlein O, Döring Y, **Weber C**, Megens RTA (2017) Functional ex-vivo imaging of arterial cellular recruitment and lipid extravasation. ***Bio Protoc.*** 7:e2344. ***(IF 3.500)***

192. **Weber C** (2017) Insights into Editor: Christian Weber, MD. ***Arterioscler. Thromb. Vasc. Biol.*** 37:e115. (***IF 6.086***)

193. ° **Weber C**, von Hundelshausen P (2017) CANTOS trial validates the inflammatory pathogenesis of atherosclerosis: setting the stage for a new chapter in therapeutic targeting. ***Circ. Res.*** 121:1119-1121. ***(IF 15.211)***

194. Wu Z, Rademakers T, Kiessling F, Vogt M, Westein E, **Weber C**, Megens RT, van Zandvoort M (2017) Multi-photon microscopy in cardiovascular research. ***Methods*** 130:79-89. (***IF 3.998***)

2018 (IF 82.9)

195. Lip GYH, **Weber C** (2018) A Happy New Year from a 60 year young journal "Thrombosis and Haemostasis". ***Thromb. Haemost.*** 118:1-3. ***(IF 4.733)***

196. **Weber C**, Lip GYH (2018) Editors' choice papers in the 60th anniversary year of "Thrombosis and Haemostasis": past, present and future. ***Thromb. Haemost.*** 118:225-227. ***(IF 4.733)***

197. Daugherty A, Lu HS, Hegele RA, Mackman N, Rader DJ, Schmidt AM, **Weber C** (2018) Response to letter regarding article, "Consideration of sex differences in design and reporting of experimental arterial pathology studies: a statement from the Arteriosclerosis, Thrombosis, and Vascular Biology Council". ***Arterioscler. Thromb. Vasc. Biol.*** 38:e101-e102. (***IF 6.618***)

198. Tuñón J, Bäck M, Badimón L, Bochaton-Piallat ML, Cariou B, Daemen M, Egido J, Evans PC, Francis SE, Ketelhuth D, Lutgens E, Matter C, Monaco C, Steffens C, Stroes E, Vindis C, **Weber C**, Hoefer IE on behalf of the ESC Working Group on Atherosclerosis and Vascular Biology (2018) Interplay between dyslipidemia and inflammation in atherosclerosis: Translating new targets to clinical practice. ***Eur. J. Prevent. Cardiol.*** 25:948-955. ***(IF 5.640)***

199. van der Vorst EPC, **Weber C**, Donners MMPC (2018) A Disintegrin And Metalloproteases (ADAMs) in cardiovascular, metabolic and inflammatory diseases: aspects for theranostic approaches. ***Thromb. Haemost.*** 118:1167-1175. ***(IF 4.733)***

200. van der Vorst EPC, **Weber C** (2018) Metabolomic profiling of atherosclerotic plaques: towards improved cardiovascular risk stratification. ***Eur. Heart J.*** 39:2311-2313. (***IF 24.889***)

201. Poller W, Dimmeler S, Heymans S, Zeller T, Haas J, Karakas M, Leistner D, Jakob P, Nakagawa S, Blankenberg S, Engelhardt S, Thum T, **Weber C**, Meder B, Hajjar R, Landmesser U (2018) Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives. ***Eur. Heart J.*** 39:2704-16. (***IF 24.889***)

202. Lu HS, Schmidt AM, Hegele RA, Mackman N, Rader DJ, **Weber C**, Daugherty A (2018) Reporting sex and sex differences in preclinical studies. ***Arterioscler. Thromb. Vasc. Biol.*** 38:e171-e184. (***IF 6.618***)

2019 (IF 125.1)

203. Lacy M, Atzler D, de Winther M, **Weber C**, Lutgens E (2019) Interactions between dyslipidemia and the immune system and their relevance as putative therapeutic targets in atherosclerosis. ***Pharmacol. Ther.*** 193:50-62. ***(IF 10.557)***

204. Lip GYH, **Weber C** (2019) Thrombosis and Haemostasis wishes you a Happy New Year ahead! ***Thromb. Haemost.*** 119:1-2. ***(IF 4.379)***

205. **Weber C**, Lip GYH (2019) Thrombosis and Haemostasis 2018 Editor's Choice papers**.** ***Thromb. Haemost.*** 119:183-186. ***(IF 4.379)***

206. Tuñón J, Bäck M, Badimón L, Bochaton-Piallat ML, Cariou B, Daemen M, Egido J, Evans PC, Francis SE, Ketelhuth D, Lutgens E, Matter C, Monaco C, Steffens C, Stroes E, Vindis C, **Weber C**, Hoefer IE on behalf of the ESC Working Group on Atherosclerosis and Vascular Biology (2019) Identifying the anti-inflammatory response to lipid lowering therapy. ***Cardiovasc. Res.*** 115:10-19. ***(IF 8.168)***

207. van der Vorst EPC, **Weber C** (2019) Novel features of monocytes and macrophages in cardiovascular biology and disease. ***Arterioscler. Thromb. Vasc. Biol.*** 39:e30-e37. (***IF 6.604***)

208. Steffens S, **Weber C** (2019) Immunotherapy for atherosclerosis - novel concepts. ***Thromb Haemost.*** 119:515-516. ***(IF 4.379)***

209. Gencer S, van der Vorst EPC, Aslani M, **Weber C**, Döring Y, Duchene J (2019) Atypical chemokine receptors in cardiovascular diseases. ***Thromb. Haemost.*** 119:534-541. ***(IF 4.379)***

210. Noels H, **Weber C**, Koenen RR (2019) Chemokines as therapeutic targets in cardiovascular disease. ***Arterioscler. Thromb. Vasc. Biol.*** 39:583-592. (***IF 6.604***)

211. van der Vorst EPC, Peters LJF, Müller M, Gencer S, **Weber C**, Döring Y (2019) G-protein coupled receptor targeting on myeloid cells in atherosclerosis. ***Front. Pharmacol.*** 10:531. (***IF 4.225***)

212. Ketelhuth DFJ, Lutgens E, Bäck M, Binder CJ, Van den Bossche J, Daniel C, Dumitriu IE, Hoefer I, Libby P, O'Neill L, **Weber C**, Evans P (2019) Immunometabolism and atherosclerosis: perspectives and clinical significance – A position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology. ***Cardiovasc. Res.*** 115:1385-1392. ***(IF 8.168)***

213. Natarelli L, **Weber C** (2019) Next-generation therapeutic concepts for atherosclerosis: focus on cell specificity and noncoding RNAs. ***Thromb. Haemost.*** 119:1199-1201. ***(IF 4.379)***

214. Busygina K, Denzinger V, Bernlochner I, **Weber C**, Lorenz R, Siess W (2019) Btk inhibitors as first oral atherothrombosis - selective antiplatelet drugs? ***Thromb. Haemost.*** 119:1212-1221. ***(IF 4.379)***

215. Eckardt V, **Weber C**, von Hundelshausen P (2019) Glycans and glycan-binding proteins in atherosclerosis ***Thromb. Haemost.*** 119:1265-1273. ***(IF 4.379)***

216. Nagy M, van Geffen JP, Stegner D, Adams D, Braun A, de Witt SM, Elvers M, Kuiypers MJE, Kunzelmann K, Oury C, Pircher J, Pleines I, Poole AW, Senis YA, Verdoold R, **Weber C**, Nieswandt B, Heemskerk JWM, Baaten CCF (2019) Comparative analysis of microfluidics thrombus formation in multiple genetically modified mice: link to thrombosis and hemostasis. ***Trends Cardiovasc. Med.*** 6:99. ***(IF 4.755)***

217. Bartelt A, Leipsic J, **Weber C** (2019) The new age of radiomic risk profiling: perivascular fat at the heart of the matter. ***Eur. Heart J.*** 40:3544-3546. (***IF 22.673)***

218. Lutgens E, Atzler D, Döring Y, Duchene J, Steffens S, **Weber C** (2019) Immunotherapy for cardiovascular disease. ***Eur. Heart J.*** 40:3937-3946. (***IF 22.673)***

2020 (IF 158.7)

219. Lu H, Schmidt AM, Hegele RA, Mackman N, Rader DJ, **Weber C**, Daugherty A (2020) ATVB annual report on sex in preclinical studies. ***Arterioscler. Thromb. Vasc. Biol.*** 40:e1-e9. (***IF 8.311***)

220. Lip GYH, Rigby A, **Weber C** (2020) A Toast to the Last Decade and a Very Happy 2020 from Thrombosis & Haemostasis! ***Thromb. Haemost.*** 120:1-4. ***(IF 5.723)***

221. **Weber C**, Rigby A, Lip GYH (2020) Thrombosis and Haemostasis 2018 Editor's Choice papers**.** ***Thromb. Haemost.*** 120:184-190. ***(IF 5.723)***

222. **Weber C** (2020) The ESC Council on Basic Cardiovascular Science. ***Eur. Heart J.*** 41:1227-1230. (***IF 29.983)***

223. Ferdinandy P, Koller A, **Weber C**, Waltenberger J (2020) Postponement of Frontiers of CardioVascular Biomedicine 2020 due to Covid-19: a look forward to 2021. ***Cardiovasc. Res.*** pii: cvaa108. ***(IF 10.787)***

224. Rigby A, Lip GYH, **Weber C** (2020) Documenting sex and sex differences in animal studies. ***Thromb. Haemost.*** 120:879-882. ***(IF 5.723)***

225. Peters LJF, Biessen EAL, Hohl M, **Weber C***, van der Vorst EPC, Santovito D (2020) Small things matter: relevance of microRNAs in cardiovascular disease. ***Front. Physiol.*** 11:793. ***(IF 4.566)*** *corresponding author.

226. ° Evans PC, Rainger GE, Mason JC, Guzik TJ, Stamataki Z, Hoefer I, Waltenberger J, **Weber C**, Bochaton-Piallat ML, Bäck M (2020) Endothelial dysfunction in COVID-19. ***Cardiovasc. Res.*** 116:2177-2184. ***(IF 10.787)***

227. Döring Y, Noels H, van der Vorst E, **Weber C** (2020) Seeing is repairing – how imaging-based timely interference with CXCR4 could improve repair after myocardial infarction. ***Eur. Heart J.*** ehaa625. (***IF 29.983***)

228. Bartelt A, **Weber C** (2020) Mitochondrial ejection for cardiac protection: the macrophage connection. ***Cell Metabol.*** 32:512-513. ***(IF 27.287)***

229. Santovito D*, Egea V*, Bidzhekov K*, Natarelli L*, Mourão A, Wichapong K, Blanchet B, Aslani M, Horckmans M, Hristov M, Lutgens E, Daemen MJAP, Hackeng T, Ries C, von Hundelshausen P, Steffens S, Duchene J, Megens RTA, Sattler M, **Weber C** (2020) Autophagy unleashes non-canonical miRNA functions. ***Autophagy*** 16:2294-2296. (***IF 16.016***)

230. Lacy M, Gencer S, Atzler D, van der Vorst E, Döring Y, **Weber C** (2020) Immuno-inflammatory, thrombohaemostatic, and cardiovascular mechanisms in COVID-19. ***Thromb. Haemost.*** 120:1629-1641. ***(IF 5.249)***

2021 (IF 105.2)

231. Lip GYH, Rigby A, **Weber C** (2021) Looking back on 2020, looking forward to 2021. ***Thromb. Haemost.*** 121:1-3. ***(IF 6.681)***

232. **Weber C**, Rigby A, Lip GYH (2021) Thrombosis and Haemostasis 2020 Editor's choice papers. ***Thromb. Haemost.*** 121:109-114. ***(IF 6.681)***

233. ° Alexander Y, Osto E, Schmidt-Trucksäss A, Shechter M, Trifunovic D, Duncker DJ, Aboyans V, Bäck M, Badimon L, Cosentino F, De Carlo M, Dorobantu M, Harrison DG, Guzik T, Hoefer I, Norata GD, Suades R, Taddei S, Vilahur G, Waltenberger J, **Weber C**, Wilkinson F, Bochaton-Piallat ML, Evans PC (2021) Endothelial function in cardiovascular precision medicine: a position paper on behalf of the European Society of Cardiology. ***Cardiovasc. Res.*** 117:29-42. ***(IF 13.081)***

234. Gencer S, Evans BR, van der Vorst EPC, Döring Y, **Weber C** (2021) Inflammatory chemokines in atheroslceorsis. ***Cells*** 10:226. ***(IF 7.666)***

235. Henderson J, **Weber C**, Santovito D (2021) Beyond self-recycling: cell-specific role of autophagy in atherosclerosis. ***Cells*** 10:625. ***(IF 7.666)***

236. Santovito D, **Weber C** (2021) Not all myocardial infarctions are created equal: the potential of circulating microRNAs to discern coronary artery dissection. ***EBioMedicine*** 67:103366. ***(IF 11.205)***

237. Evans P, Wojta J, Hoefer IE, Waltenberger J, Guzik T, Badimon L, **Weber C** (2021) The year in basic vascular biology research: from smartphone data and omics to mechanoreceptors and NETs. ***Cardiovasc. Res.*** 117:1814-1822. ***(IF 13.081)***

238. Davidson S, Prado T, Bollini S, Vilahur G, Duncker D, Evans P, Guzik T, Hoefer I, Waltenberger J, Wojta J, **Weber C** (2021) The year in basic cardiac research: from rebooting cardiac regeneration to a complete cell atlas of the heart. ***Cardiovasc. Res.*** 117:2161-2174. ***(IF 13.081)***

239. Yan Y, Thakur M, van der Vorst EPC, **Weber C***, Döring Y* (2021) Targeting the chemokine network in atheroscleorsis. ***Atherosclerosis*** 330:95-106. ***(IF 6.847)***

240. Bosmans LA, Shami A, Atzler D, **Weber C**, Gonçalves I, Lutgens E (2021) Glucocorticoid induced TNF receptor family-related protein (GITR) - a novel driver of cardiovascular disease. ***Vasc. Pharmacol.*** 139:106884. ***(IF 5.738)***

241. ° von Hundelshausen P, Lorenz R, Siess W, **Weber C** (2021) Vaccine-induced immune thrombotic thrombocytopenia (VITT): targeting pathomechanisms with Bruton tyrosine kinase inhibitors. ***Thromb. Haemost.*** 121:1395-1399. ***(IF 6.68), 81 citations)***

242. Natarelli L, Virgili F, Weber C (2021) SARS-CoV-2, cardiovascular diseases, and non-coding RNAs: a connected triad. ***Int. J. Mol. Sci.*** 22:12243. ***(IF 6.208)***

243. Soltani-Fard E, Taghvimi S, Abedi-Kichi Z, **Weber C**, Shabaninejad Z, Taheri-Anganeh M, Hossein-Khatami S, Mousavi P, Movahedpour A, Natarelli L (2022) Insights into the function of regulatory RNAs in bacteria and archaea. ***Int. J. Transl. Med.*** 1:403-423 (***IF 0.500***)

2022 (IF 203.1)

244. Lip GYH, Rigby A, **Weber C** (2022) A rollercoaster plunge into 2022. ***Thromb. Haemost.*** 122:1-4. ***(IF 6.830)***

245. **Weber C**, Rigby A, Lip GYH (2022) Thrombosis and Haemostasis 2021 Editors' choice papers. ***Thromb. Haemost.*** 122:163-170. ***(IF 6.830)***

246. Natarelli L, **Weber C** (2022) A non-canonical link between non-coding RNAs and cardiovascular diseases. ***Biomedicines*** 10:445. ***(IF 4.757)***

247. Santovito D, **Weber C** (2022) Noncanonical features of microRNAs: paradigms emerging from cardiovascular disease. ***Nat. Rev. Cardiol.*** 19:620-638. ***(IF 49.421)***

248. Zhang X, Wang Z, Zhang C, Li Y, Lu S, Steffens S, Mohanta S, **Weber C**, Habenicht A, Yin C (2022) Laser capture microdissection-based mRNA expression microarrays and single-cell RNA sequencing in atherosclerosis research. ***Methods Mol. Biol.*** 2419:715-726. ***(IF 1.370)***

249. Wang Z, Zhang X, Zhang C, Li Y, Lu S, Mohanta S, **Weber C**, Habenicht A, Yin C (2022) Combined single-cell RNA and single-cell α/β T cell receptor sequencing of the arterial wall in atherosclerosis. ***Methods Mol. Biol.*** 2419:727-746. ***(IF 1.370)***

250. Sun T, Li Y, Förstera B, Stanic K, Lu S, Steffens S, Yin C, Ertürk A, Megens R, **Weber C**, Habenicht A, Mohanta S (2022) Tissue clearing approaches in atherosclerosis. ***Methods Mol. Biol*** 2419:747-63. ***(IF 1.370)***

251. Daugherty A, Hegele RA, Lu HS, Mackman N, Rader DJ, **Weber C** (2022) Web of Science's citation median metrics overcome the major constraints of the journal impact factor. ***Arterioscler. Thromb. Vasc. Biol.*** 42:367-371. (***IF 10.514***)

252. ° Georgakis M, Bernhagen J, Heitman L, **Weber C**, Dichgans M (2022) Targeting the CCL2-CCR2 axis for atheroprotection: triangulation of evidence and steps towards clinical translation. ***Eur Heart J.*** 43:1799-1808. (***IF 35.855***)

253. Koenen R, **Weber C** (2022) JAM-A unleashed incites thrombo-inflammatory coronary artery disease. ***JACC: Basic to Translational Science*** 7:462-464. ***(IF 9.531)***

254. Engelhardt S, Dimmeler S, Heim C, Bär C, Böttger T, Boon R, Brandes RP, Braun T, Dueck A, Gagneur J, Grote P, Holdt LM, Jaé N, Krishnan J, Kupatt C, Laugwitz KL, Leisegang MS, Maegdefessel L, Meitinger T, Moretti A, Müller-McNicoll M, Sattler M, Schnieke A, Schulz M, Schunkert H, Schwalbe H, Teupser D, Thum T, Weber C, Wittig I, Zarnack K (2022) Nicht kodierende Ribonukleinsäure im kardiovaskulären System. ***Kardiologie*** 16:100-108. ***(IF 0.281)***

255. **Weber C**, Steffens S (2022) Sonderforschungsbereich 1123: Atherosklerose - Mechanismen und Netzwerke neuer therapeutischer Zielstrukturen. ***Kardiologie*** 16:122-127. ***(IF 0.281)***

256. Ferdinandy P, Koller A, **Weber C**, Wojta J, Waltenberger J (2022) Frontiers of CardioVascular Biomedicine 2022 Budapest is on in person! The excellent program proves that scientists won against Covid-19. ***Cardiovasc. Res.*** 118:e59-e61. ***(IF 13.081)***

257. Farina F, Santovito D, **Weber C** (2022) Two-faced Janus: CCR2 macrophages and their dual role in allograft rejection in the transplanted heart. ***Circulation*** 146:639-642. ***(IF 39.918)***

258. Mohanta SK, **Weber C**, Yin C, Habenicht AJR (2022) The dawn has come for new therapeutics to treat atherosclerosis: targeting neuroimmune cardiovascular interfaces in artery brain circuits. ***Clin. Transl. Med.*** 12:e1040. (***IF 8.554***)

259. Evans PC, Davidson S, Wojta J, Bäck M, Bollini S, Brittan M, Catapano A, Chaudhry B, Cluitmans M, Gnecchi N, Guzik T, Höfer I, Madonna R, Morawietz H, Osto E, Padró T, Sluimer J, Tocchetti CG, Van der Heiden K, Garcia Vilahur G, Waltenberger J, **Weber C** (2022). Basic Cardiovascular Science Highlights of 2021-2022. ***Cardiovasc. Res.*** 118:2754-2767. ***(IF 13.081)***

2023 (IF 109.1)

260. Lip GYH, Rigby A, **Weber C** (2023) A Happy New Year 2023 from Thrombosis and Haemostasis. ***Thromb. Haemost.*** 123:1-5. ***(IF 6.7)***

261. **Weber C**, Blanchet X, Lip GYH (2023) Thrombosis and Haemostasis 2022 Editors' Choice Papers. ***Thromb. Haemost.*** 123:123-130. ***(IF 6.7)***

262. Mohanta SK, Yin C, **Weber C**, Habenicht AR (2023) Neuroimmune cardiovascular interfaces in atherosclerosis. ***Front. Cell Dev. Biol.*** 11:1117368. ***(IF 5.5)***

263. Bonfiglio C, **Weber C**, Atzler D, Lutgens E (2023) Immunotherapy and cardiovascular diseases (CVD): novel avenues for immunotherapeutic approaches. ***QJM*** 116:271-278. ***(IF 13.3)***

264. Mohanta SK, Yin C, **Weber C**, Godinho-Silva C, Veiga-Fernandes H, Xu QJ, Chang RB, Habenicht AJR (2023) Cardiovascular brain circuits. ***Circ. Res.*** 132:1546-1565. ***(IF 20.1)***

265. Farina F, **Weber C***, Santovito D* (2023) Non-canonical functions of noncoding RNAs in atherosclerosis. ***Atherosclerosis*** 374:74-86. *corresponding authors. ***(IF 5.3)***

266. Blanchet X, **Weber C**, von Hundelshausen P (2023) Chemokine heteromers and their impact on cellular function. ***Int. J. Mol. Sci.*** 24:10925. ***(IF 5.6)***

267. ° **Weber C**, Habenicht A, von Hundelshausen P (2023) Novel mechanisms and therapeutic targets in atherosclerosis: beyond inflammation. ***Eur. Heart J.*** 44:2672-2681. (***IF 39.3)***

268. Mohanta SK, Sun T, Lu S, Wang Z, Zhang X, Yin C, **Weber C**, Habenicht AJR (2023) The impact of the nervous system on arteries and the heart: the neuroimmune cardiovascular circuit hypothesis. ***Cells*** 12:2485. (***IF 6.0***)

269. Kral M, van der Vorst EPC, Surnov A, **Weber C**, Döring Y (2023) ILC2 crosstalk with adaptive immunity in chronic (vascular) inflammation. ***Front. Immunol.*** 14:1326440. (***IF 7.3***)

2024 (IF 161.6)

270. Lip GYH, Rigby A, **Weber C** (2024) A Happy New Year 2024 from Thrombosis and Haemostasis. ***Thromb. Haemost.*** 124:1-3. ***(IF 4.3)***

271. **Weber C**, Rigby A, Lip GYH (2024) Thrombosis and Haemostasis 2023 Editors' Choice Papers. ***Thromb. Haemost.*** 124:80-87. ***(IF 4.3)***

272. Mohanta S, Santovito D, **Weber C** (2024) Cortico-limbic restructuring and atherosclerosis: a stressful liaison. ***Eur. Heart J.*** 45:1765-1767. ***(IF 35.6)***

273. Parma L, Duchene J, **Weber C** (2024) Breaking point: How intraplaque hemorrhage propels plaque rupture. ***Circ. Res.*** 135:317-319. ***(IF 16.2)***

274. Döring Y, van der Vorst EPC, **Weber C** (2024) Targeting immune cell recruitment in atherosclerosis. ***Nat. Rev. Cardiol.*** 21:824-840. ***(IF 44.2)***

275. Kral M, van der Vorst EPC, **Weber C**, Döring Y (2024) (Multi-) Omics studies of ILC2s in inflammation and metabolic diseases. ***Front. Cell Dev. Biol.*** 12:1473616. ***(IF 4.3)***

276. Kral M, Döring Y, **Weber C** (2024) Early intermittent cholesterol exposure accelerates atherosclerosis: an oscillating amplifier calling for preemptive control. ***Signal Transduct. Target. Ther.*** 9:313. ***(IF 52.7)***

2025

277. Lip GYH, Rigby A, **Weber C** (2025) Welcoming 2025 – A Year of Collaboration and Progress. ***Thromb. Haemost.*** 125:1-2. ***(IF 4.3)***

278. Rigby A, Albisetti M, Favaloro E, Koenen RR, Langer F, Lip, GYH, Rühl H, **Weber C** (2025) Reflections on World Thrombosis Day 2024. ***Thromb. Haemost.*** 125:3-6. ***(IF 4.3)***

279. **Weber C**, Rigby A, Lip GYH (2025) Thrombosis and Haemostasis 2024 Editors' Choice Papers. ***Thromb. Haemost.*** 125:85-91. ***(IF 4.3)***

280. Hristov M, **Weber C** (2025) Monocyte subsets in cardiovascular disease: a biomarker perspective. ***Thromb. Haemost.*** 125:93-96. ***(IF 4.3)***

281. Mohanta SK, Heron C, Klaus-Bergmann A, Horstmann H, Brakenhielm E, Giannarelli C, Habenicht AJR, Gerhardt H, **Weber C** (2025) Metabolic and immune crosstalk in cardiovascular disease. ***Circ. Res.*** 136:1433-1453. ***(IF 16.2)***

282. Pfeferman MB, Rashedi S, Lip GYH, **Weber C**, O'Donoghue ML, Nissen S, Tsimikas S, MDg, Nicholls SJ, Natarajan P, Plutzky J, Libby P, Goldhaber SZ, Piazza G, Bikdeli B (2025) Lipoprotein (a) and venous thromboembolism: association, causality, and medications. ***Thromb. Haemost.***, in press. ***(IF 4.3)***

283. Santovito D, **Weber C** (2025) Argonaute nuclear power: nuclear microRNAs control cardiac metabolism in heart failure with preserved ejection fraction. ***Eur. Heart J.***, in press. ***(IF 35.6)***

284. von Hundelshausen P, Siess W, Duan R, Bohnert T, Hopkins BT, **Weber C** (2025) Involvement of Btk in cardiovascular disease and its therapeutic targeting. ***Circulation***, in revision. ***(IF 38.6***)

Eingeladene Hauptvorträge und *Keynote Lectures* (Auswahl)

1. **Weber C** (2025) Immune and endothelial cell homeostasis in atherosclerosis. Gordon Research Conference on Atherosclerosis. Casteldelfels, Spain.
2. **Weber C** (2023) Chemokine signaling in atherosclerosis – from mechanisms to translation. Keynote Lecture. European Atherosclerosis Society (EAS), Mannheim, Germany.
3. **Weber C** (2022) Novel mechansims and therapeutic targets in atherosclerosis. William Harvey Lecture in Basic Science. European Society of Cardiology (ESC), Barcelona, Spain.
4. **Weber C** (2021) Novel mechanisms and targets in atherosclerosis. XXII Lipid Meeting, Leipzig, Germany.
5. **Weber C** (2020) Nonocanonical functions of microRNAs in vascular disease. IVBM 2020, Seoul, South Corea.
6. **Weber C** (2019) Novel strategies for immunotherapy of atherosclerosis. Gordon Research Conference on *Atherosclerosis*, Newry, Maine, USA.
7. **Weber C** (2018) Inflammation: a treatment target in CAD prevention. ESC, Munich, Germany.
8. **Weber C** (2017) Targeting chemokines to control plaque cell infiltration. Gordon Research Conference on *Atherosclerosis*, Newry, Maine, USA.
9. **Weber C** (2017) Regulation of atherosclerosis by microRNAs. European Atherosclerosis Society (EAS) Congress 2017, Prag, Czech Republic.
10. **Weber C** (2016) Chemokine interactome mapping for tailored intervention in acute and chronic inflammation. Gordon Research Conference on *Chemotactic Cytokines*, Girona, Spain
11. **Weber C** (2015) Chemokines in atherosclerosis. GTH Congress 2015, Düsseldorf, Germany.
12. **Weber C** (2015) Regulation of microRNA trafficking in atherosclerosis. Gordon Research Conference on *Atherosclerosis*, Newry, Maine, USA.
13. **Weber C** (2014) miRNAs and regional susceptibility to atherosclerosis. FCVB 2014, Barcelona, Spain.
14. **Weber C** (2014) Chemokines and miRNAs and atherosclerosis. IVBM 2014, Kyoto, Japan
15. **Weber C** (2013) MicroRNAs and atherosclerosis: from molecular mechanism to potential clinical applications. President's Lecture, Italian Society of Atherosclerosis, Roma, Italy.
16. **Weber C** (2013) Targeting platelets in vascular inflammation. European Society of Cardiology (ESC), Amsterdam, Netherlands
17. **Weber C** (2013) Dendritic and regulatory T-cells in atherosclerosis. American Diabetes Association Congress 2013, Chicago, USA.
18. **Weber C** (2013) Emerging mechanisms of chemokine receptor control of atherosclerosis. The Ottawa Research Conference, Ottawa, Canada.
19. **Weber C** (2012) CXCL12 - is it important? AHA Scientific Sessions, Los Angeles, USA.
20. **Weber C** (2012) Therapeutic targeting of microRNAs in atherosclerosis. ESC, Munich, Germany.
21. **Weber C** (2012) Role of chemokines in cardiovascular disease. Gordon Research Conference on *Chemotactic Cytokines*, Il Ciocco, Italy.
22. **Weber C** (2012) Chemokines as therapeutic targets. Internat. Atherosclerosis Society 2012, Sydney, Australia.
23. **Weber C** (2011) Chemokines and their receptors as therapeutic targets in atherosclerosis. EMBO Molecular Medicine Conference: Molecular Insights for Innovative Therapies, Heidelberg, Germany.
24. **Weber C** (2011) The inflammatory pathogenesis of atherosclerosis. Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
25. **Weber C** (2011) MicroRNAs - a novel target in cardiovascular prevention. ESC, Paris, France.
26. **Weber C** (2011) Chemokines as therapeutic targets in the treatment of atherosclerosis. 79th European Atherosclerosis Society (EAS) Congress, Gothenburg, Sweden.
27. **Weber C** (2011) Microparticles as transfer modules in cardiovascular disease. 6th European Meeting for Vascular Biology & Medicine (EVBVM), Krakow, Poland.
28. **Weber C** (2011) Role of inflammation in atherosclerosis. 10th World Congress in Inflammation. Paris, France.
29. **Weber C** (2010) Chemokines in the vascular inflammatory response. ESC, Stockholm, Sweden.
30. **Weber C** (2010) Chemokines as therapeutic targets in atherosclerosis. Kern Conferences, Aspen, USA.

31. **Weber C** (2010) Chemokines as crucial drivers of macrophage and dendritic cell function in atherosclerosis. International Vascular Biology Meeting (IVBM) 2010, Los Angeles, USA.
32. **Weber C** (2010) A miRNA-mediated mechanism for functional chemokine induction. Gordon Research Conference on *Chemotactic Cytokines*, Il Ciocco, Italy.
33. **Weber C** (2010) Role of chemokines for cell migration during inflammation. 8th World Congress on Trauma, Shock, Inflammation and Sepsis - TSIS 2010, Munich, Germany.
34. **Weber C** (2009) Progenitor cell trafficking in the vascular wall. International Society of Thrombosis and Haemostasis (ISTH) Meeting 2009, Boston, USA.
35. **Weber C** (2009) Chemokines as therapeutic targets in atherosclerosis. International Atherosclerosis Society (IAS) Meeting 2009, Boston, USA.
36. **Weber C** (2008) MIF as a pseudo-chemokine in atherosclerosis. AHA Scientific Sessions, New Orleans, USA.
37. **Weber C** (2008) Structural basis and *in vivo* relevance of chemokine heteromerization. Gordon Research Conference on *Chemotactic Cytokines*, Aussois, France.
38. **Weber C** (2008) The monocyte: function and fate. European Society of Cardiology (ESC), Munich, Germany.
39. **Weber C** (2008) Functional diversity of chemokines and mononuclear cell subsets in atherosclerosis. 77th European Atherosclerosis Society (EAS) Congress, Istanbul, Turkey.
40. **Weber C** (2008) Chemokines and chemokine-like ligands in vascular inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology Annual Conference 2008, Atlanta, USA.
41. **Weber C** (2008) Chemokine-like functions of MIF in leukocyte recruitment - Joint Lecture. Keystone Symposia Leukocyte Trafficking / Chemokines and Chemokine Receptors, Keystone, USA.
42. **Weber C** (2008) Chemokines: inflammatory mediators of atherosclerosis. 3rd Joint Meeting of French, German and Swiss Atherosclerosis Societies, St. Gervais, France.
43. **Weber C** (2007) Ambivalence of progenitor cells in vascular repair and plaque instability, Royal Netherlands Academy of Arts and Sciences, Amsterdam, Netherlands.
44. **Weber C** (2007) Role of EPCs in cardiovascular repair, European Society of Cardiology (ESC), Wien, Austria.
45. **Weber C** (2007) Basic Science Key Note - Cytokine in der Atherosklerose: Angriffspunkte für die therapeutische Intervention? 74th Annual Congress of the German Cardiac Society (DGK), Mannheim, Germany.
46. **Weber C** (2007) Chemokines & atherosclerosis, 7th World Congress Trauma, Shock, Inflammation & Sepsis TSIS 2007, Munich, Germany.
47. **Weber C** (2007) Platelet & inflammatory cell interactions. British Atherosclerosis Society, Glasgow, UK.
48. **Weber C** (2006) Cross-talk between blood cells in inflammation. European Society of Cardiology (ESC) and World Congress of Cardiology (WCC), Barcelona, Spain.
49. **Weber C** (2006) Chemokines in vascular cell recruitment, UK/German Adhesion Society, London, UK.
50. **Weber C** (2006) Chemokines in arterial pathology. Int. Vascular Biology Meeting, Amsterdam, Netherlands.
51. **Weber C** (2006) Cell-cell interactions in the vascular wall. III. Cardiovascular Healing Symposium, Leopoldina Akademie der Naturforscher, Würzburg, Germany.
52. **Weber C** (2005) Interplay of chemokines and platelets in vascular cell recruitment, 3rd European Vascular Biology Meeting (EVBM), Hamburg, Germany.
53. **Weber C** (2004) Platelet-derived mediators and atherosclerosis. AHA Scientific Sessions, New Orleans, USA.
54. **Weber C** (2004) Role of JAM-A in inflammatory & atherogenic leukocyte recruitment. Gordon Research Conference *Immunoglobulin Family Members in Infection, Immunity & Cancer*, Massachussetts, USA.
55. **Weber C** (2004) Role of chemokines in arteriogenesis and angiogenesis, Working Group Vascular Biology, 70th Annual Congress of the German Cardiac Society, Mannheim, Germany.
56. **Weber C** (2003) Novel molecular targets to modulate monocyte recruitment. Mario-Negri-Institute, Milan, Italy.
57. **Weber C** (2002) Involvement of JAM-1 as a newly identified ligand of LFA-1 in leukocyte transendothelial migration. 2nd Joint UK/German adhesion meeting, German Society of Immunology, Berlin, Germany.
58. **Weber C** (1998) Adhesion molecules, chemokines and the cytoskeleton in arteriosclerosis, Working group Pathogenesis Arteriosclerosis, 65th Annual Congress of the German Cardiac Society, Mannheim, Germany.
59. **Weber C** (1998) Antioxidant effects on monocyte-endothelial cell interactions & vascular cell apoptosis. FASEB Summer Research Conference *Mechanisms of Antioxidant Action*, Copper Mt., Colorado, USA.